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Background: Recent studies have shown that human papillomavirus (HPV) is an 
etiologic agent for oropharyngeal squamous cell carcinomas (OPSCC). Although 
individuals with HIV are presumably at increased risk of developing OPSCC, it is 
unknown to what extent the HIV status contributes to prevalence of oral HPV infections. 
This study was conducted to evaluate the prevalence and risk factors in three diverse 
groups in Washtenaw and surrounding counties in Michigan. 
Methods: Participants were recruited to form three study groups: 1) HIV-positive 
patients seen at the University of Michigan Health System; 2) HIV-negative individuals 
tested at an HIV screening clinic; and 3) self-reported HIV-negative individuals. Oral 
rinse samples were collected from participants and were tested for presence and type of 
HPV DNA with PGMY09/11 primers and Sanger sequencing. In addition, HPV type and 
copy number were examined by HPV MultiPlex PCR-MassArray for 15 discrete high-
risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 73) and 3 
low-risk HPV types (HPV 6, 11, and 90). Study participants completed a survey to 
ascertain medical, social, and behavioral risk factors. Clinical information pertaining to 
HIV disease status was collected for HIV patients.  
Results: The total of 266 community-based participants (107 HIV-infected, 69 tested 
HIV-negative, and 90 self-reported HIV-negative) were enrolled. The overall crude 
prevalence of oral HPV DNA was 10.5%. The HIV-infected group had the highest 
prevalence (20.1%), followed by the self-reported HIV-negative group (5.6%) and the  
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HIV-negative group that received HIV testing (1.4%). Male partner's circumcision status 
was significantly associated with oral HPV infection (aOR=3.85). In univariate analysis, 
male gender, lifetime number of vaginal sex partners, and higher viral load were 
associated with increased risk of oral HPV infection. 
Conclusion: The data supports previous findings that  higher prevalence of oral HPV 








 Individuals with HIV infection are at increased risk of developing a variety of 
virally induced tumors, including those associated with human papillomavirus (HPV) (1-
4). Recent studies have shown that HPV is an etiologic agent for a rapidly growing 
subset of head and neck squamous cell carcinomas, particularly oropharyngeal 
squamous cell carcinomas (5-9). However, to date, very little is known about the natural 
history of HPV infection in the oral cavity of HIV-positive and HIV-negative individuals. 
Of note, it is unknown to what extent HIV infection contributes to acquisition of active 
infection or persistent and/or recurrent oral co-HPV infections. Given that oropharyngeal 
cancer rates are expected to surpass that of cervical cancer by 2020 (10), not only is 
there a critical need to investigate the HPV infection rates in HIV positive and negative 
populations from the clinical standpoint, but it is also important to understand specific 
molecular and behavioral risk factors that affect oral HPV incidence and prevalence for 
prevention and screening purposes.  
 One of the major challenges in oral cancer prevention is that, unlike screening for 
HPV-related cervix cancer, no standard screening methods for oral cancer currently 
exist. To this end, this dissertation research was conducted to identify individuals with 
risk of oropharyngeal cancer using HPV as proxy, and to document the effectiveness of 
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Multiplex PCR MassArray, a high-throughput assay for HPV detection that has been 
developed by colleagues at the University of Michigan Cancer Center (11, 12).  
 To test the central hypothesis that HIV-positive individuals are more likely to be 
susceptible to oral HPV infection compared to HIV-negative individuals due to their 
immunosuppression and high-risk behaviors, this study was conducted to investigate 
clinical, molecular, and behavioral factors in transmission of oral HPV in three study 
groups: 1) HIV-positive patients seen at the University of Michigan Health System; 2) 
HIV-negative individuals tested at an HIV screening clinic; and 3) self-reported HIV-
negative individuals from the general public. The specific aims and corresponding 
hypothesis are as follow: 
 
1) To determine and compare the prevalence, HPV type distribution and risk 
factors of oral HPV infection in HIV-positive and -negative groups. This aim 
tested the hypotheses that higher prevalence of oral HPV infection will be 
observed in HIV individuals than in both reference groups (i.e. HIV-negative 
individuals tested at an HIV screening clinic and self-reported HIV-negative 
individuals from the general public), and that more high-risk HPV types and 
higher viral copy numbers will be observed in HIV-positive individuals compared 
to HIV-negative groups. Furthermore, it was hypothesized that prevalence of 
HPV infections will be related to certain high risk behaviors and, in HIV-positive 




2) To evaluate the validity of the questionnaire that was used for aim #1 by 
assessing the informational concordance between self-reported data and data 
abstracted from medical records. The aim is to test the hypothesis that the 
patient survey is a better data source for certain items whereas the medical 
record is a better source for others. 
 
The Organization of the Dissertation 
 This dissertation takes an unconventional format such that the two chapters that 
immediately follow this overview will be comprised of the literature review (Chapter 2) 
and overall study methods (Chapter 3), respectively. Chapter 4 will present the overall 
findings of the study, and Chapter 5 will specifically discuss the methods used to 
validate the questionnaire that was used in the study by assessing concordance of 
patients' self-reported knowledge and physicians' documented knowledge of selected 
clinical and behavioral information. Chapter 6 will take a drastic shift to provide a 
systematic literature review of the global incidence and prevalence of systemic lupus 
erythematosus (SLE). Although this systematic literature review is not directly part of the 
epidemiological research of oral HPV infection, SLE is an autoimmune disease that is 
presumed to have important relevance to HPV. My epidemiological study consisted of 
an immunocompromised population (i.e., HIV-infected patients), but it is hypothesized 
that patients with autoimmune disease may mimic HIV-infected populations. This is 
because autoimmune disease patients, such as those with SLE, are often prescribed 
immunosuppressant therapy. Therefore, it was important to document the global burden 
of SLE to establish a baseline for future HPV research in this unique population. 
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Chapter 7 will serve as the final chapter and conclude with the summary of results, 
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CHAPTER 2 
 Background and Significance  
 
Human Papillomavirus 
 Human papillomavirus (HPV) is an encapsulated, non-enveloped double-
stranded DNA virus. There are five major HPV genera in the Papillomaviridae family: 
Alpha-papillomavirus, Beta-papillomavirus, Gamma-papillomavirus, Mu-papillomavirus, 
and Nu-papillomavirus (1). The viral genome is about 8,000 base pairs in length, and 
consists of eight genes that are categorized into either early (E) or late (L) regions which 
reflects the temporality of their expression in relation to cell cycle (2, 3). Genes 
expressed early in the HPV cycle are generally involved in viral replication as well as 
gene expression regulation (3-5). The E6 and E7 proteins have received much interest 
because of their ability to disrupt the function of tumor suppressor proteins, p53 and 
pRb, respectively (6-8). While E6 and E7 are expressed in both oncogenic and non-
oncogenic HPV types, the high risk of E6 and E7 differ in that high risk E6 contains 
introns that result in alternate splice forms (9, 10), higher E7 expression (11) and 
oncogenesis that are absent in low risk HPV types (12, 13). The genes of the L region 
(i.e., L1 and L2) code for capsid proteins. L1 is the most conserved region, and 
represents 80% of protein in the viral capsids (14).  
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 Approximately 120 different genotypes have been identified to date (15, 16). The 
subtypes have been classified based on phylogenic position and ability to infect 
mucosal or cutaneous surfaces (5, 16). The International Agency for Research on 
Cancer (IARC) at the World Health Organization (WHO) has further categorized HPV 
subtypes into high-risk (HR) and low-risk (LR) according to carcinogenicity (17-19). 
Oncogenic HPV types are: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73 (17-
19). Thirteen HPV types are considered non-oncogenic: 6, 11, 26, 40, 42, 53, 54, 55, 61, 
62, 64, 66, 67, 69, 70, 71, 72, 81, 82, 83, 84, CP6108, and IS39 (20). Other HPV types 
have not been classified to date. 
 
HPV-associated Cancers in the Head and Neck Region in HIV-uninfected 
Populations 
 Head and neck cancer (HNC) is the sixth most common cancer in the world (21), 
and ranks as the eighth most common cause of cancer death (22). Malignancies of the 
lip, oral cavity, nose, and paranasal sinuses, nasopharynx, oropharynx, hypopharynx, 
and larynx all fall within the category of HNC (23). Squamous cell carcinomas are the 
most frequent malignancy in the head and neck region (24, 25). Traditional risk factors 
for cancer, such as alcohol consumption and tobacco smoking, are the most important 
risk factors for head and neck squamous cell carcinoma (HNSCC) (26).  
 With a decline in smoking rates, HNCs have decreased over time in the United 
States and Europe (27-29). In the meanwhile, a growing subset of HNC, particularly 
oropharyngeal squamous cell carcinomas (OPSCC) of the base of tongue and tonsil, 
has been observed (30, 31). In fact, the incidence of oropharyngeal cancer is expected 
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to surpass the incidence of cervical cancer by 2020 (32). It has also been noted that the 
steady increase in OPSCC in the United States tends to affect men who lack significant 
smoking or drinking history and are on average 9 years younger than the typical 
HNSCC patient (30, 33, 34). Similar observations have been made in European 
countries (34-38). These trends have suggested that there is an alternative etiology for 
this particular set of HNC. 
 HPV has been implicated in the pathogenesis of HNSCC. Ragin and Taioli 
conducted a meta-analysis reporting the prevalence of HPV in cancers that have the 
primary site in the head and neck region (39). In this meta-analysis, HPV prevalence 
ranged from 0 to 40.5%, with the tonsil having the highest prevalence, followed by 
oropharynx. Further, Hobbs et al. calculated the odds of finding HPV type 16 stratified 
by head and neck anatomical site, and found that the tonsil had the greatest odds of 
oral HPV16 prevalence, followed by other oropharynx sites, oral cavity, and larynx (40). 
These findings strengthen the idea that oral cavity/oropharynx is a good reservoir for 
HR HPV. Indeed, not only is HPV type 16 the most commonly found HR HPV type in 
HPV-positive tumors in the head and neck region (41-45), but it is also the most 
common infection in the oral cavity (1, 20, 46). Other HR HPV types in the oral cavity 
include HPV types 66 and 51, mimicking the distribution of HPV types in the cervix (47).  
 Despite its oncogenic property, HPV is associated with better prognosis and 
survival in HPV-positive OPSCCs when compared to HPV-negative oropharynx tumors 
(48). HPV-associated HNCs have 72% reduction in mortality compared to their HPV-
negative counterparts (49). The progression of HPV-positive HNSCCs and OPSCCs 
was 60% and 52% lower than corresponding HPV-negative tumors at these sites. 
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Further, recurrence was 59% and 63% less for individuals with HPV-positive HNSCCs 
and OPSCCs, respectively, compared to HPV-negative counterparts (49, 50). It must be 
noted, however, that patients with HPV-associated HNSCCs are often younger (51). 
Therefore, favorable clinical outcome may in part be attributed to their younger age. 
 Leemans et al. (52) summarized the major differences between HPV-positive 
and HPV-negative HNSCC. HPV-negative HNSCCs are decreasing in incidence, have 
smoking and excessive alcohol use as the primary risk factors, affect older age, have 
evidence for field cancerization, have frequent TP53 mutations, and have poor 
prognosis (52). On the contrary, HPV-positive HNSCCs are increasing in incidence, are 
associated with oral sex, affect younger population, have infrequent TP53 mutations, 
are primarily found in the oropharynx, and have favorable prognosis and survival. Based 
on such a comprehensive review comparing HPV-positive and HPV-negative HNSCCs, 
it has become quite clear that HPV-positive and HPV-negative tumors represent distinct 
epidemiologic, clinicopathological, and molecular entities (28, 31, 48, 53-61). 
 
HPV Infection in HIV-uninfected Populations 
 Since there is mounting evidence to suggest that the increasing incidence of 
OPSCCs is due to HPV, which is a sexually transmitted disease (STD), epidemiologic 
investigations have focused on identifying specific behaviors that are associated with 
the risk of oral HPV infection. HPV is the most common STD in the United States with 
approximately 5 million new infections occurring annually (62, 63). More than 50% of 
sexually active adults have been infected with one or more genital HPV types, and by 
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the age of 50, more than 80% of women will have acquired at least one genital HPV 
type (64) 
 Prevalence and incidence of HPV in the genital region has been studied 
extensively. According to a systematic literature review of HPV infection in women in the 
United States, the prevalence varied from 10 to 90%, and the incidence ranged from 7 
to 20% (65). The prevalence also varied among American men, ranging from 1.3 to 
72.9% (66). The incidence of HPV infection in men was 29% over 12 months (67). 
However, in a different population, namely college men, the incidence of over a 24-
month period was as high as 62.4% (68). While the variations in rates are partly due to 
age distribution in the study populations and HPV detection methods, the transient 
nature of HPV infection makes it difficult to accurately estimate the occurrence and type 
distribution of the virus. 
 The burden of non-head and neck cancers that are associated with HPV is 
significant. Cervical cancer is the most common cancer in women worldwide with 
470,000 new cases each year, and more than half of these result in death (69). The 
incidence of anal cancer is low relative to cervical cancer as the rate of anal cancer in 
the general population is approximately 2 per 100,000 per year (70). However, the rates 
are much higher in at-risk populations, specifically men who have sex with men (MSM) 
and immunocompromised individuals (71-76). The proportion of cancers positive for 
HPV16 is greater among anal cancer cases (i.e., over 70%) than cervical cancer cases 
(i.e., over 50%) (77). On the contrary, penile cancer occurs less frequently than cervical 
and anal cancers as it represents less than 1% of new cancers among the U.S. men. 
Moreover, the link between HPV and penile cancer has not been demonstrated 
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convincingly. It has been reported that at least 40% of penile cancers were HPV 
positive, and HPV16 and 18 accounted for over 70% of these HPV-positive cases (78). 
The difference in rates may be due to the virus’ capability to harbor in the genital area 
and overall hygiene. For example, it has been demonstrated that circumcision serves as 
a protective factor for penile cancer (79). 
 In the oral cavity of healthy individuals, the prevalence is less than that observed 
in OPSCC patients. Whereas HPV prevalence in OPSCCs has ranged from 2.9% in 
Australia, Cuba, and Sudan (80) to 80.4% in Japan (81), HPV prevalence in healthy 
populations has ranged from 0% in a very small study sample in the United Kingdom 
(82) to 20.7% in Brazil (83). Globally, the prevalence of oral HPV infection is estimated 
to be 4.5% among healthy individuals (84). Carcinogenic HPV types were seen in 3.5% 
of this global population, with the prevalence of HPV 16 in the oral cavity being only 
1.3% (84). The prevalence appears to be affected by the economic status of countries; 
the prevalence of any HPV type in developing countries (7.3%) is two-fold higher than 
that in developed countries (3.6%) (84). Further, the prevalence of HPV 16 is 4.3% 
among healthy individuals in developing countries, whereas it is only 0.7% in developed 
countries (84). 
 In comparing the prevalence between oral HPV infection and genital HPV 
infection, specifically in the cervix, oral HPV infection rates appear to be lower. Oral 
HPV prevalence is five to ten-fold lower than cervicovaginal HPV prevalence (47). 
Gillison et al. recently conducted the first nationwide study of oral HPV infection in the 
United States using the data from the National Health and Nutrition Examination Survey 
(NHANES), reporting an oral HPV prevalence of approximately 7% (85). The 
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prevalence among women in this study is 3.6%, which is nearly ten-fold lower than the 
average prevalence of HPV in the cervical and vaginal region, which is approximately 
34% (86, 87). Among men in the general population, oral HPV prevalence is 10% 
whereas the prevalence in their genital region is generally over 20% (66).   
 A single risk factor for oral HPV infection has not been identified, but a 
combination of risk factors plays a role in oral HPV infection. There is a great deal of 
evidence to suggest that the risk factors for oral HPV infection are similar to those in 
genital HPV infection. Prevalence of oral HPV infection increases with number of 
partners (85, 88) and lack of condom use (85). Open-mouth kissing was recently added 
as another risk factor (88, 89). Tobacco smoking, marijuana use, and excessive alcohol 
consumption have been known to be positively associated with oral HPV infection (56, 
90). Chronic inflammation in the oral cavity arising from poor hygiene has also been 
documented as a risk factor for oral HPV infection (91). Although there have been only 
a handful of studies, co-infection with other infectious agents, including bacteria and 
viruses, has been suggested. Previously, oral HPV infection was detected in 
conjunction with Epstein Barr virus (92) and herpesvirus (93, 94). Although not 
statistically significant, there was also concomitant infection with the following types of 
bacteria: Dialister pneumosintes, Filifactor alocis, Porphyromonas gingivalis, Olsenella 
uli, and  Pyramidobacter piscolens (93). 
 Despite the aforementioned similarities between genital and oral HPV infection, 
HPV infection in the oral cavity has notable differences from that in the genital region in 
terms of risk factors. As with HPV-positive HNSCC, oral HPV infection in non-cancer 
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populations is associated with young age (85, 88, 95), higher socioeconomic status, 
higher education, and white race (96).  
 Although autoinoculation has not been reported as a risk factor of oral HPV 
infection, this is still possible in theory. The same HPV types in the hand or fingernails 
as those in the genital area have been observed in both men and women (68, 97, 98). 
In the study by Partridge et al., HPV types detected were HPV 26 and HPV 36 (68). 
Winer et al. reported HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 66, and 82, in 
addition to numerous LR HPV types (98). Widdice et al. also reported a wide range of 
HPV types, including types 6, 16, 31, 35, 39, 42, 51, 52, 53, 58, 59, 61, 62, 66, 67, 70, 
73, 84, and CP6108 (97). With all these results combined, it is clear that a variety of 
mucosal HPV types could be found on the skin. Such findings suggest that there is a 
potential that HPV could be self-inoculated to the oral cavity. 
 
HPV-associated Non-HNCs in HIV-infected Populations 
 The prevalence of oral HPV infection is thought to be exacerbated in HIV-positive 
populations because of immunosuppression. HPV-related tumors are known to be 
associated with immunosuppression in individuals with immunodeficiency diseases and 
in organ transplant recipients (99-101). An increased incidence of HPV-related cancers 
has also been documented in men who have sex with men (MSM) and HIV-positive 
populations, suggesting that there is an increased risk of HPV transmission and 
oncogenesis in these individuals (71, 73, 74, 102, 103).    
 Compared to the general population, individuals with HIV are at increased risk of 
developing several cancers linked to HPV because of high HPV prevalence and HPV-
14 
 
associated cellular abnormalities. HIV-infected women are two to three times more likely 
than HIV-uninfected women to have detectable levels of cervical HPV DNA (104-108). 
In addition, HIV-infected women were more likely to have a higher HPV detection rate 
than HIV-uninfected women, and the detection rates depended on the level of CD4 
count (109). Similar differences between HIV-positive and HIV-negative women 
regarding cancer risk have been observed even in younger women. A three-fold risk of 
HPV infection and squamous intraepithelial lesions was reported in HIV-infected 
adolescent females compared to HIV-uninfected adolescent females (110, 111). 
Likewise, HIV-infected men have approximately a three-fold higher risk of being infected 
with HPV than HIV-uninfected men, and such risk is observed primarily in the anus 
among men who have sex with men (71, 103).  
 Given the higher prevalence rates of HPV in the HIV population in the context of 
immunosuppression, it is not surprising to find higher rates of HPV-associated cancers. 
The incidences of cervical and anal cancers steadily increase as CD4 count declines 
(112, 113). A risk of developing invasive cervical cancer is five- to 15-fold greater in 
women with HIV (114, 115). Low CD4 count (109) and high HIV viral load are 
significantly associated with HPV DNA detection in cervical squamous intraepithelial 
neoplasia (116). In addition to the influence of immunosuppression on cancer risk, it has 
also been reported that HIV-infected individuals are less likely to have received cervical 
cancer screening (115, 117-119), making this group even more vulnerable. 
 HIV-infected men are also at higher risk of HPV-associated cancers. Although 
studies directly comparing the rates of penile cancer in HIV-infected and -uninfected 
men are rare, it has been noted that HIV-infected men are more likely to have HR HPV 
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on their penis than HIV-negative men (120). High rates of HR HPV (i.e., 78, 36 and 30% 
in the anus, penis and mouth, respectively) have been observed in HIV-positive men 
(121). Moreover, HIV-infected men have roughly 37-fold higher risk of anal cancer than 
the general population (122). These anogenital carcinomas associated with oncogenic 
HPV suggest a gradual loss of control over HPV-infection with progressing 
immunosuppression.  
  
HPV-associated HNCs in HIV Populations 
 Given that immunosuppression and risky sexual risk behaviors have contributed 
to greater risks of anogenital cancers in HIV-positive individuals compared to HIV-
negative individuals, it is hypothesized that HIV-positive individuals are also at an 
increased risk of HNCs. This notion especially holds because evidence strongly 
suggests that HPV-associated HNCs, particularly OPSCCs, are sexually transmitted. 
However, it remains unclear whether HIV-infected individuals are indeed at a greater 
risk. Further, it is unknown to what extent HNC incidence and prevalence are affected 
by HIV disease progression.  
 To date, a limited number of studies have compared HNC rates between HIV-
positive and HIV-negative populations. Modest risk of HNCs has been observed among 
HIV-infected populations compared to HIV-negative counterparts in large studies. In a 
meta-analysis of the head and neck cancers in developed countries between 1980 and 
2007, HIV-infected individuals had a two-fold increase (21). This and another meta-
analysis cited a two-fold increase, when specifically assessing the cancer rates in the 
oropharynx (21, 123). Such findings are comparable to studies performed in the United 
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States. Three investigators have compared the incidence rates of oropharyngeal 
cancers between HIV-positive and HIV-negative populations, and the incidence ratios 
ranged from 1.4 to 1.8 (124-126). In tonsillar cancers, the incidence ratio was 2.6 times 
higher in the HIV-positive population in the United States (122). The largest difference 
was observed in Switzerland, where the HIV-positive population had a four-fold increase 
in the cancers of the lip, oral cavity, and pharynx compared to the HIV-negative 
population (127).  
 The extent to which immune effects may play a role in new and recurrent HNCs 
in HIV populations remains unknown. Furthermore, the role of highly active antiretroviral 
therapy (HAART) in oral HPV infection is unknown. The literature indicates that the 
incidence of HPV-related anogenital cancers has not declined with antiretroviral therapy 
(103). In the oral cavity, HAART use has been associated with persistence of oral HPV 
infection (128). Given that the incidence of HPV-associated diseases have not declined 
in the HAART era and that HAART may actually prolong HPV infection, HPV-associated 
oral cancers may increase over time in the HIV-population. It is troubling that there is 
already some evidence pointing to this direction (129-132).  
 
Oral HPV-infection in HIV-infected Populations 
 Because cancer is a rare event, much of the work on HPV-associated HNC has 
focused on epidemiologic studies using oral HPV infection as a proxy. In the HIV 
population, the prevalence of oral HPV infection has ranged from 14 to 45% (88, 94, 95, 
128, 133-146). In the United States, where the prevalence of oral HPV infection in the 
general population is 7% (85), the oral HPV prevalence in HIV-positive populations has 
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been 33%, on average (95, 134, 136, 138, 140, 144, 145, 147). The average oral HPV 
prevalence rates among HIV-positive individuals were 28.5% and 26.5% in Italy and 
South Africa, respectively (94, 139, 141, 142). There was one study each in Australia 
and Spain, for which the prevalence was 16% and 19% (146). 
 The prevalence of oncogenic HPV in HIV populations has also varied. In a review 
conducted by Beachler and D'Souza, the prevalence of oncogenic HPV ranged between 
12 and 26% (147). This is significantly higher than the 3.7% observed in the U.S. 
general population (85). Also in the same review, the prevalence of HPV 16, which has 
been found in over 80% of oropharyngeal cancers (80, 84), ranged from not being 
detected at all to as high as 6.1% in the HIV-positive populations (147). Since the 
prevalence of HPV 16 in the U.S. general population is 1% (85), it could imply that HIV-
positive individuals may incur a risk that is as high as six-fold.  
 The risk factors that were previously described to have an association with HNC 
must be taken into account in the investigation of oral HPV infection, especially in HIV-
positive populations. This is because HIV and HPV share similar risk factors for 
infection. An increased number of sexual partners for vaginal, oral, and anal sex has 
been associated with oral HPV infection (85, 95, 133, 134, 136), as well as HPV-
associated HNC (90). Barrier use during oral sex is a protective factor (85). Sexual 
orientation appears to be associated, but the specific sexual preference that is 
responsible for oral HPV infection has not been identified, as the data are conflicting (85, 
94, 136). Smoking (85, 88, 148, 149), alcohol consumption (90), and marijuana use (90) 
that are often associated with risky sexual behaviors are also known to be risk factors 
for oral HPV infection.  
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 As observed in HPV-associated HNCs, oral HPV infection has distinct risk factors 
that are not observed in HPV-negative HNCs.  These risks include male gender (85, 95, 
136), high socioeconomic status (96), and education (96, 150). It remains unclear as to 
why these risks are prominent in oral HPV infection.  
 
HPV Detection 
 As described earlier, there is tremendous heterogeneity in the oral HPV 
prevalence rates. Other than the differences arising from population demographics, risk 
factors, and study design (i.e., cross-sectional, case-control, cohort, or clinical trial), the 
heterogeneity is largely caused by the methods employed in these studies. Sources of 
variability include method of specimen collection, processing methods, and detection 
methods. Regarding specimen collection, oral rinses have an advantage of sampling 
the entire oral cavity, maximizing potential for detection (56, 89, 128, 133, 136, 143, 
151); however, this method offers no information about the site of oral HPV infection. 
Site-specific sampling targets a potential or actual site of oncogenesis, but the 
sensitivity may not be as high (152-154). Detection of oral HPV infection is further 
affected by sample purification method since contaminants that inhibit polymerase chain 
reaction (PCR) could underestimate the prevalence of HPV infection (155).  Finally, 
there is a variety of HPV detection methods that are currently available or in 
development (table 2.1). The use of different approaches has contributed to significant 




Table 2.1. Molecular Diagnostic Methods for HPV Detection.  
Adapted from “Molecular Diagnostics of Human Papillomavirus,” by A. Arney and K. M. 
Bennett, 2010, LabMedicine, 41, p. 523-530. Copyright 2010 by WebMD LLC. Adapted 
with permission. (156) 
 
Test Principle Comments Low-Risk Strains High-Risk Strains 








6, 11, 61, 62, 64, 67, 
69, 72, 81, 89 
16,18, 26, 31, 33, 
35, 39, 40, 42, 45, 
51 to 59, 66, 68, 
73, 82, 83, 84 





followed by line 
hybridization 
CE-Marked for 
use in Europe 
6, 11, 40, 42, 53, 54, 
55, 61, 62, 64, 67, 
69, 70, 71, 72, 81, 
84, IS39, CP6108 
16, 18, 26, 31, 33, 
35, 39, 45, 51, 52, 
56, 58, 59, 66, 68, 






primers at L1 region, 
reverse hybridization 
CE-Marked for 
use in Europe 
6, 11, 40, 43, 44, 54, 
70 
16, 18, 26, 31, 33, 
35, 39, 45, 51, 52, 
53, 56, 58, 59, 66, 









use in Europe N/A 
16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 




of E1 for genotyping; 
PCR/DNA-array 
CE-Marked for 
use in Europe 6, 11, 40, 42, 43, 44 
16, 18, 31, 33, 35, 
39, 45, 51, 52, 53, 
56, 58, 59, 66, 68, 









only 6, 11, 42, 43, 44, 70 
16, 18, 26, 31, 33, 
35, 39, 45, 51, 52, 
53, 56, 58, 59, 66, 
68, 73, 82 
GenoID Real-Time 
HPV Assay (GenoID) 
Target amplification 




use in Europe 
6, 11, 42, 43, 44 
(Lightcycler only) 
16, 18, 31, 33, 35, 
39, 45, 51,52, 56, 
58, 59, 66, 68 
Digene Hybrid 
Capture II (HC2) HR 
HPV DNA Test 
(Digene/Qiagen) 
Signal amplification 




16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 68 
Digene Hybrid 




for detection; hybrid 
capture, semi-
quantitative 
FDA-approved 6, 11, 42, 43, 44 
16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 68 
CareHPV (Qiagen) 
Signal amplification 
for detection; rapid 
test related to HC2 




16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 66, 68 
Cervista HPV HR 
(Hologic) 
Signal amplification 
for detection; Invader 
technology 
FDA-approved N/A 
16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 66, 68 
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CHAPTER 3 
 Study Methods  
Infrastructure of the Study 
 Prior to the inception of the study, collaboration with the following organizations 
was established to enable recruitment of three different populations: The University of 
Michigan (UM) School of Public Health (SPH) Department of Epidemiology; UM Medical 
School Department of Otolaryngology; and UM Division of Infectious Diseases within 
Department of Internal Medicine; and the HIV/AIDS Resources Center (HARC), a 
community-based non-profit organization in Ypsilanti, Michigan. Recruitment, 
enrollment, and data collection described below were performed between May 2012 
and August 2013. Specimen processing, HPV detection, and data management were 
performed in parallel to maximize efficiency. This chapter describes the overall 
framework of study activities that pertain to all aims of this dissertation.  
 
Identification of Study Subjects 
 After IRB approval was obtained, recruitment of study participants took place at 
three different sites: UM HIV/AIDS Treatment Program within the Division of Infectious 
Diseases, HARC, and the School of Public Health. Since each site had its own business 




Recruitment of HIV-infected Patients 
 The following two methods were utilized to recruit HIV-positive participants:  
 1) Active, in-person method: HIV patients were recruited from the UM HIV/AIDS 
Treatment Program within the Division of Infectious Diseases. Health care providers in 
the HIV Clinic informed current and newly diagnosed HIV-seropositive patients of the 
opportunity to participate in the study in compliance with IRB regulation and approval. 
Once patients expressed their interest in participating in the study, they were referred to 
the study staff for further screening for eligibility. (See eligibility criteria below.) 
 2) Passive, in-person method: The recruitment announcements were placed in 
clinic rooms and on the UM clinical research volunteer’s website 
(www.umclinicalstudies.org). (Appendix 1). In this method, potentially interested 
participants who are HIV-positive contacted the Principal Investigator (PI), Mikiko Senga, 
to determine eligibility. If they met the eligibility, the PI arranged to obtain written 
informed consent during their regular visit at the HIV Clinic. 
 Once eligibility was confirmed, informed consent was obtained in a private clinic 
room, and study activities followed. 
 
Individuals Tested HIV-negative 
 Individuals with an HIV-negative test result were recruited using an active, in-
person method. All recruitment activities for this study group took place at HARC. The 
Michigan Department of Community Health (MDCH) requires that any new HIV cases 
be reported for surveillance purposes. Therefore, to maintain compliance with this 
requirement, test counselors at HARC obtained MDCH consent to report any new HIV 
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cases identified through this study to the Michigan State Health Department. Test 
counselors proceeded to perform HIV testing and counseling per HARC's HIV testing 
protocol. Individuals who received an HIV-negative test result were informed by the test 
counselors about the opportunity to participate in the study. Potentially interested 
participants were then referred to the study staff  for more information and to screen for 
their eligibility.  
 Once eligibility was confirmed, informed consent was obtained in a private office 
room, and study activities followed. 
 
Self-reported HIV-negative Individuals 
 Individuals with self-reported HIV-negative status were recruited online. The 
recruitment announcement was posted on the UM clinical research volunteer’s website 
(www.umclinicalstudies.org). As of March 2012, there were over 10,350 potential 
research participants registered in this website. This registry was the chosen method of 
recruitment for this study population because these potentially eligible research 
participants reflected Michigan demographics due to similarities in age, gender, race, 
and ethnicity between Michigan residents and individuals registered on this website.  
 In an active, online recruitment method, the Principal Investigator screened the 
registry for potential study volunteers based on eligibility criteria, and contacted them 
directly to assess their interest in participating. In a passive, online recruitment method, 
interested individuals with the self-reported HIV-negative status contacted the Principal 
Investigator to determine eligibility.  
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 Once eligibility was confirmed, informed consent was obtained in a private room 




 Patients who have been treated in the University of Michigan Health System 
(UMHS) were considered for enrollment if they fulfilled the following eligibility criteria:  
(1) HIV seropositive;  
(2) Age of 18 years or older; and 
(3) Ability and willingness to provide written informed consent.   
 
Individuals Tested HIV-negative 
 Individuals who were tested for HIV through HARC, and had an HIV-negative test 
result were deemed eligible. In addition, the following criteria had to be met:  
(1) HIV seronegative; 
(2) Age of 18 years or older; and 
(3) Ability and willingness to provide written informed consent.   
 
Self-reported HIV-negative Individuals 
 Healthy volunteers, who responded to the online recruitment announcement on 
the UM Clinical Research Volunteer’s website (www.umclinicalstudies.org), were 
considered for enrollment if they fulfilled the following eligibility criteria: 
(1) HIV negative by self report; 
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(2) Age of 18 years or older; and 
(3) Ability and willingness to provide written informed consent.   
 
Consent Process 
 After participant eligibility was confirmed, informed consent was obtained using 
the consent forms approved by UM IRBMED B1 (IRB# HUM00047989). (Appendices 2 
& 3). Participants were informed of the study purpose, overall study design, study 
activities (i.e. specimen collection and survey administration) and corresponding risks 
and benefits, the right to withdraw participation, types of information collected, ways in 
which the information may be used, confidentiality of information, and protection of 
research participants. Participants were given ample time and opportunities to ask 
questions prior to deciding whether or not they wanted to enroll in the study.  
 
Data Collection 
 Data collection consisted of multiple components. During the study visit, 
biological samples (i.e. saliva and oral rinses) were collected. Additionally, a survey was 
administered to each participant to ascertain social and health behaviors. After the 
study visit, HIV-positive participants' medical records were reviewed, and laboratory 
experiments were performed to produce HPV-related data. Each of the aforementioned 





Oral Specimen Collection (All study groups) 
 Saliva was collected by asking participants to expectorate their saliva into 
commercially available kits (i.e. Oragene DISCOVER OGR-500 and Oragene RNA RE-
100). Participants who had difficulty generating saliva were provided with a 2"x2" 
Parafilm square that could be chewed on to stimulate saliva production. After 1mL of 
saliva was collected, the collection tubes were sealed with a cap containing RNA 
stabilizing solution. The kit was designed such that, as the cap screwed onto the 
collection tube, the seal containing RNA stabilizing solution would break, allowing this 
solution and the saliva to mix. The saliva sample was stored at -4˚C until further 
processing.  
 After saliva was collected, oral rinse was collected. Participants were asked to 
swish and gargle 10 mL of SCOPE mouthwash 30 seconds, and then expectorate into a 
sterile, 50 mL conical tube. The oral rinse sample was stored at -4˚C until further 
processing. 
 
Social Behaviors and Family History Survey (All study groups) 
 All study participants were asked to complete a questionnaire that consisted of 
questions related to demographic information, alcohol, tobacco, and other drug use, 
sexual practices, diet, environmental exposures, oral hygiene, general hygiene, cancer 
history, and general health. (Appendices 4 & 5). In addition, HIV patients were asked 
questions related to their HIV disease status, such as CD4 count, viral load, and 
medication adherence. For women, Pap smear history was asked. For men, Pap smear 
history of their current partner was asked. Participants completed the questionnaire in a 
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quiet, private room. They were asked to label their questionnaire with their unique study 
identification number. As an added measure of privacy, the participants were provided a 
manila envelope into which the completed questionnaire was enclosed. For participants 
who could not read, study staff read and recorded responses to survey questions. 
 
Medical Record Abstraction (Only HIV-Patients) 
 IRB approval allowed for collection of selected clinical information that is relevant 
to the oral HPV infection. The information was abstracted from only HIV-positive study 
participants' medical record. The medical record review was conducted only for HIV 
patients because there was no guarantee that participants in other study groups (i.e. 
HARC clients and self-reported HIV-negative individuals from the UM Clinical Research 
Volunteers registry) had been seen in the University of Michigan Health System. Using 
Careweb, the UMHS's electronic medical record system, HIV viral load, CD4 cell count, 
CD4 cell nadir, current HIV medications, sexually transmitted diseases (STD), previous 
cancer diagnosis, and evidence of non-oral HPV-associated diseases were abstracted 
from patients' medical records. 
 
Participant Reimbursement 
 Participants were compensated $10 in cash at the end of the study visit. Cash 
was the chosen method of reimbursement to protect the identity of participants, 






DNA Isolation and Purification 
 The oral rinse specimens were transferred into a 15-mL tube and centrifuged at 
3,000 × g for 10 minutes at 4°C. The supernatant was decanted. The pellet was 
resuspended in 10 mL phosphate-buffered saline (PBS), and centrifugation was 
repeated. The supernatant was pipeted out. The pellet was resuspended in 1 mL 
Puregene Cell Lysis Solution and mixed by inverting 50 times. The sample was 
incubated at 37°C for 15 minutes. After incubation, the sample was digested with 
DNase-free RNase A (5 μg/ml) for 30 minutes at 37°C. Puregene Proteinase K was 
added to a final concentration of 0.5 mg/mL, and mixed by inverting three times. The 
sample was vortexed vigorously at high speed for 20 seconds to mix. The sample was 
digested overnight at 55°C.  
 On the following day, the sample was heat inactivated at 95°C for 10 minutes, 
and was cooled to room temperature. 340 µL of Protein Precipitation solution was 
added to each sample. The sample was vortexed vigorously for 20 seconds at high 
speed. The sample was then incubated for 10 minutes on ice to ensure a tight pellet in 
the next step. The sample was centrifuged for 10 minutes at 2000 x g (3300 rpm). In a 
new 15-mL tube, 1 mL of isopropanol and 2 µL of glycogen solution were combined, 
and the tube was placed on ice. After centrifugation, the supernatant containing the 
DNA was poured into the new 15-mL tube, containing isopropanol and glycogen 
solution, leaving behind the precipitated protein pellet. The samples were mixed by 
inverting gently 50 times. The samples were centrifuged for 5 minutes at 2000 x g (3300 
rpm). The supernatant was carefully discarded, and the tube was drained by inverting 
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on a clean piece of absorbent paper, taking care that the pellet remained in the tube. 
One milliliter of 70% ethanol was added to the tube and inverted several times to wash 
the DNA pellet. The tube was centrifuged for one minute at 2000 x g (3300 rpm). The 
supernatant was carefully discarded. The tube was drained on a clean piece of 
absorbent paper, taking care that the pellet remained in the tube. The tube was air-dried 
for 10 minutes. 50 µL DNA Hydration Solution was added to the tube containing DNA 
and vortexed for 5 seconds at medium speed to mix. The samples were incubated at 
65°C for 1 hour to dissolve the DNA. The samples were incubated at room temperature 
overnight with gentle shaking. Following the overnight incubation, the samples were 
centrifuged briefly and transferred to a 1.5-ml Eppendorf tube and stored at -80°C (1). 
 
Quantification of DNA Concentration 
 To measure DNA concentration, a Qubit® 2.0 Fluorometer (Invitrogen) was used. 
To prepare the samples for measurement, an appropriate volume of Qubit® working 
solution was made by diluting the Qubit® dsDNA BR reagent 1:200 in Qubit® dsDNA 
BR buffer. Then two assay standards were created by aliquoting 190 µL of Qubit® 
working solution into two 0.5-mL PCR tubes and 10 µL of each Qubit® standard (i.e. 
Standard #1 and Standard #2) were added to the appropriate tube. The standards were 
mixed by vortexing a few seconds. The remaining working solution was aliquoted into 
the appropriate number of new 0.5-mL PCR tubes to accommodate the number of DNA 
samples. One microliter of DNA was combined with 199 µL of the working solution in 
each tube to make the volume in each assay tube equal to 200 µL. All sample tubes 
were vortexed for a few seconds and incubated at room temperature for 2 minutes. The 
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samples were read using the Qubit® 2.0 Fluorometer, selecting dsDNA Broad Range as 
the assay type. If a sample had a DNA concentration too low to be quantified with 
Qubit® dsDNA Broad Range assay (i.e. less than 500 ng/mL), the process was 
repeated using Qubit® dsDNA High Sensitive assay. 
 
HPV Detection 
 Isolated DNA was tested for presence and type of HPV using two different 
detection methods: 1) Multiplex PCR MassArray, and 2) PCR followed by sequencing. 
 1) HPV Multiplex PCR MassArray: DNA samples were assayed in quadruplicate 
using a validated, ultra-sensitive method utilizing real-time competitive polymerase 
chain reaction, followed by probe-specific single base extension and matrix-assisted 
laser desorption/ionization-time of flight mass spectroscopy with separation of products 
on a matrix-loaded silicon chip array. Multiplex PCR amplification of the E6 region of 15 
discrete high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 
and 73), 3 low-risk HPV types (HPV 6, 11, and 90), and a human GAPDH control was 
processed to saturation, followed by a shrimp alkaline phosphatase quenching. 
Amplification reactions included synthetic competitor oligonucleotides identical to each 
natural amplicon except for a single nucleotide difference. This method of amplification 
suppressed background and false-positive signal generation. Multiplex single base 
extension reactions employed probes that identified unique sequences in the E6 region 
of each hrHPV type, extending at the single distinguishable base of wild type and 
competitor amplicons. Each hrHPV type and its competitor were recognized by mass in 
assay-defined profiles when analyzed on the MALDI-TOF mass spectrometer (2).   
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 2) HPV-L1-PCR followed by sequencing: Consensus PCR targeting the L1 
region of the HPV viral genome was performed on all DNA samples using PGMY 09/11 
primers (3). Gel electrophoresis was performed with a 1.5% agarose gel containing 0.25 
ug/mL ethidium bromide in 1X TAE buffer at 90V for 80 minutes. The PCR products with 
450bp fragments were purified with QIAquick PCR Purification Kit (Qiagen) according to 
the manufacturer's protocol and were sequenced using Sanger method to identify the 
HPV type. 
 These two detection methods were used because, in theory, the combined 
approach would yield a higher frequency of samples detected. The HPV multiplex PCR 
MassArray is ideal for high throughput testing of multiple samples resulting in immediate 
identification of the HPV types present in each sample. While the use of PGMY 09/11 
L1 consensus primer is currently the gold standard for detection of HPV types not 
represented in the Multiplex assay, it is not as sensitive as HPV Multiplex PCR 
MassArray, and it requires a second sequencing step to identify the HPV type. However, 
since we did not want to restrict HPV detection to the 18 HPV types in the HPV 
Multiplex PCR MassArray, the DNA samples that were detected to contain HPV were 
sequenced. Sequencing, in return, allowed for detection of a wider range of low risk and 
cutaneous HPV types. 
 
Statistical Analysis 
 Prevalence of oral HPV infections was calculated for each study group. The χ2 
test or the Fisher's exact test, where appropriate, was used to test for heterogeneity. 
Logistic regression models were used to estimate odds ratios (ORs) and 95% 
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confidence intervals (CIs) for associations between demographic and exposure 
variables from the survey and medical record abstraction and the presence of oral HPV 
DNA. HPV DNA positivity was defined as any positive test result for at least one of the 
18 genotypes detected by HPV Multiplex PCR MassArray or any HPV genotype 
detected from sequencing. Tests for trend were conducted across ordered groups. 
Variables that were significant in univariate analysis were evaluated in a multiple logistic 
regression model, as were variables that were considered to be relevant based on a 
priori knowledge. The final model was created by the inclusion of variables with 
potential biological significance, as well as those that remained statistically significant 
after adjustment. P-values less than 0.05 were considered statistically significant, and 
all p-values reported were 2-sided. All analyses were performed using SAS version 9.3 
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CHAPTER 4 
 HIV-Infected Individuals Are at Increased Risk of Oral HPV Infection: 
Findings from the Epidemiology of Papillomavirus Infections Study 
  
Abstract 
Background: Recent studies have shown that human papillomavirus (HPV) is an 
etiologic agent for oropharyngeal squamous cell carcinomas (OPSCC). Although 
individuals with HIV are presumably at increased risk of developing OPSCC, it is 
unknown to what extent the HIV status contributes to acquisition, persistence, and/or 
recurrent oral HPV infections. This study was conducted to investigate whether HIV-
positive individuals are more likely to be infected with oral HPV compared to HIV-
negative individuals.  
Methods: Participants were recruited to form three study groups: 1) HIV-positive 
patients seen at the University of Michigan Health System; 2) HIV-negative individuals 
tested at an HIV screening clinic; and 3) self-reported HIV-negative individuals from 
Washtenaw and neighboring counties in Michigan. Oral rinse samples were collected 
from participants and were tested for presence and type of HPV DNA with PGMY09/11 
primers and Sanger sequencing. In addition, HPV type and copy number were 
examined by HPV MultiPlex PCR-MassArray for 15 discrete high-risk HPV types (HPV 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 73) and 3 low-risk HPV types 
(6, 11, and 90). Study participants completed a survey to ascertain medical, social, and 
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behavioral risk factors. Clinical information pertaining to HIV disease status was 
collected for HIV-infected patients.  
Results: A total of 266 community-based participants (107 HIV-infected, 69 tested HIV-
negative, and 90 self-reported HIV-negative) were enrolled. The overall crude 
prevalence of oral HPV DNA was 10.5%. The HIV-infected group had the highest 
prevalence (20.1%), followed by the self-reported HIV-negative group (5.6%) and the 
HIV-negative group that received HIV testing (1.4%). Male partner's circumcision status 
was significantly associated with oral HPV infection. Among the HIV patients, higher 
viral load was associated with increased risk of oral HPV infection. 
Conclusion: The data supports previous findings that prevalence of oral HPV infection 
is higher in HIV-positive individuals compared to HIV-negative individuals. 
 
Introduction 
 Human papillomavirus (HPV) is an etiologic agent that is associated with a 
subset of head and neck cancers, specifically oropharyngeal squamous cell carcinomas 
(OPSCC) (1-5). In the United States, the incidence of oropharyngeal cancer is expected 
to surpass the incidence of cervical cancer by 2020 (6). It is hypothesized that the lack 
of validated screening method for oral cancer and changes in sexual behavior are 
responsible for the shift in this trend. However, the natural history of oral HPV infection 
is not well understood, and independent risk factors for oral HPV infection remain 
unexplored. 
 Compared to the general population, in which the prevalence of male and female 
oral HPV infection has been estimated to be approximately 7% and 1%, respectively (7), 
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oral HPV detection rates in HIV-positive individuals appear to be greater, with 
prevalence ranging from 14 to 39 % (8-13). The elevated risk of oropharyngeal cancer 
among HIV-infected individuals may be due to higher rates of tobacco and alcohol use 
(8, 14-16), the shared sexual risk factors between HIV and HPV, and sexual 
preferences (9, 12, 13, 17, 18). While severity of immunosuppression appears to be a 
risk factor (9, 10, 12), reductions in HPV-related malignancies or oral HPV prevalence in 
the post-HAART era have not been observed (10, 19-21).  
 To date, the majority of studies comparing oral HPV infection rates between HIV-
positive and HIV-negative populations have been performed in inner-city populations. 
To expand knowledge about oral HPV infection in other populations, we investigated the 
prevalence and type distribution of oral HPV infection, and identified risk factors for oral 
HPV infection among HIV-positive and HIV-negative individuals in a midwestern college 
population that has relatively high educational and socioeconomic status. To our 
knowledge, this is the first study to compare oral HPV prevalence in HIV-positive 




 We conducted a cross-sectional study between May 2012 and August 2013 to 
examine the prevalence of oral HPV infection in an HIV-infected population compared to 
two different HIV-negative populations with different risk factors for HIV acquisition. HIV-
infected patients were recruited from the HIV/AIDS Treatment Program at the University 
of Michigan. To form a comparable HIV-negative group with similar risk factors, 
50 
 
individuals who referred themselves for screening and tested HIV-negative were 
recruited at a community health organization (HIV/AIDS Resources Center in Ypsilanti, 
MI [HARC]). In addition, self-reported HIV-negative individuals in Washtenaw County, 
Michigan, and surrounding counties were recruited through the University of Michigan's 
Clinical Studies electronic registry. For all study groups, partners of index study 
participants were recruited and enrolled whenever this was possible. The study was 
approved by the Institutional Review Board of the University of Michigan Medical School 
(application number HUM00047989), and written informed consent was obtained from 
all participants.  
 
Social Behaviors and Family History Survey (All study groups) 
 All study participants were asked to complete a questionnaire that consisted of 
questions related to demographic information, alcohol, tobacco, and other drug use, 
sexual practices, diet, environmental exposures, oral hygiene, general hygiene, cancer 
history, and general health. In addition, HIV-infected patients were asked questions 
related to their HIV disease status, such as CD4 cell count, HIV viral load, and 
medication adherence. For women, Pap smear history was asked. For men, Pap smear 
history of their current partner (if female) was asked. Few men had received anal pap 
smears. 
 
Medical Record Abstraction (HIV-infected Patients) 
 Selected clinical information that is relevant to oral HPV infection was abstracted 
from the medical records. The information was abstracted from only HIV-infected study 
51 
 
participants' medical records. The medical record review was conducted only for HIV 
patients because there was no guarantee that participants in other study groups (i.e. 
HARC clients and self-reported HIV-negative individuals from the UM Clinical Research 
Volunteers registry) had been seen in the University of Michigan Health System. Using 
Careweb, the UMHS's electronic medical record system, HIV viral load, CD4 cell count, 
CD4 cell nadir, current HIV medications, sexually transmitted diseases (STD), previous 
cancer diagnosis, and evidence of non-oral HPV-associated diseases were abstracted 
from patients' medical records. 
 
Specimen Collection (All study groups) 
 Oral rinse samples were collected from study participants using a validated 
method as previously described (22). Ten mL of mouthwash was swished and gargled 
for 30 seconds, and expectorated into a sterile tube. Specimens were refrigerated at 
4°C until processed. The oral rinse samples were centrifuged at 3,000g for 10 min at 
4°C. The supernatant was decanted, and the pellet was resuspended in 10 ml of 
phosphate-buffered saline. The centrifugation was repeated and DNA isolation 
immediately followed. 
 
DNA Isolation (All study groups) 
 DNA was extracted using Puregene DNA Purification Kit according to the 
manufacturer's protocol. This kit was chosen because it has been shown that other 
methods have resulted in a greater loss of DNA during the purification process. These 
methods included: proteinase K digestion (PKD) and heat inactivation; PKD and ethanol 
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precipitation (EP); PKD, phenol-chloroform extraction, and EP; and the QIAamp DNA 
Blood Midi kit. In addition, DNA obtained from these methods may result in PCR 
inhibition (23). Replicate study Isolated DNA was stored at -80°C until HPV detection 
and genotyping were conducted. 
 
HPV Detection (All study groups) 
 Isolated DNA was tested for presence and type of HPV using two different 
detection methods: 1) Multiplex PCR MassArray, and 2) PCR followed by sequencing. 
 1) HPV Multiplex PCR MassArray: DNA samples were assayed in quadruplicate 
using a validated, ultra-sensitive method utilizing real-time competitive polymerase 
chain reaction, followed by probe-specific single base extension and matrix-assisted 
laser desorption/ionization-time of flight mass spectroscopy with separation of products 
on a matrix-loaded silicon chip array. Multiplex PCR amplification of the E6 region of 15 
discrete high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 
and 73), 3 low-risk HPV types (HPV 6, 11, and 90), and a human GAPDH control was 
processed to saturation, followed by shrimp alkaline phosphatase quenching. 
Amplification reactions included synthetic competitor oligonucleotides identical to each 
natural amplicon except for a single nucleotide difference. This suppressed background 
and false-positive signal generation. Multiplex single base extension reactions 
employed probes that identified unique sequences in the E6 region of each hrHPV type, 
extending at the single distinguishable base of wild type and competitor amplicons. 
Each hrHPV type and its competitor were recognized by mass in assay-defined profiles 
when analyzed on the (Matrix Assisted Laser Desorption Ionization-Time of Flight) 
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MALDI-TOF mass spectrometer (24) thus identifying the presence and type of  HPV in 
the sample.   
 2) HPV-L1-PCR followed by sequencing: Consensus PCR targeting the L1 
region of the HPV viral genome was performed on all DNA samples using PGMY 09/11 
primers (25). Gel electrophoresis was performed with a 1.5% agarose gel containing 
0.25 ug/mL ethidium bromide in 1X TAE buffer at 90V for 80 minutes. The PCR 
products with 450bp fragments were purified with QIAquick PCR Purification Kit 
(Qiagen) according to the manufacturer's protocol and were sequenced using Sanger 
method to identify the HPV type. 
 HPV types detected from these two detection methods were categorized into 
high-risk (oncogenic) and low-risk (non-oncogenic) types according to the classification 




 Prevalence of oral HPV infections was calculated for each study group. The 
demographic characteristics of HIV-positive and HIV-negative groups were compared 
using χ2 test or the Fisher's exact test, where appropriate, for categorical variables, 
whereas ANOVA was used for continuous variables. Logistic regression models were 
used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations 
between demographic and exposure variables from the survey and medical record 
review and the presence of oral HPV DNA. HPV DNA positivity was defined as any 
positive test result for at least one of the 18 genotypes detected by HPV Multiplex PCR 
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MassArray or any HPV genotype detected from sequencing. Tests for trend were 
conducted across ordered groups. Variables that were significant in univariate analysis 
were evaluated in multiple logistic regression models. Variables that were considered to 
be relevant based on a priori knowledge were also included. The final multivariate 
model for the overall study included gender, lifetime number of vaginal sex partners, 
and male partner circumcision. Study group could not be included in the final 
multivariate model because of small numbers of HPV detected in the "tested HIV-
negative" and the "self-reported HIV-negative" groups. An attempt was made to include 
HIV status in the final multivariate model; however, the number of HPV detected in the 
HIV-negative population was still too small, even after combining the two HIV-negative 
groups. For the HIV-infected group, the final multivariate model included gender, lifetime 
number of vaginal sex partners, male partner circumcision status, and HIV RNA load. 
Because such a small number of HPV-positive individuals was detected in the HIV-
negative groups, meaningful models could not be created after stratification. Therefore, 
separate multivariate models were created for all three study groups combined. The 
final multivariate model for this included gender, lifetime number of vaginal sex partners, 
and male partner circumcision status. P-values less than 0.05 were considered 
statistically significant, and all p-values reported were 2-sided. All analyses were 







 A total of 266 individuals participated in the study, 107 of whom were HIV-
infected patients, 69 who tested HIV-negative, and 90 self-reported HIV-negative 
individuals. The characteristics of the study population, stratified by study site, are 
shown in table 1. All three study groups were primarily White (>50%). While HIV-
positive and self-reported HIV-negative groups were similar in median age (47 years vs. 
45 years, respectively), the "tested HIV-negative" group was considerably younger (28 
years). A majority of HIV-positive and "tested HIV-negative" groups were male, while 
self-reported HIV-negative had a roughly equal proportion of male and female 
participants. Overall, participants were well-educated, with more than 85% having 
completed high school. The HIV-positive group was more likely to have smoked 
cigarettes at least once (60%) and to currently smoke marijuana. The highest proportion 
of current drinkers was among "tested HIV-negative" individuals. 
 Table 2 describes characteristics related to sexual behavior. In the HIV-positive 
group, nearly 70% of men were men who have sex with men (MSM) and 16% were 
bisexual, whereas all 18 women were heterosexual. In the "tested HIV-negative" group, 
a majority of men (61%) were also MSM, and a majority of women reported being 
heterosexual. Both self-reported HIV-negative men and women were predominantly 
heterosexual. HIV-positive men reported the youngest average age at first anal 





Prevalence of HPV DNA by Study Group 
 Two hundred sixty six oral rinses were collected. To date, all 266 have been 
tested for HPV infection using PGMY 09/11 L1 consensus primers. These samples 
were determined as evaluable based on the presence of β-globin. Of these 266 
samples, 228 (105 HIV-positive, 52 tested HIV-negative, and 71 self-reported HIV-
negative) were also tested for HPV infection via multiplex PCR MassArray. The 
remainder has not been tested due to time constraints. With the PGMY and PCR 
MassArray results combined, oral HPV infections were detected in 20.1% (22/107) of 
HIV-positive individuals, 1.4% (1/69) of individuals that tested HIV-negative, and 5.6% 
(5/90) of self-reported HIV-negative individuals. The overall prevalence of oral HPV 
infection in the study was 10.5% (table 3). Eight individuals had more than one HPV 
type. Of the 28 HPV DNAs detected in the oral rinses from the whole group, 75% 
(21/28) were high-risk, and 14.3% (4/28) were low-risk types. In the HIV-positive group, 
75% (17/22) of HPV DNAs detected were high-risk HPV types (hrHPV) while 14% 
(3/22) were low-risk HPV types (lrHPV). The remaining 27% (4/22) were unclassifiable 
because they are not known to belong to either category at this present time (26-28). 
These percentages exceed 100% because there were six HIV-positive individuals who 
were infected with more than one HPV type. Of the hrHPV types detected in this study 
group, 59% (10/17) were HPV 16. In the "tested HIV-negative" group, the only HPV-
positive case that was detected was not a mucosal high-risk or low-risk type. In the self-
reported HIV-negative group, 80% (4/5) oral HPVs were hrHPV while 20% (1/5) were 
lrHPV. There was also one sample that contained and unclassifiable HPV type and also, 
contained HPV type 31. Of 28 HPV-positive samples, 24 were detected by multiplex 
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PCR MassArray, and 4 additional samples were detected by L1 PCR and sequencing. 
Two of 28 DNA-positive samples were type-concordant between two detection methods 
(data not shown). In all study groups, HPV was detected more frequently in males.   
 As shown in table 4, gender, lifetime number of vaginal sex partners, and male 
partner circumcision were associated with oral HPV infection in univariate analysis. The 
odds of oral HPV infection were significantly higher among men (OR, 3.6; 95% CI, 1.1-
12.4). The odds of oral HPV infection were significantly higher with increasing number 
of vaginal sex partners (OR, 3.4; 94% CI, 1.53-7.69). Having an uncircumcised male 
partner significantly increased the odds of oral HPV infection by nearly four-fold (OR, 
3.93, 95% CI, 1.36-11.39). Alcohol use, which was marginally significant, had a 
protective effect against oral HPV infection (p=0.058, for trend). In addition to these 
factors, among HIV-positive individuals, the odds of oral HPV infection significantly 
increased with increasing HIV viral load (p=0.041, for trend) (table 5). 
 In multivariate analysis, the only variable that was significantly associated with 
oral HPV infection was male partner circumcision (table 6). In the HIV-positive group, 
having an uncircumcised partner significantly elevated the odds of oral HPV infection 
(OR, 4.54; 95% CI, 1.44-14.31). Similarly, in the overall study, the same variable 
increased the risk of oral HPV infection (OR, 3.85; 95% CI,1.28-11.56). The odds of oral 
HPV infection with increasing lifetime number of vaginal sex partners were marginally 
significant in both the HIV-positive group (OR, 3.12; 95% CI, 0.85-11.53) and the study 
as a whole (OR, 2.91; 95% CI, 0.82-10.35). Among HIV-positive individuals, the odds of 
oral HPV infection tended to increase with higher viral load, specifically over 100,000 
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copies/µl (OR, 16.24; 95% CI, 0.88-305.08); this relationship was marginally significant 
(p=0.063). 
 
Concordance between Sexual Partners 
 Fourteen couples participated in the study. The characteristics of the couples and 
their HPV status are shown in table 7. Of the 14 couples, oral HPV infection was 
detected in only one pair. Both partners were HIV-positive and MSM. The partners' HPV 
DNA genotypes were not concordant, with partner A having three different types (HPV 
32, 42, and 66) while partner B had four different types (HPV 13, 16, 52, and 74). 
 
Discussion 
 In the present cross-sectional study, HIV-positive individuals are significantly at 
increased risk of oral HPV infection compared to HIV-negative individuals. The 
prevalence of 20.1% in the HIV-positive group was within the range of previously 
reported HPV detection rates in HIV-positive populations, although this study was on 
the lower end of the spectrum (8-13, 17, 21, 29-38). In addition, hrHPV was more 
prevalent in the HIV-positive group than in HIV-negative groups. In this study, 
prevalence of hrHPV among HIV-positive individuals was 15.9%, which was in line with 
previous literature (9, 12, 29, 30, 34). Also consistent with the literature, HPV 16 was 
the most commonly detected hrHPV type (7-9, 12, 13, 21). However, provided that the 
prevalence of oral HPV 16 among HIV-infected adults has ranged from 0 to 6.1%, at 
9.3%, the prevalence of HPV 16 in our study was the highest ever reported in an HIV-
positive population (39). In contrast, the prevalence of lrHPV among HIV-positive 
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individuals (4.4%) was considerably lower than previously reported (8, 10, 11, 31). In 
addition to the classified hrHPV and lrHPV mucosal types (26-28), we detected 12 other 
HPV types that are considered mucosal and/or cutaneous from sequencing.  
 Given that we utilized two highly robust methods of HPV detection that included 
sequencing, it is unclear as to why the prevalence of oral HPV infection in our HIV-
positive group is in the lower margin of previously reported prevalence ranges among 
HIV-positive populations in the United States, yet the prevalence of HPV 16 in the oral 
cavity of our HIV-positive patients is the highest documented. Since reduced CD4 count 
is associated with increased oral HPV prevalence (9, 12, 21, 29), the relatively low 
prevalence of oral HPV infection in our HIV-positive group may be explained by the 
larger proportion of immunocompetent HIV-positive patients who are very adherent with 
their antiviral medication regimens.  
 Despite the low overall prevalence of oral HPV infection in our HIV-positive 
individuals, a high prevalence of oral HPV 16 was observed. To explain the high 
prevalence of oral HPV 16, we hypothesize this may be partly due to risky behaviors 
practiced among MSM, specifically anal-to-oral sex. It has been shown that prevalence 
of genital HPV 16 is high among MSM (34, 40, 41). Our findings did not support an 
association between oral HPV infection and oral or anal sex as well as corresponding 
number of partners. Likewise, the lack of condom use for these behaviors was not 
associated with oral HPV infection. Since anal-to-oral sex was not assessed in this 
study, this could be an area that could be further explored.  
 This study compared oral HPV prevalence in HIV-positive individuals with the 
use of two HIV-negative reference groups. Due to the small sample size, we could not 
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stratify the HIV-negative groups to thoroughly assess risk factors. However, it is 
important to note that higher oral HPV prevalence was observed among self-reported 
HIV-negative individuals than those who tested HIV-negative. This observation is 
counter-intuitive because one would expect that the "tested HIV-negative" group would 
be at higher risk since it is assumed that those who voluntarily seek out HIV testing 
must have had some level of risk to seek testing. However, it is quite possible that this 
group that was presumed to be of high risk may actually be the more conscientious 
group (e.g., repeat testers for HIV who had more exposure to sexual health education) 
compared to the self-reported HIV-negative group. Therefore, assessing knowledge and 
attitudes regarding sexual health could have explained this difference. In addition, the 
"tested HIV-negative" group was considerably younger than the HIV-positive group and 
the "self-reported HIV-negative" group. Oral HPV infection has been associated with 
increasing age (7). The younger average age of the "tested HIV-negative" group could 
explain the lower prevalence of the infection in this group compared to the "self-reported 
HIV-negative" group. 
 In reviewing the overall study findings, several factors that have previously been 
associated with oral HPV infection were not found to be significant in this study. For 
example, tobacco smoking, which was associated with oral HPV infection in a few 
studies (7, 17, 42), was not associated in the study, most likely due to a small number of 
heavy smokers in a study that consisted of 266 participants. Further, in previous 
studies, men had higher risk of oral HPV infection than women (6, 12, 43). However, we 
did not observe this in our study, nor did we observe an association between oral HPV 
infection and previously reported factors, including oral or anal sex (7, 8, 12, 17, 44); 
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corresponding number of partners (7, 9, 12, 29, 30); condom use for these sexual 
behaviors (7); sexual orientation (29, 31, 34, 45, 46); and open-mouth kissing (17, 47). 
Surprisingly, alcohol consumption had a protective effect against oral HPV infection 
although this association was not statistically significant. This effect was possibly driven 
by the larger proportion of drinkers in the "tested HIV-negative" group which incidentally 
was our youngest study group since risk of oral HPV infection is associated with 
increasing age (7, 12, 17). Alternatively, to explain a similar finding, Pickard and 
colleagues (47) cited that alcohol may denature HPV viral capsid and prevent infection 
(47, 48).  
 To our knowledge, this is the first study to report an association between oral 
HPV infection and male partner circumcision. Lack of circumcision has been associated 
with penile cancers (49-53), and 95% of penile cancers are squamous cell carcinoma, 
of which HPV accounts for 22 to 66% (49). Lack of circumcision has been associated 
with HIV transmission in the African continent, leading public health experts to propose 
adult male circumcision as a means of intervention (54-56). Given the reported 
association between oral sex and oral HPV infection (7, 12, 17), our finding implies that 
circumcision could also reduce HPV transmission by removing the likely penile reservoir 
for HPV. 
 There are a few limitations. The most obvious is the total sample size and power, 
limiting the analysis of stratification by study group to compare oral HPV risk factors. 
Second, the cross-sectional design did not allow us to establish a temporal relationship. 
Third, the convenience sample of well-controlled HIV-positive patients at the University 
of Michigan and HIV-negative individuals from Washtenaw county and surrounding 
62 
 
counties is dissimilar to the types of urban populations frequently studied in the United 
States.  
 Despite these limitations, our study has notable strengths. The study may 
represent middle America more appropriately; there was little variation in the HIV-
positive population based on stable HIV disease status; and yet we still observed much 
higher incidence of oral HPV infection in this population. Our data is consistent with 
significantly previous reports of higher risk of oral HPV infection in HIV-positive 
individuals than in HIV-negative individuals (ref).  Whether this is due to HIV status 
increasing risk of infection or to other risk factors is unknown.  This is the first study to 
report that male circumcision may play a role in the transmission of oral HPV infection. 
Future studies will improve the understanding of risk factors for oral HPV infection, and 
should be carried out in a variety of populations to better investigate those factors 
associated with HPV-associated cancer. Ultimately developing specific preventative 
strategies to prevent oral HPV infection and developing screening tools may be of 




Table 4.1: Characteristics of the Enrolled Study Population, by Study Group 
 
Characteristics Overall HIV+ Tested HIV- Self-reported HIV- 
           n  %           n       %      n       % 
Total 266 107 40.2 69 26.0 90 33.8 
 
Gender 
       
    Female 75   18 16.8 18 26.1 39 43.3 
    Male 191   89 83.2 51 73.9 51 56.7 
        
Age (median) 41.5 47 (19-75) 28 (18-83) 45 (18-83) 
    Female 41 52.5 (33-63) 32 (19-64) 45 (18-83) 
    Male 45 46 (19-75) 26 (18-83) 44 (19-82) 
        
Race        
    Asian 12 1 0.93 5 7.25 6 6.67 
    Black 53 31 28.97 13 18.84 9 10.00 
    Hispanic 5 4 3.74 1 1.45 0 0.00 
    Native American 2 1 0.93 0 0.00 1 1.11 
    White 165 63 58.88 37 53.62 65 72.22 
    Other 24 4 3.74 12 17.39 8 8.89 
    Unknown 5 3 2.80 1 1.45 1 1.11 
        
Education        
    < High school 18 12 11.21 3 4.41 3 3.33 
    High school graduate 55 23 21.50 16 23.53 16 17.78 
    Some college 88 39 36.45 21 30.88 28 31.11 
    College graduate 55 24 22.43 10 14.71 21 23.33 
    Advanced degree 45 7 6.54 16 23.53 22 24.44 
    Unknown 4 2 1.86 2 2.94 . . 
        
Marital Status        
    Married 56 19 17.76 4 5.80 33 36.67 
    Living as married 22 10 9.35 4 5.80 8 8.89 
    Single 145 61 57.01 52 75.36 32 35.56 
    Widowed 8 4 3.74 1 1.45 3 3.33 
    Divorced 33 12 11.21 8 11.59 13 14.44 
    Unknown 2 1 0.93 . . 1 1.11 
        
Place lived longest        
    USA 246 101 94.39 61 88.41 84 93.33 
    Other countries 15 4 3.74 6 8.70 5 5.56 
    Unknown 5 2 1.87 2 2.90 1 1.11 
        
Tobacco use        
    Current smoker 55 27 25.23 18 26.09 10 11.11 
    Former smoker 77 36 33.64 11 15.94 30 33.33 
    Never smoker 133 43 40.19 40 57.97 50 55.56 
    Unknown 1 1 0.93 . 0.00 . 0.00 
        
Alcohol use        
    Current drinker    166 59 55.14 53 76.81 54 60.00 
    Former drinker 75 38 35.51 9 13.04 28 31.11 
    Never drinker 23 10 9.35 6 8.70 7 7.78 
    Unknown 2       . . 1 1.45 1 1.11 
        
Marijuana use        
    Current user 60 34 31.78 19 27.54 7 7.78 
    Former user 93 35 32.71 22 31.88 36 40.00 
    Never user 113 38 35.51 28 40.58 47 52.22 
        
Other substance use        
    No 245 96 89.72 62 89.86 87 96.67 
    Yes 19 11 10.28 7 10.14 1 1.11 
       Cocaine 10 7 N/A 2 N/A 1 N/A 
       Heroin 1 1 N/A 0 N/A 0 N/A 
    Unknown 2 0 0.00 0 0.00 2 2.22 
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Table 4.2: Characteristics Related to Sexual Behavior, by Study Group  
 
 HIV+ Tested HIV- Self-reported HIV- 
Characteristics M F M F M F 
 n (%) n (%) n (%) n (%) n (%) n (%) 
 
Sexual Preference       
    Sex with men 62(69.66) 18(100.00) 31(60.78) 15(83.33) 5(9.80) 38(97.44) 
    Sex with women 13(14.61) 0(0.00) 16(31.37) 0(0.00) 43(84.31) 1(2.56) 
    Sex with men and women 14(15.73) 0(0.00) 4(7.84) 3(16.67) 2(3.92) 0(0.00) 
    Unknown 0(0.00) 0(0.00) 0(0.00) 0(0.00) 1(1.96) 0(0.00) 
       














       
Lifetime number of vaginal sex 
partners       
    0-5 70(78.65) 16(88.89) 39(76.47) 17 (94.44) 25(49.02) 38(97.44) 
    ≥ 6 19(21.35) 2(11.11) 12(23.53) 1(5.56) 26(50.98) 1(2.56) 
       
Condom use during vaginal sex       
    Never 21(23.60) 2(11.11) 5(9.80) 3(16.67) 7(13.73) 5(12.82) 
    Rarely 14(15.73) 6(33.33) 6(11.76) 4(22.22) 13(25.49) 12(30.77) 
    Most of the time 20(22.47) 7(38.89) 11(21.57) 6(33.33) 24(47.06) 11(28.21) 
    All the time 10(11.24) 2(11.11) 8(15.69) 4(22.22) 2(3.92) 4(10.26) 
    Unknown 24(26.97) 1(5.56) 21(41.18) 1(5.56) 5(9.80) 7(17.95) 
       














       
Lifetime number of oral sex 
partners       
    0-5 80(89.89) 18(100.00) 40(78.43) 17(94.44) 31(60.78) 38(97.44) 
    ≥ 6 9(10.11) 0(0.00) 11(21.57) 1(5.56) 20(39.22) 1(2.56) 
       
Condom use during oral sex       
    Never 57(64.04) 9(50.00) 38(74.51) 9(50.00) 38(74.51) 24(61.54) 
    Rarely 21(23.60) 2(11.11) 9(17.65) 6(33.33) 3(5.88) 6(15.38) 
    Most of the time 7(7.87) 0(0.00) 1(1.96) 1(5.56) 2(3.92) 0(0.00) 
    All the time 1(1.12) 1(5.56) 1(1.96) 0(0.00) 0(0.00) 0(0.00) 
    Unknown 3(3.37) 6(33.33) 2(3.92) 2(11.11) 8(15.69) 9(23.08) 
       














       
Lifetime number of anal sex 
partners       
    0-5 89(100.00) 18(100.00) 48(94.12) 18(100.00) 50(98.04) 39(100.00) 
    ≥ 6 0(0.00) 0(0.00) 3(5.88) 0(0.00) 1(1.96) 0(0.00) 
       
Condom use during anal sex       
    Never 10(11.24) 5(27.78) 4(7.84) 5(27.78) 8(15.69) 7(17.95) 
    Rarely 30(33.71) 3(16.67) 10(19.61) 2(11.11) 2(3.92) 2(5.13) 
    Most of the time 32(35.96) 0(0.00) 20(39.22) 3(16.67) 5(9.80) 0(0.00) 
    All the time 9(10.11) 0(0.00) 10(19.61) 1(5.56) 7(13.73) 1(2.56) 
    Unknown 8(8.99) 10(55.56) 7(13.73) 7(38.89) 29(56.86) 29(74.36) 
       














       
Lifetime number of kissing 
partners       
    0-5 70 (78.65) 18(100.00) 30(58.82) 16(88.89) 23(45.10) 37(94.87) 







Table 4.3: HPV Prevalence and Type Distribution, by Study Group 
 
 
*The number of individuals with oral HPV infection, using which the prevalence was calculated. There were 6 persons in HIV+ 
group, 1 person in HIV- group, and 1 person in self-reported HIV- group who were infected with more than one HPV type. The rest 
of the table show HPV type distribution and corresponding prevalence. 
  
 Overall (n=266) HIV+ (n=107) Tested HIV- (n=69) Self-reported HIV- (n=90) 







All 28* 10.5 22* 20.1 1* 1.4 5* 5.6 
  Male    25 9.4 19 17.8 1 1.4 5 5.6 
  Female  3 1.1 3 2.8 0 0.0 0 0.0 
High-risk 
mucosal 21* 7.9 17* 15.9 0 0.0 4* 4.4 
16 13 4.9 10 9.3 0 0.0 3 3.3 
18 1 0.4 1 0.9 0 0.0 0 0.0 
31 1 0.4 0 0.0 0 0.0 1 1.1 
33 2 0.8 2 1.9 0 0.0 0 0.0 
39 1 0.4 1 0.9 0 0.0 0 0.0 
52 1 0.4 1 0.9 0 0.0 0 0.0 
56 1 0.4 1 0.9 0 0.0 0 0.0 
58 1 0.4 1 0.9 0 0.0 0 0.0 
59 1 0.4 1 0.9 0 0.0 0 0.0 
Low-risk 
mucosal 4* 1.5 3* 2.8 0* 0.0 1* 1.1 
6 2 0.8 1 0.9 0 0.0 1 1.1 
11 1 0.4 1 0.9 0 0.0 0 0.0 
42 2 0.8 2 1.9 0 0.0 0 0.0 
53 1 0.4 1 0.9 0 0.0 0 0.0 
66 1 0.4 1 0.9 0 0.0 0 0.0 
70 1 0.4 1 0.9 0 0.0 0 0.0 
Other  8* 3.0 6* 5.6 1* 1.4 1* 1.1 
2 1 0.4 1 0.9 0 0.0 0 0.0 
2a 1 0.4 1 0.9 0 0.0 0 0.0 
13 1 0.4 1 0.9 0 0.0 0 0.0 
27 1 0.4 1 0.9 0 0.0 0 0.0 
27b 1 0.4 1 0.9 0 0.0 0 0.0 
32 1 0.4 2 1.9 0 0.0 0 0.0 
44 1 0.4 0 0.0 1 1.4 0 0.0 
55 1 0.4 0 0.0 1 1.4 0 0.0 
57b 1 0.4 1 0.9 0 0.0 0 0.0 
74 1 0.4 1 0.9 0 0.0 0 0.0 
90 2 0.8 1 0.9 0 0.0 1 1.1 
107 1 0.4 1 0.9 0 0.0 0 0.0 
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Table 4.4: Risk Factors for Oral HPV Infection, Univariate Analysis 
 
Variable Univariate OR (CI) Variable Univariate OR (CI) 
Sex  Condom use during oral sex  
    Female REF     Most of the time REF 
    Male 3.61 (1.06-12.36)     Rarely 0.92 (0.17-5.11) 
    p-value 0.028     Never 0.45 (0.09-2.28) 
Current age (in years)       p for test for trend 0.128 
    < 30 REF Age at first anal sex  
    30-39 1.18 (0.30-4.64)     ≥ 18 REF 
    40-49 1.90 (0.57-6.35)     < 18 0.86 (0.45-2.17) 
    50-59 3.78 (1.20-11.90)     p-value 0.704 
    ≥ 60 0.72 (0.13-3.87) Lifetime number of anal sex partners  
    p for test for trend 0.324     0 REF 
Tobacco use      1-3 1.26 (0.43-3.70) 
    Never smoker REF     ≥ 4 1.32 (0.39-4.89) 
    Former smoker 1.51 (0.62-3.67)     p for test for trend 0.648 
    Current smoker 1.24 (0.44-3.48) Condom use during anal sex  
    p for test for trend 0.54     All the time REF 
Second-hand smoking       Most of the time 3.57 (0.42-30.49) 
    No REF     Rarely 6.07 (0.73-50.76) 
    Yes 0.52 (0.22-1.27)     Never 3.09 (0.33-30.49) 
    p-value 0.279     p for test for trend 0.358 
Alcohol use  Age at first kiss  
    Never drinker REF     ≥ 16 REF 
    Former drinker 0.49 (0.15-1.65)     < 16 1.41 (0.64-3.10) 
    Current drinker 0.33 (0.11-1.03)     p-value 0.387 
    p for test for trend 0.065 Lifetime number of kissing partners  
Age at first vaginal sex      0-5 REF 
    ≥ 16 REF     ≥ 6 1.88 (0.83-4.23) 
    < 16 1.72 (0.78-3.78)     p-value 0.124 
    p-value 0.179 Male partner circumcision  
Lifetime number of vaginal sex partners      Yes REF 
    0-5 REF     No 3.93 (1.36-11.39) 
    ≥ 6 3.43 (1.53-7.69)     p-value 0.011 
    p-value 0.002 Study group  
Condom use during vaginal sex      Self-reported HIV- REF 
    All the time REF     Tested HIV- 0.25 (0.03-2.19) 
    Most of the time 0.74 (0.17-3.17)     p-value 0.211 
    Rarely 1.76 (0.44-7.07)     HIV positive 4.40 (1.59-12.16) 
    Never 1.46 (0.36-6.36)     p-value 0.004 
    p for test for trend 0.270 Sexual Preference*  
Age at first oral sex      Sex with women REF 
    ≥ 16 REF     Sex with men 1.12 (0.43-2.89) 
    < 16 1.78 (0.81-3.92)     p-value 0.821 
    p-value 0.150     Sex with men and women 2.66 (0.76-9.32) 
Lifetime number of oral sex partners      p-value 0.124 
    0-5 REF   
    ≥ 6 1.93 (0.77-4.89)   
    p-value 0.158   
    
    




Table 4.5: Characteristics Related to HIV Disease Status and Risks Associated with Oral HPV 
Infection, Univariate Analysis  
 
Characteristics N % Univariate OR (CI) 
    
Nadir CD4 count (cells/µl), median (IQR) 553  (389-847)  
    ≥ 200 72 (69.90) REF 
    < 200 31 (30.10) 1.86 (0.70-4.95) 
    p-value   0.216 
CD4 count (cells/µl), median (IQR) 553  (389-847)  
    ≥ 200 103  (88.35) REF 
    < 200 12 (11.65) 1.32 (0.27-6.54) 
    p-value   0.734 
HIV viral load (copies/µl), median (IQR) 0  (0-39)  
    Undetectable 244  (91.73) REF 
    40-99,999 20  (7.52) 2.40 (0.74-7.79) 
    ≥ 100,000 2  (0.75) 9.61 (0.58-158.78) 
    p-value   0.041 
Current ART Therapy    
    Yes 97 (90.65) REF 
    No 10 (9.35) 0.96 (0.19-4.89) 





Table 4.6: Risk Factors for Oral HPV Infection, Multivariate Analysis 
 
Variable Multivariate OR (CI) p-value 
All 3 Groups Included   
Sex   
    Female REF  
    Male 2.59 (0.67-10.00) 0.166 
Lifetime number of vaginal sex partners   
    0-5 REF  
    ≥ 6 2.91 (0.82-10.35) 0.099 
Male partner circumcision   
    Yes REF  
    No 3.85 (1.28-11.56) 0.016 
HIV Group Only   
Sex   
    Female REF  
    Male 2.33 (0.59-9.17) 0.227 
Lifetime number of vaginal sex partners   
    0-5 REF  
    ≥ 6 3.12 (0.85-11.53) 0.088 
Male partner circumcision   
    Yes REF  
    No 4.54 (1.44-14.31) 0.001 
HIV viral load (copies/µl)   
    Undetectable REF  
    40-99,999 1.78 (0.30-10.42) 0.524 




Table 4.7: Concordance of Oral HPV Infection between Partners 
 
Couple Gender HIV Status HPV Status (Type) Sexual Preference 
1 Male HIV- Negative Heterosexual 
 Female HIV- Negative Heterosexual 
2 Male HIV+ Negative Heterosexual 
 Female HIV- Negative Heterosexual 
3 Male HIV- Negative MSM 
 Male HIV- Negative Bisexual 
4 Male HIV- Negative Heterosexual 
 Female HIV- Negative Heterosexual 
5 Male HIV- Negative Heterosexual 
 Female HIV- Negative Heterosexual 
6 Male HIV- Negative MSM 
 Male HIV- Negative MSM 
7 Male HIV- Negative Heterosexual 
 Female HIV- Negative Heterosexual 
8 Male HIV- Negative Heterosexual 
 Female HIV- Negative Heterosexual 
9 Male HIV+ Negative Heterosexual 
 Female HIV+ Negative Heterosexual 
10 Male HIV+ Negative MSM 
 Male HIV+ Negative MSM 
11 Male HIV+ Negative Bisexual 
 Female HIV- Negative Heterosexual 
12 Male HIV+ Positive (66, 32, 42)  MSM 
 Male HIV+ Positive (16, 13, 52, 74) MSM 
13 Male HIV+ Negative MSM 
 Male HIV- Negative MSM 
14 Male HIV+ Negative MSM 
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CHAPTER 5 
 Assessment of Informational Concordance  
between HIV Patients and Physicians 
 
Abstract 
Background: For research studies collecting self-reported data, the validity of data is 
often unknown, especially when studies involve sensitive populations. Whenever 
possible, it is important to cross-check the data with other data sources.  
Methods: This study was nested within a cross-sectional study that investigated the 
prevalence of oral HPV infection in HIV-positive and HIV-negative individuals in 
Michigan. A self-administered questionnaire was completed by all study participants. 
For HIV-infected participants, medical records were abstracted for selected variables 
that are known to be associated with HPV infection and for information related to HIV 
disease status. Concordance, sensitivity, and specificity were assessed between the 
data from the self-report and the medical records. 
Results: Of 266 participants in the main cross-sectional study, 106 HIV-positive 
individuals were eligible for the nested analsis. Therefore, information from the medical 
records was obtained from these 106 study participants. Overall there was good 
concordance between the self-reported data and the medical records. The items that 
had substantial agreement were related to the family history of cancer. The items that 
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were least likely to be concordant were patients' condom use, alcohol consumption, and 
marijuana use.  
Conclusion: Our findings indicate that concordance varied depending on questionnaire 
items The self-administered questionnaire tended to be more reliable for questions that 
were more sensitive in nature, while the medical records were more reliable for items 
that required laboratory testing and confirmation of disease status. 
 
Introduction 
 Epidemiological studies often utilize questionnaires to gather self-reported 
information from study participants. In such studies, the validity relies heavily on the 
quality of the data that study participants provide. There is a variety of sources that may 
undermine the quality of self-reported information. While a recall bias due to time lapse 
is a well-known source of error (1-3), personal characteristics, such as age, 
socioeconomic status, education, patient's medical knowledge, and anxiety level have 
also been associated with accuracy of self-reported information (3-6). Biases may also 
stem from sources other than study participants, including questionnaire 
content/wording, interviewing technique, and environment in which a study is conducted 
(1, 3, 4, 7-9). Further, it has been suggested that trust in the healthcare system may 
affect participation in research studies (10).  
 Important work has been done to compare informational concordance between 
physicians and patients. A vast majority have focused on healthcare utilization (11-19), 
diagnostic tools (7, 20-23), specific diseases (24, 25), and medication use (26-29). 
However, little research has been done on the validity of self-reporting for disease 
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classification in research studies (30, 31), even though self-reported information could 
also play a role in improving the quality of care. 
 HIV-positive individuals are at risk of co-infection with different sexually 
transmitted diseases (STDs). This is partly due to the shared sexual behavioral factors 
(32) as well as other behaviors, such as substance use, that are associated with risky 
sexual behaviors (33-35). Assessing risky behaviors in conjunction with HIV co-infection 
is not only important from the patient treatment perspective, but also from the 
prevention standpoint. However, because providers must ask sensitive questions 
regarding patient behavior, it is challenging to accurately assess the patient's risk for 
other diseases. There are studies that have evaluated which source of data (i.e., 
physicians vs. patients) is more reliable (24, 36, 37). However, such a question has not 
been thoroughly explored in HIV-positive populations.  
 Our group recently completed a cross-sectional study consisting of HIV-infected 
individuals in a university hospital setting to investigate the prevalence and risk factors 
for oral HPV infection. Since this study gathered information through participant self-
report and medical record review, we performed sub-analysis to assess the agreement 




 This analysis is nested within our cross-sectional study to investigate the 
prevalence of oral HPV infection in HIV-infected population compared to two different 
HIV-negative populations. HIV-infected patients were recruited from the HIV/AIDS 
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Treatment Program at the University of Michigan (UM) between May 2012 and August 
2013. Two HIV-negative study groups were formed: individuals who tested HIV-negative 
at HIV/AIDS Resources Center (HARC), a community health organization serving 
several counties in Michigan; and self-reported HIV-negative individuals in the UM 
Clinical Research Volunteers registry. The study was approved by the Institutional 
Review Board of the University of Michigan Medical School (application number 
HUM00047989), and written informed consent was obtained from all participants. 
 
Social Behaviors and Family History Survey  
 A questionnaire was administered to all study participants. The following 
information was collected: demographic factors, alcohol, tobacco, and other drug use, 
sexual practices, diet, environmental exposures, oral hygiene, general hygiene, cancer 
history, and general health. In addition, the HIV-infected participants were asked about 
their HIV disease status and medication adherence. Participants completed the 
questionnaire in a quiet, private room, and were asked to place the questionnaires into 
a plain envelope upon completion.  
 
Medical Record Abstraction 
 Selected clinical information that was relevant to oral HPV infection was 
abstracted from medical records based on a priori knowledge. These are tobacco, 
alcohol, and marijuana use, sexually transmitted diseases, condom use, previous 
cancer diagnosis, and evidence of non-oral HPV-associated diseases. Additionally, the 
following clinical and laboratory information pertaining to HIV was abstracted: HIV viral 
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load, CD4 cell count, CD4 cell nadir, and current HIV medications. The medical record 
review was conducted for only HIV-infected patients because the participants in other 
study groups (i.e., HARC clients and self-reported HIV-negative individuals from the UM 
Clinical Research Volunteers registry) are not necessarily seen in the University of 




 Although our questionnaire consisted of a wide range of questions, our analysis 
in this study was focused on the items that could be obtained from the medical records, 
since many of the variables in our questionnaire are not typically asked by the clinicians 
as part of the standard of care. Therefore, we focused our abstraction on three main 
domains which are as follow: substance use, health status, and family history of cancer. 
  
 We report the demographic characteristics and frequency of the aforementioned 
questionnaire items. To assess the degree of overlap between patient self-reported data 
and corresponding items in the medical records, we computed the percent total 
agreement, defined as the sum of percent agreement on positives and negatives. To 
evaluate concordance, Cohen's kappa statistic was computed (38). Since the p-value 
for kappa indicates whether the estimated kappa is not due to chance (39), 95% 
confidence intervals were generated to evaluate the degree of agreement.  
 Due to the assumption that either data source could serve as the gold standard 
and that which data source should serve as the gold standard depends on the nature of 
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the question, the sensitivity and specificity were calculated twice. The first approach 
considered the self-reported data as the gold standard, and second approach 
considered the medical records as the gold standard. The sensitivity and specificity 
were calculated for only dichotomous variables. For condom use, the answer choices in 
our survey was ordinal (i.e., always, almost always, rarely, and never), but such a way 
of reporting was not available in the medical records. Therefore, this variable was 
dichotomized by considering the responses in the "always" and "almost always" 
categories as using condoms, whereas the responses in the "rarely" and "never" 
categories were defined as not using condoms.  All statistical analysis was performed 




 Of 266 individuals who participated in the study, 107 were HIV-infected patients. 
Medical records were available from 106 HIV-infected patients. One patient was newly 
diagnosed and therefore did not have sufficient information in the medical records to be 
included in our analysis. The characteristics of the study population are shown in table 1. 
The majority of participants are white (59%) and male (83%). They are well-educated, 
with 87% having completed high school. The median age was 47 (52.5 in women, 46 in 






 Table 2 describes the frequencies of self-reported and abstracted data items, 
their corresponding agreement in percentages, kappa values, and 95% confidence 
intervals. In addition, two sets of sensitivity, and specificity are reported, one assuming 
the patient self-reported data is the gold standard, and the other assuming the medical 
records is the gold standard.   
 Overall, there was good agreement between the self-reported data and the 
medical records. There was over 80% total agreement on the majority of the items, and 
only four items had less overlap. These latter items, namely condom use, alcohol 
consumption, marijuana use, and skin warts, had total agreement percentages of 48%, 
61%, 63%, and 66%, respectively.  
 Concordance was also good according to kappa. Patient's mother's cancer 
status (kappa=0.84) had almost perfect agreement. Substantial concordance (kappa 
between 0.61 and 0.80) was observed in tobacco smoking, tobacco chewing, patients' 
CD4 count ever falling below 200, patient's father's cancer status, patient's own cancer 
status, and patient's children's cancer status. Items with moderate concordance (kappa 
between 0.41 and 0.60) were HPV vaccine status, genital warts, genital herpes, syphilis, 
marijuana use, other substance use, patient's sister's cancer status, and patient's 
brother's cancer status. There was a fair degree of concordance (kappa between 0.21 
and 0.40) in alcohol consumption and cigar use. Slight agreement (kappa between 0.01 
and 0.20) was observed among chlamydia, oral herpes, skin warts, and HIV medication 
adherence. Concordance was the lowest in condom use, and this agreement was less 
than by chance. 
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Sensitivity and Specificity 
 There was a great variety in the sensitivity and specificity between the two gold 
standards (table 3). High sensitivity and high specificity were observed in both the self-
reported data and the medical records for the following items: tobacco chewing, 
chlamydia, HIV-medication adherence, and ever having CD4 count fall below 200. Low 
sensitivity and low specificity were observed in both data sources for condom use. 
When the self-reported data was considered as the gold standard, sensitivity was 
considerably lower than that of the medical records for the following variables: cigar use, 
other substance use, syphilis, genital warts, skin warts, and the receipt of HPV vaccine. 
The specificity was comparable between the two data sources for all variables except 
other substance use and skin warts. Specificity for other substance use in the self-
reported data was lower than in the medical records. On the contrary, it was higher for 
skin warts in the self-reported data than the medical records.  
 With regard to the family history of cancer, sensitivity varied again between the 
two data sources, but specificity was comparable across all variables. Sensitivity ranged 
from 50 to 100% when the self-reported data was considered the gold standard, and it 
ranged from 43% to 86% when the medical records were used as the gold standard. 
  
Discussion 
 Moderate to substantial agreement between the self-reported data and the 
medical records was observed in this study. The questionnaire offered a greater 
abundance of information relevant to the EPI study than the medical records. Since the 
purpose of the questionnaire was to ascertain the risk factors for oral HPV infection, the 
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information for which was asked in the questionnaire may not have been covered 
extensively in the medical records. Further, the same questionnaires were administered 
to all our study participants, ensuring consistency of the information captured. However, 
the extent of information in the medical records varied by physicians. In addition, the 
survey questions were worded to cover the lifetime of patients; however, our medical 
records do not necessarily account for this, and we had no access to outside medical 
records for patients who are concurrently seeking or previously sought care at other 
institutions. Therefore, missing data may have contributed to the discrepancies in the 
frequency of the reported items. 
 Among the items in the substance use category, there was substantial 
agreement between the self-reported data and the medical records for tobacco smoking 
and tobacco chewing. However, there was only fair agreement for cigar use and alcohol 
consumption, and moderate agreement for marijuana use and substance use. Cigar use 
is a rare event in the current generation (i.e., there were only two individuals identified in 
the medical records), and for rare findings, low kappa values may not necessarily reflect 
overall agreement (39). Regarding alcohol consumption, marijuana use, and other 
substance use, discordance may have resulted from the social desirability effect. It is 
well-known that behaviors that are perceived to be socially undesirable may be 
underreported (1, 40, 41). As an added explanation as to why the sensitivity was 
particularly low for "other substance use" question, the way in which this question was 
posed may have been an issue. This question required an open-ended response, and it 
has been reported that the open-ended format can decrease agreement (42). Further, in 
studies examining the sensitivity of recollection of drug use, sensitivity was higher for 
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questions about medications used for a specific indication than for the open-ended 
questions (9). It is important to note that the variables assessed in this category are 
dynamic in nature. Behaviors could have changed over time between the time they 
were reported in the medical records and the time the self-administered survey was 
completed. Therefore, a time lag could in part explain the discordance.  
 In the health category, sensitivity was higher for all items, except condom use, 
when the medical records were considered as the gold standard. With regard to STDs, 
a possible explanation for such a trend is that STDs are often asymptomatic and require 
laboratory testing for accurate diagnosis. If infected individuals are not aware of their 
STD status, this could lead to underreporting. Even if they are symptomatic, they may 
misclassify symptoms for another disease. These hypotheses may explain the low 
sensitivity when self-reported data was used as the gold standard. Previously, it has 
been suggested that for diseases that require testing for diagnosis, self-reporting is 
highly accurate (30). This reasoning probably holds for our observations, given that very 
high specificity was observed in all questionnaire items regarding STDs and HPV 
vaccination status. Further, these high specificity values were comparable to those of 
the medical records, when the self-reported data were used as the gold standard. 
Therefore, the lack of patients' awareness of the disease and vaccination status may 
have contributed to moderate agreement according to the kappa statistics. 
 The highly discordant reporting regarding condom use is troubling. It is unlikely 
that dichotomizing this variable led to such a low percentage of total agreement and a 
low kappa value; in fact, dichotomizing should have boosted the values since it reduced 
opportunities for misclassification. Patients are likely to know that physicians expect 
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patients to report consistent condom use, and that if patients report otherwise, this will 
lead to extensive counseling. Therefore, social undesirability should be high when 
responding to physicians. Likewise, such biases are prevalent in questions associated 
with condom use (43-46). Thus we attribute discordant results due to recall bias and 
social desirability bias. 
 For the family history of cancer, the agreement ranged from "moderate" to 
"almost perfect." The percentage of individuals who self-reported the presence of 
cancer agreed with the medical records was 90%, which is consistent with a study 
previously done in an HIV-positive population (31). The sensitivity in our study was 
higher. The difference could be explained by a higher proportion of white participants 
and lower prevalence of substance use in our population, as these factors are 
associated with more accurate reporting (30, 31). Although the study in question did not 
measure the participants' level of education, this factor may also explain the difference 
since higher education attainment is associated with improved self-reporting of cancer 
diagnoses (47). As for the concordance rates, sensitivity, and specificity of family 
members' cancer status, the accuracy of reporting may have been influenced by the 
degree in which the study participants are affected by their family members' disease. It 
has been reported that the individuals who correctly reported disease status were most 
likely to  be first-degree relatives, such as parents, siblings, and offsprings (48).  
 There are important implications of validation studies such as this study. From 
the research standpoint, reliance on patient self-reporting without validation can lead to 
misclassification of disease, which in turn may affect outcomes of a study. Consistent 
with previous studies, our study indicates that accuracy of self-reporting differs by 
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disease classification. The data from our study suggests that medical records are a 
more reliable source of information for STDs. This study of concordance between self-
reported data and medical records also has clinical significance, as the results could 
serve as an indicator of the level of patient-physician interaction. Improving 
communication and efforts to educate some patients regarding their own health status is 
encouraged. 
 Our study had important limitations. First, given the small sample size, the results 
must be interpreted with caution. Second, even if the percent total agreement and 
kappa values were perfect, we cannot be certain of the veracity of the information 
provided. By definition, sensitivity is the proportion of individuals who have the disease 
that report having the disease, and specificity is the proportion of individuals who do not 
have the disease that report not having the disease (49). However, in reality just as 
there is a possibility that individuals have always told the truth (i.e., to their medical 
providers and in our study questionnaires), it is also possible that individuals 
consistently provided false information. Therefore, misclassification of information is 
inevitable. Third, there was considerable variability in physician reporting of patients' 
medical information. Even though we utilized two independent individuals to extract 
relevant information from the medical records to ensure a thorough review, we 
recognize that some information was not available because of the degree of 
thoroughness in physician clinic notes. Lastly, the findings from this study cannot be 
generalized to other HIV-positive populations across the United States due to 
demographic differences.  
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 In spite of these limitations, we identified preferred data sources for each of the 
questionnaire items. The self-administered questionnaire was more reliable for the 
items related to substance use, while the medical records were more accurate in the 
reporting of health-related items. Both sources of data were equally reliable in reporting 
the family history of cancer. Since concordance between patient self-reporting and 
medical records could vary depending on the domain and item of questions asked, 
recall ability, and disease area (1, 30, 50-52), additional research is needed to include a 
wider range of questions and domains while carefully designing the study and 






Table 5.1: Study Participant Characteristics 
  Characteristics      n % 
Total 107 40.2 
Gender   
    Female   18 16.8 
    Male   89 83.2 
   
Age (median) 47 (19-75) 
    Female 52.5 (33-63) 
    Male 46 (19-75) 
   
Race   
    Asian 1 0.93 
    Black 31 28.97 
    Hispanic 4 3.74 
    Native American 1 0.93 
    White 63 58.88 
    Other 4 3.74 
    Unknown 3 2.80 
   
Education   
    < High school 12 11.21 
    High school graduate 23 21.50 
    Some college 39 36.45 
    College graduate 24 22.43 
    Advanced degree 7 6.54 
    Unknown 2 1.86 
   
Marital Status   
    Married 19 17.76 
    Living as married 10 9.35 
    Single 61 57.01 
    Widowed 4 3.74 
    Divorced 12 11.21 
    Unknown 1 0.93 
   
90 
 
Table 5.2: Measures of Concordance 
 Frequency Reported Measures of Concordance 
Item Patient Only Physician Only % Total Agreement Kappa (CI) 
Substance Use     
Tobacco smoking     
    Current smoker 27 30 85.7 0.78 (0.68-0.88) 
    Former smoker 36 34   
    Never smoker 43 42   
Cigar use     
    Former user 14 2 91.3 0.34 (-0.01-0.69) 
    Never user 91 79   
Tobacco chewing     
    Former user 102 89 95.0 0.73 (0.51-0.96) 
    Never user 4 3   
Marijuana use     
    Current user 34 33 62.9 0.44 (0.31-0.56) 
    Former user 35 13   
    Never user 38 59   
Other substance use     
    Current user 11 6 91.5 0.43 (0.12-0.73) 
    Never user 96 100   
Alcohol consumption     
    Current drinker 59 59 61.3 0.38 (0.27-0.50) 
    Former drinker 38 11   
    Never drinker 10 36   
Health     
Chlamydia     
    Yes 22 1 79.3 0.08 (-0.07-0.23) 
    No 77 93   
Genital herpes     
    Yes 11 11 90.8 0.48 (0.19-0.77) 




Oral herpes     
    Yes 11 7 86.3 0.17 (-0.11-0.45) 
    No 86 98   
Syphilis     
    Yes 19 12 83.3 0.45  (0.22-0.69) 
    No 80 91   
Genital warts     
    Yes 20 20 88.0 0.58 (0.37-0.80) 
    No 82 86   
Skin warts     
    Yes 35 5 66.0 0.07 (-0.06-0.19) 
    No 66 101   
Condom use     
    Yes 61 42 48.4 -0.11 (-0.35-0.13) 
    No 45 23   
HPV vaccine     
    Received 10 5 92.9 0.58 (0.26-0.90) 
    Not received 61 101   
HIV medication adherence     
    Take medicines everyday 98 83 82.8 0.13 (-0.08-0.35) 
    Do not take medicines     
    everyday 6 18   
 
Ever had CD4 count below 200     
    Yes 47 51 84.7 0.70 (0.54-0.85) 
    No 41 53   
Family History of Cancer     
Patient’s cancer status 25 20 89.7 0.69 (0.52-0.86) 
Father's cancer status 21 22 89.3 0.71 (0.53-0.89) 
Mother's cancer status 21 21 94.6 0.84 (0.71-0.98) 
Brother's cancer status 4 4 90.0 0.44 (-0.01-0.90) 
Sister's cancer status 7 7 89.4 0.49 (0.11-0.87) 
Children's cancer status 1 2 90.0 0.62 (-0.04-1.00) 
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Table 5.3: Sensitivity and Specificity 
 Patient self-report as Gold Standard Physician-report as Gold Standard 
Item Sensitivity Specificity Sensitivity Specificity 
Substance Use     
Tobacco smoking     
    Current smoker - - - - 
    Former smoker     
    Never smoker     
Cigar use     
    Former user 22.2 100 100.0 (n=2) 91.0 
    Never user     
Tobacco chewing     
    Former user 80.0 96.6 72.7 97.7 
    Never user     
Marijuana use     
    Current user - - - - 
    Former user     
    Never user     
Other substance use     
    Current user 36.4 63.4 66.7 93.0 
    Never user     
Alcohol consumption     
    Current drinker - - - - 
    Former drinker     
    Never drinker     
Health     
Chlamydia     
    Yes 94.7 100.0 (n=0) 100.0 (n=1) 79.1 
    No     
Genital herpes     
    Yes 45.5 96.6 62.5 93.3 




Oral herpes     
    Yes 18.2 (n=2) 95.2 33.3 (n=2) 90.0 
    No     
Syphilis     
    Yes 42.1 96.1 72.7 86.9 
    No     
Genital warts     
    Yes 50.0 98.6 90.9 87.7 
    No     
Skin warts     
    Yes 8.57 (n=3) 96.9 60.0 66.3 
    No     
Condom use     
    Yes 61.5 38.5 57.1 31.8 
    No     
HPV vaccine     
    Received 44.4 100.0 (n=4) 100.0 (n=4) 92.4 
    Not received     
HIV medication adherence     
    Take medicines everyday 84.2 50.0 (n=2) 97.6 11.76 
    Do not take medicines     
    everyday     
 
Ever had CD4 count below 
200 
    
    Yes 83.0 86.8 88.6 80.5 
    No     
Family History of Cancer     
Patient’s cancer status 68.0 96.3 85.0 90.8 
Father's cancer status 84.2 90.8 72.7 95.2 
Mother's cancer status 90.0 95.8 85.7 97.2 
Brother's cancer status 50.0 (n=2) 94.4 50.0 (n=2) 94.4 
Sister's cancer status 75.0 90.7 42.9 97.5 
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Incidence and Prevalence of Systemic Lupus Erythematosus from 
around the World: A Systematic Literature Review 
 
Abstract 
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that has 
received little public health attention. We conducted a systematic literature review to 
investigate the global pattern of incidence and prevalence of SLE. 
Methods: Four electronic databases were searched to identify cohort and cross-
sectional studies, published from 1990-2010, describing incidence and/or prevalence of 
SLE. Crude incidence and prevalence rates and corresponding 95% confidence 
intervals were computed based on the number of cases and population at risk. Results 
were stratified by continent, and by physician-confirmed diagnosis versus self-report.  
Heterogeneity was assessed by exact likelihood ratio tests. Pooled estimates were 
calculated when heterogeneity was not detected, weighted by denominator. 
Results: Of 11,870 screened articles, 65 (49 prevalence & 32 incidence) from 5 
continents met eligibility criteria and were included in the analysis. Studies from all 
regions yielded annual incidence rates between 0.3 and 8.7 per 100,000 and 
prevalence between 1.1 and 534.9 per 100,000. High incidence was observed in the 
United States, Caribbean, Brazil, and Sweden. Prevalence was much higher in the 
United States than in Europe and Asia. Prevalence was also higher among studies with 
self-reported physician-diagnosed SLE cases compared to physician confirmed cases. 
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Conclusions: There was considerable variability in both incidence and prevalence 
across different regions. To allow for improved comparison of studies, multiple sources 
of discrepancy must be considered: study design, case ascertainment method, type of 
surveillance, race, gender, and method of case classification. 
 
Introduction 
 Systemic lupus erythematosus (SLE) is an autoimmune disease with a significant 
impact on morbidity, mortality, and quality of life. Although the etiology of disease is not 
well-understood, the production of autoantibodies, which mediate tissue damage, 
appears to interact with and is triggered by certain genetic and environmental factors. 
SLE displays variable manifestations affecting almost every organ, contributing to 
cutaneous, joint, internal, neurologic, and hematologic problems. However, clinical 
manifestations of SLE vary in individuals. Severity and recurrence of disease may also 
differ from patient to patient. Furthermore, there are considerable geographic and ethnic 
variations with SLE disproportionately affecting women of childbearing age and those 
who are African Americans, Afro-Caribbeans, and Asians (1, 2). 
 Incidence and prevalence are often used as simple measures to describe 
epidemiology of disease. However, in SLE, accurately quantifying incidence and 
prevalence has proven to be complicated for a number of reasons. First, since SLE is a 
relatively rare, complex disease, research studies classically focus on the tertiary care 
setting due to practicality. This introduces biases since the patient populations are often 
highly selective due to factors such as health care utilization patterns, socioeconomic 
status, and race, and thus may not fully represent the spectrum of disease. Second, 
case definition is not always consistent among studies. Some studies have classified 
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individuals as having SLE based on retrospective review of medical records while some 
others have developed separate case definitions for their research purposes. However, 
most research investigations utilize the American College of Rheumatology (ACR) SLE 
criteria for determination of eligibility. One issue with this criteria is that when these 
criteria were evaluated in external populations as opposed to the original test 
population, the sensitivities were as low as 78% (versus 96% in the test population) (3, 
4). This problem leads to the systematic exclusion of lupus patients who may have mild, 
early or atypical presentations, but who nonetheless should be advocated for and 
included in research. Third, studies use different case ascertainment methods. Most 
studies turn to hospital admission and billing databases, records from rheumatology 
clinics, and academic registries to identify SLE cases. Multiple sources are often used, 
and cases are confirmed upon review of medical records or patient examination by a 
rheumatologist. However, rigorous case ascertainment does not always take place due 
to limited resources, inability to contact patients, or unavailability of medical records. 
Furthermore, self-report of a physician-diagnosed SLE lacks precision (5). 
 The reports of incidence and prevalence of SLE described in literature are 
obviously conflicting, and no systematic literature review has been conducted to date. 
The objective of this review is to establish the best estimates of incidence and 
prevalence of SLE in different parts of the world. Specifically, self-reported incidence 






Identification of Studies 
 We identified studies describing the incidence and/or prevalence of SLE, 
published between 1990 and 2010. The following electronic databases were used for 
our primary search: 1) Medline/Pubmed (1947 - July 2010), 2) Scopus (1823 - July 
2010), 3) ISI Web of Science (1900 - July 2010), and 4) Embase (1947 - July 2010). 
Google Scholar was used to supplement the search. For each database, a customized 
search strategy was formulated in consultation with a medical librarian. The combination 
of the search terms are presented in Table 1. No language restrictions were applied. All 
electronic database searches were conducted on July 3, 2010. Review articles 
published within the last 20 years on the epidemiology of autoimmune diseases, 
including SLE, were also identified. Reference lists from all relevant articles were hand 
searched for additional articles that were not captured by the electronic database 
searches. When articles could not be located through the University of Michigan 
libraries or its affiliates, we made every effort to obtain the original article from the 
authors. 
 Studies were eligible for inclusion in the review if they were cohort or cross-
sectional studies reporting incidence and/or prevalence of SLE. SLE cases in patients of 
all ages were included. Both self-reported cases of physician-diagnosed SLE and non 
self-reported cases (e.g. hospital chart review, population-based registries, physician 
diagnosis, etc.) were included. Studies were excluded if: (1) they were non-human 
studies; (2) they consisted of lupus diagnoses that were not SLE; (3) their results were 
not based on primary data; (4) they were not published within the past 20 years; and (5) 
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they did not assess general arthritis or rheumatic conditions without specifically 
screening for lupus. Serial reports from the same study were excluded; only the most 
recent or most comprehensive data available from a given series were utilized to avoid 
over-weighing of a single study. Studies which restricted their study population to 
include only a specialized population (e.g. environmentally exposed clusters or other 
high risk groups) were also excluded. 
 A primary reviewer screened the titles and abstracts of all publications identified 
by the literature search, based on the predetermined eligibility criteria. Articles were 
rejected if they clearly did not meet the eligibility criteria. The full-text of all remaining 
articles that possibly or definitely met the eligibility criteria were obtained and reviewed 
to further screen these articles. A secondary reviewer was consulted in cases where 
article eligibility was unclear. Four articles were translated to English. We used a 
standardized data extraction form to extract the data, including (1) administrative 
details: author(s); year of publication; journal title; article title; year(s) in which the study 
was conducted; study objective; Pubmed identification number; (2) details of the study: 
study design; geographic location of study; type of surveillance (For our review, active 
surveillance was defined as the identification of cases via medical chart review, door-to-
door visits, and medical/physical evaluations conducted directly by study investigators. 
We considered studies to have used passive surveillance if (a) they relied on voluntary 
reporting mechanisms for case identification (b) they used randomization to search for 
cases; (c) they reported cases as a result of secondary data analysis; or (d) they 
reported cases that arose from questionnaires that relied on participants’ willingness to 
return the questionnaire); (3) details of study population: demographic information 
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(race/ethnicity, sex, age distribution); patient inclusion and exclusion criteria; 
classification criteria for diagnosis of SLE; validation of SLE diagnosis; (4) details of 
outcomes: incidence rate (crude and age- and/or sex-adjusted rates if available); 
prevalence rate (crude and age- and/or sex-adjusted rates if available); actual number 
of incident SLE cases; actual number of prevalent SLE cases; population denominator 
to calculate the incidence and/or prevalence rates (i.e. population at risk); and (5) types 
of biases.    
 
Analysis 
 We computed crude incidence and prevalence rates and corresponding 95% 
confidence intervals (CIs) based on the number of cases and the population at risk 
reported in the articles. Where no crude data were available, age- and/or sex-adjusted 
estimates were used to derive the incidence and prevalence rates. Where data were 
given from more than one time period, the most recent figures were used. Where 
multiple study sites were presented in one article, the data were compiled to compute 
an overall estimate for the country the article represented. For the articles without the 
actual number of cases, we derived the best estimate of the numerator by using other 
available data (i.e. incidence and/or prevalence rates and the population size.) Similarly, 
when the population at risk was not given, the best estimate of the denominator was 
derived from other information given (i.e. incidence and/or prevalence rates and the 
number of identified cases). In the event the denominator could not be inferred, the best 
estimate of the population size was obtained from an appropriate population census. 
We report the incidence rate as a number of new cases per 100,000 of the population 
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per year and the prevalence rate as a cross-sectional estimate of the number of cases 
per 100,000 of the population. We also report the incidence and prevalence rates as 
presented in the original articles. Our results are stratified by the geographic region. We 
generated forest plots according to region where the symbols, which were weighed by 
denominator, represent point estimate, and the horizontal line represents the CIs. Exact 
95% CIs were calculated based on binomial distribution. We followed recommendations 
by Schriger et al. (2010) to order the forest plots by effect size (6). We assessed 
heterogeneity using the chi-square test with α = 0.05 for statistical significance. As we 
observed the presence of statistical heterogeneity due to differences in geographic 
region, we present the results according to these sub-groups. Where studies were 
comparable, we calculated pooled estimates using denominator as the weight. Data 
management and analysis were conducted using R 2.11.1. software (R Development 
Core Team, 2010) and Stata version 11 (Stata Corp., College Station, TX). 
Heterogeneity was computed using StatXact (StatXact9 for Windows, Cytel Software, 
Cambridge, MA).   
 
Results 
Description of studies 
 We identified 11,870 publications from the electronic searches, of which we 
determined 74 articles to be potentially eligible based on initial screening. Of these, 61 
met eligibility criteria. 8 additional articles were identified from reference lists, of which 4 
met eligibility criteria. Thus, in total, 65 articles were included in this review as outlined 
in the flow chart. (Figure 1). Of these, 49 described prevalence and 32 described 
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 Overall, studies from all regions yielded annual incidence rates from 0.3 to 8.7 
per 100,000. All studies reported the incidence of SLE using non self-reported 
physician-diagnosed SLE as a case finding method. Significant heterogeneity existed 
among all studies (p<0.01), and stratification by continent did not resolve heterogeneity. 
In Asia, there were 3 studies with annual incidence ranging from 0.3 to 3.1 per 100,000. 
2 studies (7, 8) used cohort design and utilized hospital records or databases while one 
study (9) was a cross-sectional survey-based study. Removing the latter study resulted 
in similar estimates (p=0.53). There was one study in Australia for which incidence 
could be calculated (10). With 13 new cases among Aborigines between 1986 and 1990 
this study reported incidence of at least 11/100,000. In Europe, annual incidence ranged 
from 0.4 to 4.9 per 100,000 among 17 studies. 13 of these were cohort studies (11-23) 
and 4 were cross-sectional studies (24-27). Further stratification by study design, 
country, and surveillance type did not impact heterogeneity. There were 10 studies in 
North America where incidence varied between 0.4 and 6.0 per 100,000. 7 of these 
studies were cohort studies (28-34) and 3 were cross-sectional studies (35-37). Only 
stratification by sub-region within North America (i.e. USA, Canada, and Caribbean) 
resulted in two Caribbean studies (31, 35) being similar (p=0.98). Two studies that used 
passive surveillance were also similar (p=0.24) despite the difference in study 
population (29, 36). There was one study in South America (38) reporting annual 
107 
 
incidence of 8.7/100,000. Out of 32 studies there were 5 population-based studies (11, 
19, 22, 26, 37). A graphical summary of incidence studies is displayed in Figure 2. 
 
Prevalence  
 Overall, there were 49 studies with prevalence rates ranging from 1.1 to 534.9 
per 100,000. 43 articles reported non self-reported prevalence which spanned from 1.5 
to 158.7 per 100,000 (8, 10, 13, 14, 16, 18, 19, 23-27, 29-32, 35, 36, 39-63). Among 
non self-report studies, there were 2 studies (14, 24) that reported age-adjusted 
estimates, and there was 1 study (29) that adjusted for both sex and age. With the 
exception of studies describing non self-reported prevalence in Australia, there was 
strong evidence of heterogeneity for all geographic region and reporting type 
combinations (all p<0.001, Australia p=0.071). Upon stratification of non self-reported 
studies by continent, 8 studies were found in Asia, 4 in Australia, 18 in Europe, and 13 
in North America. Prevalence in Asia ranged from 3.4 to 47.2 per 100,000. One of the 8 
studies in Asia was performed among men and women, but only female cases were 
found (40). In Australia, it ranged from 45.4 to 88.4 per 100,000. A pooled prevalence 
estimate for the 4 Australian studies was 49.4/100,000. Prevalence in Europe varied 
from 1.5 to 70.7 per 100,000. We could not derive an overall crude prevalence for one 
of the studies (64)  in Europe because it reported age- and sex stratified results, and we 
could not obtain denominator for each group. North America exhibited the widest range, 
extending from 3.6 to 158.7 per 100,000. 6 studies (40, 42, 45, 49, 50, 59) examined 
prevalence of SLE based on self-reported symptoms but no physician diagnosis. In 
addition to these studies, we found 4 studies (65-68) that also relied on self-reported 
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symptoms for SLE case detection; however, we did not include these studies in our 
analysis because their study instruments covered a broad spectrum of rheumatic 
diseases without a specific focus on SLE. A graphical summary of prevalence studies is 
displayed in Figure 3. 
 There were 6 articles describing self-reported physician-diagnosed prevalence of 
SLE (5, 69-74). All studies with the self-report method were cross-sectional studies. 
Since significant heterogeneity was observed among all self-reported studies, we 
stratified the studies by country. We found 2 studies in Europe and 4 studies in North 
America, and stratification could not recover heterogeneity. The lowest self-reported 
prevalence rate of 1.1 per 100,000 was reported in Greece (70). The highest self-
reported prevalence rate of 534.9 per 100,000 was reported in a study conducted in the 
United States that used random-digit telephone dialing and involved no follow-up in-
person examination of patients by a rheumatologist (71). Aside from one study in 
Europe, all studies consisted of study population ≥16 years old. All studies in Europe 
had lower prevalence rates than all studies in North America. 
 
Discussion 
 This review included 65 studies on prevalence and incidence of SLE from 5 
continents. No studies from Africa were found. Significant heterogeneity across all 
studies in examining both incidence and prevalence was observed, and thus required 
us to stratify our results. Our comparison of studies included stratification by geographic 
region and by self- vs. non-self report of physician-diagnosed SLE cases, as it is fairly 
well established that heterogeneity may be due to differences in study methodology and 
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population. To the best of our knowledge, this review represents the first systematic 
attempt to summarize the global incidence and prevalence of SLE.  
 Our findings were consistent with previous reviews done on this topic, 
highlighting disparities of SLE (1, 2, 75, 76). As expected, the highest annual incidence 
rates (>4/100,000) were observed in studies consisting of Aborigines (Australia), 
populations with a high proportion of individuals of African descent (Curaçao and 
Martinique), and migrants (United States). Countries with moderate (between 2 and 4 
per 100,000) and low (<2/100,000) annual incidence rates were in Europe. Similarly, the 
global prevalence rates were the highest in the migratory populations in the United 
States, followed by Caribbean countries. European and Asian countries had much lower 
prevalence than the United States. These observations may be explained by a variation 
in demographic composition, with the United States and Caribbean countries having a 
higher proportion of people of African descent. These results still must be interpreted 
with caution, since the rates not only varied within different continents but also within the 
same country.  
 Since previous reviews have stratified results by gender, we took a different 
approach in our analysis by comparing self- to non-self report of physician-diagnosed 
SLE. Despite the small number of studies using the self-report method, we found that 
prevalence was higher among studies with self-reported SLE cases than those with non 
physician-confirmed cases in North America. Interestingly, the opposite was observed in 
Europe. This difference may have implications on case findings in the context of health 
disparities. Despite its obvious drawbacks (1), self-reporting could serve as a useful tool 
in detecting individuals in heterogeneous populations that need access to care and/or in 
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areas where rheumatologists are not easily accessible. We did not stratify by age 
because cases are not detected as often in children. 
 Numerous factors are likely to have contributed to the broad spectrum of results. 
While the most recently accepted classification method of SLE is the 1997 updated 
ACR criteria (77), the studies that we identified in this review used different classification 
criteria. This review included the 1982 ACR criteria and ARA criteria, in addition to the 
1997 updated ACR criteria, because the studies spanned 20 years. Ascertainment of 
cases ranged from patient physical examination performed by rheumatologists to coding 
of SLE diagnosis in administrative databases to medical chart review. Surveillance 
method and source of data may also have impacted case findings. Finally, as there is 
usually a lag time between the initial onset of symptoms and the diagnosis meeting at 
least four criteria, incident cases are more prone to measurement error.  
 Given variability between studies, we could not perform meta-analyses, including 
pooled estimation of incidence and prevalence. Although we were able to extract or 
derive raw numbers for the incident and prevalent cases from the majority of the articles 
to calculate our crude estimates, some studies reported adjusted estimates, making it 
difficult for real comparison. Publication bias is another issue in that studies with positive 
results may be more likely to be published. We attempted to prevent this bias by 
searching for articles using Internet search engines (e.g., Google) and for conference 
abstracts in dating between 2006 and 2009 in the ACR/ARHP Annual Scientific 
Meetings Conference database. Several abstracts were retrieved but excluded because 
they were later published in a journal.  
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 The findings summarized in the present review demonstrated considerable 
variability in both incidence and prevalence across different regions. This variability may 
arise from a variety of sources including study design, case ascertainment method, type 
of surveillance, race, gender, and method of case classification. Future studies 
accounting for these factors could greatly improve case findings.  
 
Acknowledgements 
 We thank Ms. Whitney Townsend for her assistance with the development of 
search terms, and Dr. Sergei M. Chernyak, Dr. Marta Mosca, Ms. Sarah Tersegno, and 





Table 6.1: Search terms used for five major databases and conference abstracts 
Database Search Terms Items Found 
Medline/Pubmed 
 
"Lupus Erythematosus, Systemic/epidemiology*" AND "Prevalence" AND ("humans" AND 
"1990/05/31"[PDAT] : "2010/06/01"[PDAT]) 
412 
 
 "Lupus Erythematosus, Systemic/epidemiology*" AND "Incidence" AND ("humans" AND 
"1990/05/31"[PDAT] : "2010/06/01"[PDAT]) 
250 
 
 "Incidence" AND "Prevalence" AND "Lupus Erythematosus, Systemic/epidemiology" AND 
("humans" AND "1990/05/31"[PDAT] : "2010/06/01"[PDAT]) 
86 
 
 "Autoimmune Diseases/epidemiology" OR "Autoimmunity" AND lupus 2,963 
 "Lupus Erythematosus, Systemic/epidemiology" AND ("humans" AND Review[ptyp] AND 
"2005/06/03"[PDat] : "2010/06/01"[PDat]) 
75 
 
 "Lupus Erythematosus, Systemic/epidemiology*"[Mesh] AND "Prevalence"[Mesh] AND 
("humans"[MeSH Terms] AND "1990/05/31"[PDAT] : "2010/06/01"[PDAT]) 
376 
 
 "Lupus Erythematosus, Systemic/epidemiology*"[Mesh] AND "Incidence"[Mesh] AND 
("humans"[MeSH Terms] AND "1990/05/31"[PDAT] : "2010/06/01"[PDAT]) 
250 
 
 "Incidence"[Mesh] AND "Prevalence"[Mesh] AND "Lupus Erythematosus, 




 "Autoimmune Diseases/epidemiology"[Mesh] OR "Autoimmunity"[Mesh] AND lupus 3,796 
 "Lupus Erythematosus, Systemic/epidemiology"[Mesh] AND ("humans"[MeSH Terms] AND 
Review[ptyp] AND "2005/06/03"[PDat] : "2010/06/01"[PDat])  
106 
 
Scopus ("systemic lupus erythematosus" AND "prevalence" AND "epidemiology") AND PUBYEAR 
AFT 1990 AND ( LIMIT-TO(EXACTKEYWORD,"Systemic lupus erythematosus" ) OR 
LIMIT-TO(EXACTKEYWORD,"Human" ) OR LIMIT-TO(EXACTKEYWORD,"Prevalence" ) 
OR LIMIT-TO(EXACTKEYWORD,"Humans" ) )   
157 
 
 ("systemic lupus erythematosus" AND "incidence" AND "epidemiology") AND PUBYEAR 
AFT 1990 AND ( LIMIT-TO(EXACTKEYWORD,"Human" ) OR LIMIT-
TO(EXACTKEYWORD,"Systemic lupus erythematosus" ) OR LIMIT-
TO(EXACTKEYWORD,"Humans" ) OR LIMIT-TO(EXACTKEYWORD,"Incidence" ) )  
130 
 
 ("systemic lupus erythematosus" AND "incidence" AND "prevalence" AND "epidemiology") 
AND PUBYEAR AFT 1990 AND ( LIMIT-TO(EXACTKEYWORD,"Systemic lupus 
erythematosus" ) OR LIMIT-TO(EXACTKEYWORD,"Human" ) OR LIMIT-
TO(EXACTKEYWORD,"Prevalence" ) OR LIMIT-TO(EXACTKEYWORD,"Incidence" ) OR 
LIMIT-TO(EXACTKEYWORD,"Humans" ) )  
61 
ISI Web of 
Science 
 
Topic=("systemic lupus erythematosus") AND Topic=(prevalence) AND 
Topic=(epidemiology) 
Timespan=1990-2010. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
193 
 
 Topic=("systemic lupus erythematosus") AND Topic=(incidence) AND Topic=(epidemiology) 
Timespan=1990-2010. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH 
109 
 
 Topic=("systemic lupus erythematosus") AND Topic=(incidence) AND Topic=(prevalence) 
AND Topic=(epidemiology) 




'systemic lupus erythematosus'/exp OR 'systemic lupus erythematosus' AND 
('prevalence'/exp OR 'prevalence') AND ('epidemiology'/exp OR epidemiology) AND 
[humans]/lim AND [1990-2010]/py 
1,604 
 
 'systemic lupus erythematosus'/exp OR 'systemic lupus erythematosus' AND 
('incidence'/exp OR 'incidence') AND ('epidemiology'/exp OR epidemiology) AND 
[humans]/lim AND [1990-2010]/py 
936 
 
 'systemic lupus erythematosus'/exp OR 'systemic lupus erythematosus' AND 
('prevalence'/exp OR 'prevalence') AND ('incidence'/exp OR 'incidence') AND 
('epidemiology'/exp OR epidemiology) AND [humans]/lim AND [1990-2010]/py 
255 
 
Google Scholar “systemic lupus erythematosus” 294,000 
 “systemic lupus erythematosus” “prevalence” 49,200 
 “systemic lupus erythematosus” “incidence” 64,600 
 "systemic lupus erythematosus" "incidence" "prevalence" 22,700 
 “systemic lupus erythematosus” “prevalence”, limit to 1990-2010 9,950 
 “systemic lupus erythematosus” “incidence”, limit to 1990-2010 13,100 
 "systemic lupus erythematosus" "incidence" "prevalence", limit to 1990-2010 5,470 
Conference Abstracts 
Year Search term: “Incidence lupus” Search term: “Prevalence lupus” 
2009 31 hits (1 relevant abstract) 60 hits (1 relevant abstract) 
2008 31 hits (1 relevant abstract) 58 hits (1 relevant abstract) 
2007 23 hits (0 abstract) 55 hits (1 relevant abstract) 
2006 37 hits (1 relevant abstract) 67 hits (2 relevant abstracts) 
113 
 





Studies excluded from systematic 
review 




• Clearly not meeting eligibility 
criteria (n=6,280) 
• Duplicates (n=5,408) 
Additional articles identified 
from article references (n=8) 
Studies retrieved from more 
detailed evaluation (n=182) 
 
Potentially relevant articles 
identified for initial screening 
(n=11,870) 
Studies Analyzed in systematic review (n= 65: 61 from original search + 4 from hand-search) 
 
Potentially appropriate articles 
to be included in the systematic 
review (n=74)  
Excluded (n=13) 
• Failed to meet 
• eligibility criteria 
(n=3) 
• Serial reports from 
the same study 
(n=8) 




• Failed to meet 
eligibility criteria 
(n=3) 
• Serial report from 






Table 6.2: Incidence of SLE, by Geographic Region 
 






















data in 2006) 
Iseki et al. (1994) 1972-1991 Japan 5-77 All 
Clinical, hospital 
records 34 1,223,395 
2.8 
(1.9-3.9) 2.37* 
Fujikawa et al. 




Anstey et al. 
(1993) 
1984-




13 24,900 12 (2.5-35.2) 11 
Europe Somers et al. 
(2007) 
1990-
1999 UK All All 
General Practice 




et al. (2000) 
1981-




41 172,300 4.6 (2.0-9.1) 4.8 
Jonsson et al. 
(1990) 
1981-




38 200,470 4 (1.7-7.9) 4 
Johnson et al. 
(1995) 
1991-




33 872,877 3.8 (2.6-5.3) 3.8 









23 613,700 3.7 (2.4-5.6) 3.7 




14 387,841 3.6 (2-6.1) 




et al. (1990) 
1975-




76 227,742 3.5 (1.5-6.9) 3.3 
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UK All All 
Clinical, hospital, 
prescription records 390 12,911,216 
3 
(2.7-3.3) 3.02 
Eilertsen et al. 
(2009) 
1978-
2006 Norway All All Hospital registries 139 177,640 
2.8 
(0.9-6.6) 2.8 
Nossent et al. 
(2001) 
1978-




mortality DB, general 
practitioners 
83 177,033 2.8 (0.9-6.6) 
2.6 (adult 
estimate) 
Govoni et al.(2006) 1996-2002 Italy ≥16 All 
Hospital, clinical 
records; National 
Health Care System 
9* 346,826 2.6 (1.2-4.9) 
2.6 (used the 
most recent 
data) 
Lopez et al. (2003) 1992-2003 Spain All All 
Clinical, hospital 
records 116 1,073,971 
2.1 
(1.4-3.2) 2.15 
Alamanos et al. 
(2003) 
1982-
2001 Greece All All 
Clinical, hospital 
records 9* 488,435 
1.8 
(0.8-3.5) 1.9 
Laustrup et al. 
(2009) 
1995-





4 385,093 1 (0.3-2.7) 1.04 
Kaipiainen-
Seppanen et al. 
(1996) 
1980-




7 270,000 0.7 (0.1-2.7) 0.8 
Huemer et al. 
(2001) 
1997-
1998 Austria ≤16 All Hospital registries 6 618,311 
0.5 
(0.1-1.4) 0.48 
Pelkonen et al. 
(1994) 
1983-





15 1,016,619 0.4 (0.1-1) 0.37 
North 




USA 10-62 All Insurance database 299 5,000,000 
6 
(5.3-6.7) 6 





USA All All 
Electronic database 
by the Rochester 
Epidemiology Project 









USA 14-90 All 
Community clinic 





Nossent et al. 
(1992) 
1980-




68 146,500 4.8 (1.9-9.8) 4.63 
Deligny et al. 
(2002) 
1990-




180 381,427* 4.7 (2.8-7.5) 4.7 
Bernatsky et al. 
(2007) 
1994-




and procedure data 
219 7,492,300 2.9 (2.5-3.3) 3 









191 8,018,694 2.4 (2.1-2.7) 2.4 










Physicians survey 37 128,685 2.3 (0.5-6.8) 
Ranges from 
0.0 to 7.4 
Malleson et al. 
(1996) 
1991-
1993 Canada ≤16 All Physicians survey 52 4168731** 
0.6 
(0.4-0.9) 0.28 





USA ≤18 All 
Hospital/clinical 





Pereira Vilar et al. 
(2002) 2000 Brazil >15 All 
Clinical, hospital, 
laboratory records 43 493,239 
8.7 
(6.3-11.7) 8.7 
Eilertsen had incidence data that were split into 2 time periods; however, prevalence estimate was from the entire observation period. Therefore, we report the incidence to reflect 





Table 6.3: Prevalence of SLE, by Geographic Region 
 















Iseki et al. (1994) 1972-1991 Japan 5-77 All 
Clinical, hospital 
records 462 1223395 
37.8  
(34.4-41.4) 37.76* 




records 539 1253488* 
43 
 (39.4-46.8) 43 




4 9720 41.2  (11.2-105.3) 41* 
Al-Arfaj et al. 
(2002) Unknown 
Saudi 




2 10372 19.3  (2.3-69.6) 19.28 




1 8998 11.1  (0.3-61.9) 11.1* 




365 5775640 6.3  (5.7-7.0) 6.3 
Karadsheh et al. 
(2000) 
1969-
1997 Jordan 9-60 All 
Clinical, hospital 
records 76 2235294* 
3.4  
(2.7-4.3) 3.4 
Malaviya et al. 












22 24900 88.4  (55.4-133.7) 52 
Grennan et al. 




23 45305 50.8  (32.2-76.2) 50.77* 
Segasothy et al. 
(2001) 
1990-





physicians survey 24* 50000 
48  
(30.8-71.4) 48* 
Bossingham et al. 
(2003) 
1996-









Europe Benucci et al. 
(2005) 2002 Italy >18 All 
Clinical records, 




et al. (2000) 
1981-








Eilertsen et al. 
(2009) 
1978-
2006 Norway All All Hospital registries 114 177640 
64.2  
(52.9-77.1) 64.1 
Govoni et al. 
(2006) 
1996-





201 346826 58.0  (50.2-66.5) 57.9 
Andrianakos et al. 
(2003) 
1996-
1999 Greece >18 All 
Clinical, hospital 
records 7* 14233 
49.2  
(19.8-101.3) 49.18* 









666 1635169 40.7  (37.7-43.9) 
40.7 (most 
recent) 
Alamanos et al. 
(2003) 
1982-
2001 Greece All All 
Clinical, hospital 




et al. (1990) 
1975-




86 239498 35.9  (28.7-44.3) 
35.9 (age-
adjusted) 
Lopez et al. (2003) 1992-2003 Spain All All 
Clinical, hospital 
records 367 1073971 
34.2  
(30.8-37.9) 34.12 
Eaton et al. (2007) 1977-2001 Denmark All All 
The National 
Hospital Register of 
Denmark 
1732 5472032 31.7  (30.2-33.2) 31.65* 
Laustrup et al. 
(2009) 
1995-






109 385155 28.3  (23.2-34.1) 28.3 
Johnson et al. 
(1995) 
1991-




242 872877 27.7  (24.3-31.4) 27.7 
Samanta et al. 
(1992) 1989 
Leicaster, 







50 191469 26.1  (19.4-34.4) 26.1 
Gourley et al. 
(1997) 
1992-




415 1631800 25.4  (23.0-28.0) 25.4 
119 
 









147 610000 24.1  (20.4-28.3) 
24 (age-
adjusted) 




84 387841 21.7  (17.3-26.8) 21.7 
Dadoniene et al. 
(2006) 2004 Lithuania All All 
Population-based 
registry 76 470451 
16.2  
(12.7-20.2) 16.2 
Mazur et al. (1995) Unknown Moldova Adults All Clinical, hospital records 116 3222222 
3.6  
(3.0-4.3) 3.6 
Zink et al. (2001) 1993-1998 Germany ≥15 All 
Clinical, hospital 




et al. (2010) 
2007-















Ward et al. (2004) 1988-1994 
Nationwide, 
USA ≥18 All 
Self-reported 
physician diagnosis 

















USA All All 
Electronic 













≥18 All Telephone survey 5 4304 123.9  (40.3-289.0) 
124 
(validated) 
Chakravarty et al. 
(2007) 2000 
California, 
USA ≥18 All 
Hospitalization 











20 19489 102.6  (62.7-158.4) 103 




records 9 9770 
92.1 (42.1-
174.8) 91.7 





USA 14-90 All 
Community clinic 





Post et al. (1998) 1996 Moorpark, California 34-67 All 
Patients survey, 
physicians survey 20 29310 
68.2 (41.7-
105.4) 68.23 
Deligny et al. 
(2002) 
1990-




245 381427* 64.2 (56.4-72.8) 64.2 
Bernatsky et al. 
(2007) 
1994-
2003 Canada All All 
Administrative 
data: billing codes, 
hospitalization data 
and procedure data 
3825 7492300 51.1 (49.4-52.7) 




Nossent et al. 
(1992) 
1980-




69 146500 47.1 (36.6-59.6) 47.6 





USA All All 
Physicians survey, 
patients survey 454 1086124 
41.8 (38.0-
45.8) 41.8 










Physicians survey 257 1100295 23.4 (20.6-26.4) 22.1 
Balkaran et al. 
(2004) 
1992-
2001 Trinidad 5-17 All 
Clinical, hospital 
records 33 168860* 
19.5 (13.5-
27.4) 19.54* 
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CHAPTER 7 
 Conclusions and Future Directions  
 
Summary of Study Results  
 The overarching goal of this dissertation was to describe the prevalence, type 
distribution, and risk factors of oral HPV infection in three populations: 1) HIV-positive 
patients seen at the University of Michigan; 2) HIV-negative individuals with confirmed 
HIV-negative status; and 3) self-reported HIV-negative individuals. By making such 
comparisons, the study was intended to improve the understanding of risks of 
oropharyngeal cancers in HIV-positive and HIV-negative individuals, using oral HPV 
infection as a proxy.  
 Chapter 4 presented the overall findings from the study. As hypothesized, the 
prevalence of oral HPV infection was the highest in the HIV-positive group. This finding 
is consistent with previous studies comparing HIV-positive and HIV-negative 
populations (1-5). Previously reported risk factors, such as increasing age (3-8), sexual 
orientation (9, 10), lifetime number of sexual partners (5, 6, 11, 12), certain sexual 
behaviors (5, 6, 9), open-mouth kissing (11, 12), alcohol consumption (9), smoking (5, 
6, 8, 9), lower CD4 count (3, 6, 8), and current HIV therapy (8) were not significantly 
associated with oral HPV infection in this study. However, there were variables that 
were significantly associated with oral HPV infection in the univariate analyses that were 
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consistent with previous literature. These risk factors included male gender (3, 5, 6), 
lifetime number of vaginal sex partners (5, 11, 12), and HIV viral load (6). In this study, it 
was found for the first time that male partner's circumcision status significantly affects 
the risk of oral HPV infection. Like Pickard and colleagues (11), the decreased odds of 
oral HPV infection with alcohol consumption was observed in this study.  
 Another interesting finding from this study is that the HIV-negative population that 
was presumed to be at higher risk actually had lower oral HPV prevalence than the HIV-
negative population that was presumed to have the lowest risk. Specifically speaking, 
HARC participants were selected to be in the "tested HIV-negative" group, under the 
assumption that those seeking HIV testing may have shared risk factors with HIV-
positive individuals. Therefore, forming this "tested HIV-negative" group was a way 
minimize confounding by creating a group that is comparable to the HIV-positive group. 
Even though the sample sizes of each study group were small, the study findings 
suggest that, in this particular study population, the "tested HIV-negative" individuals 
may have lower risk of oral HPV infection. Factors that could account for this 
observation are younger age, access to free counseling, health education, and condom 
use. Frequent clients at HARC have multiple opportunities to receive to these 
resources, further increasing the level of knowledge and awareness related to 
prevention of STDs. In addition, the "tested HIV-negative" group was about 20 years 
younger than the HIV-infected and the self-reported HIV negative groups. Since 
increasing age is associated with oral HPV infection (5), the younger age in the "tested 
HIV-negative" group may also explain the lower prevalence observed in this group. 
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 Given that the great majority of our HIV-positive participants were 
immunocompetent and highly adherent to their HIV therapy, it remains unknown 
whether HIV-related immunosuppression is a risk factor for oral HPV infection. In this 
study, lower CD4 count was not associated with oral HPV infection; however, increasing 
HIV viral load increased the risk. This suggests that viremia, which also may have a 
deleterious effect on immune function,  may be associated with increased oral HPV 
prevalence. Despite its association with increased oral HPV infection, viremia could be 
confounded by risky sexual behaviors, lack of medication adherence, and older age. 
However, such interactions could not be assessed due to a small number (n=2) of HIV-
infected participants with HIV viral load ≥100,000 copies/µL, and remain an important 
area to be explored in future studies. 
 Chapter 5 assessed the concordance of information between patient self-report 
and medical chart review for HIV-infected study participants. This assessment served 
as a validation tool to determine the accuracy of the findings reported in chapter 4. 
Consistent with previous literature, it was found that the degree of agreement between 
the two data sources largely depends on the type of questions and disease 
classification (13, 14). Since this study consisted of HIV-infected individuals, questions 
related to STDs were the main focus of the questionnaire. With that being said, 
sensitivity was higher when the medical records were used as the gold standard, 
because accurate reporting depended on diagnostic tools (13). However, high 
specificity of STD reporting in both data sources suggests that the negative STD status 
is often correctly reported. As with previous studies, accurate reporting of condom use 
continues to be problematic (15-18). Despite the variability in concordance, sensitivity, 
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and specificity between to the data sources, it is unlikely that these discrepancies 
affected the overall study results regarding oral HPV risk calculation for HIV-infected 
participants. The errors were minimized because the clinical data abstracted from the 
medical records were utilized in the statistical models. 
 Chapter 6 highlighted the global incidence and prevalence of SLE between 1990 
and 2010. Due to significant heterogeneity of incidence and prevalence across 
geographic regions, the pooled estimates were not computed. However, the systematic 
literature review determined that SLE disproportionately affects women of childbearing 
age and individuals of African origin. There were several notable reasons that may have 
contributed to the variability in incidence and prevalence across the world and even 
within a same country. First, incidence and prevalence were affected by demographic 
factors. For example, the studies with higher proportions of women and individuals of 
African descent had higher incidence and/or prevalence. Likewise, studies performed in 
children had lower rates of SLE since the average onset of SLE is 31 years old (19). 
Second, the accuracy in incidence and prevalence depended on the study design. 
While a cohort design allowed for changes in incidence and prevalence to be observed 
over time, a cross-sectional design provided only a snapshot, limiting the amount of 
data for this analysis. Third, surveillance method may have affected case finding, as 
active surveillance typically leads to more cases found. Fourth,  case definition and 
ascertainment method may have affected incidence and prevalence estimates. Broader 
case definition and less stringent ascertainment methods are likely to have led to more 
cases being identified. Fifth, it is likely that differences in case reporting mechanism 
resulted in misclassification. For example, physician-diagnosed reporting of SLE is more 
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accurate than patient self-reporting. Lastly, incidence and prevalence may have been 
underestimated in circumstances where undiagnosed cases in a community had not 
reached the healthcare system for screening and diagnosis. It is also possible that 
some other cases may have received care outside of the catchment area. Therefore, 
catchment area of a study may have affected incidence and prevalence rates.  
 Although SLE itself has not been identified as a risk factor for oral HPV infection, 
it has been reported that SLE increases the risk of HPV in the genital region and HPV-
associated cancers (20-22). Given that patients with SLE are often prescribed 
immunosuppressant drugs, the findings from the HIV-infected population in the EPI 
Study may extend to other individuals with immunodeficiency. Further, there may be 
important implications related to the immunogenicity of HPV vaccines in this population, 
which in turn could have consequences on the HPV incidence and prevalence as well 
as HPV-associated cancers. 
 
Public Health Implications 
 Because the study was conducted in Michigan, where HIV incidence and 
prevalence are considerably lower than the vast majority of the world, it is expected that 
the findings from the EPI Study would have even greater implications for future 
prevention and control of HPV infection and head and neck cancers in other geographic 
regions, particularly in areas where oral HPV infection rates may be more amplified due 
to higher HIV incidence and prevalence. 
 Unlike cervical cancer, there are currently no standard, validated methods for 
oral cancer screening. Due to the anatomic location and lack of screening methods, oral 
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cancers are diagnosed at later stages, often with distant metastases (23). Until an 
effective oral cancer screening method is developed, prevention strategies must focus 
on risk reduction. This dissertation identified male circumcision as a potential tool to 
decrease the risk of oral HPV infection. It is well-documented that male circumcision 
significantly decreases the risk of HIV acquisition and transmission (24). It has also 
been reported that male circumcision could reduce prevalence and viral load of penile 
HPV (25, 26). However, this practice is controversial and is not widely accepted due to 
religious and/or cultural beliefs (27). Therefore, more commonly accepted sexual 
prevention measures should continue to be encouraged.    
 The implications of validation studies such as the one performed as part of this 
dissertation are profound. As mentioned, there is variability in the degree of 
concordance, sensitivity, and specificity depending on the questionnaire items. 
Research studies that rely on self-report without validation could incur errors due to 
misclassification of disease status, leading to incorrect inferences regarding study 
outcomes. In clinical practice, patient-physician concordance could influence a variety of 
outcomes, including decision-making related to HIV treatment and medication 
adherence (28). Therefore, the findings from this dissertation encourages good patient-
physician relationship and communication to improve patient's knowledge and 






Strengths and Limitations 
 One of the notable strengths of this dissertation is the unique epidemiological 
study design. Two HIV-negative groups were utilized for comparison to the HIV-positive 
group. The use of two HIV-negative groups as a reference has not been done in 
previous studies. By evaluating the prevalence in three populations, this study was able 
to more clearly demonstrate that patients with HIV infection have an increased risk of 
oral HPV infection compared to HIV-negative populations. Further, it was learned that 
an HIV-negative population that was presumably at risk actually had lower oral HPV 
prevalence than the HIV-negative population that presumably had the least risk. Such 
findings emphasize the importance of replicating similar epidemiological studies in other 
populations. Another strength of this dissertation is that a validation study was 
performed to evaluate the accuracy of data. Since this study consisted of primary data 
collection, it was especially important to compare the participant self-reported data to 
the medical records. Overall, there was good agreement between the two data sources. 
For the laboratory component of this research, two detection methods were utilized, 
which led to more HPV infections being detected. This approach also allowed for 
detection of concomitant HPV infections. The method-specific strengths of the multiplex 
PCR-MassArray were that it allowed for detection and identification of multiple high-risk 
HPV types and represented low risk-types, HPV 6, 11, and 90, using only 10 ng/µL of 
sample in a high throughput assessment.. The second method uses multiple primer 
sets, PGMY09/11 (29) to detect additional HPV types which can then be assessed by 
sequencing. This allowed for detection of HPV types that were not included in the 
multiplex PCR-MassArray assay, leading to a greater variety of HPV types detected. As 
137 
 
demonstrated previously, the use of more than one detection method greatly improves 
the detection rates (30), and this approach was essential in a study with such a small 
sample size. 
 There are several limitations. The most obvious is the limited sample size and 
power. In studies among cancer-free populations that had small sample sizes (i.e., less 
than 200 study participants), it has been reported that the HPV prevalence appeared to 
have an inversely proportional relationship to the study sample size (31). This suggests 
that, while the prevalence reported in this dissertation may be elevated, the findings 
from this study cannot be generalized to other populations because the study relied on 
the convenience sample of HIV-positive patients at the University of Michigan and HIV-
negative individuals from Washtenaw and surrounding counties. The characteristics of 
this study population were unique. Of note, the HIV-positive participants were mostly 
MSM, and the study participants were receiving HAART therapy and responding well to 
treatment with CD4 cell counts in the normal range. Little variation in the HIV disease 
status means that the effect of immunosuppression on oral HPV infection could not be 




 Despite considerable progress in improving the understanding of HPV-
associated OPSCC, it is clear that more research, particularly prospective studies, is 
needed to evaluate the natural history of oral HPV infection. There are now several 
variables that are associated with oral HPV infection. Since there is considerable 
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variability in HPV prevalence which likely arises from differences in the variety of 
behavioral risk factors, further research is needed determine independent factors that 
affect the acquisition, persistence, and recurrence of oral HPV infection.  
 The long term clinical implications for individuals who have had HPV DNA 
detected in their oral cavities is unknown. A potential way to improve the understanding 
of the clinical significance of oral HPV infection is to examine the state of viral activation 
by assessing viral transcripts. For example, since the expression of E6 and E7 
oncoproteins is required for maintenance of transformation (32), it could imply that 
individuals having such a status may have persistent HPV infection that may require 
monitoring over time. Partial transcripts with high levels of E6 and E7 and low levels of 
E1 and E2 may imply that viral transformation has occurred (33), and individuals with 
these conditions should be surveilled for possible oral cancer. 
 A multi-site case-control study investigating the risk of HNCs is currently 
underway through the Head & Neck Cancer Specialized Program of Research 
Excellence (SPORE). However, because there are so few studies that have compared 
HNCs between HIV-positive and HIV-negative populations, more research is need to 
better understand the clinical implications of HNCs in the HIV population. 
 From the research standpoint, there is a need to improve the tools to effectively 
capture data, both in the field and in the laboratory. This dissertation clearly 
demonstrated the importance of validated questionnaires, especially for covering 
sensitive topics such as HPV and HIV. The improvement must also take place in the 
laboratory. Currently, tests for HPV detection is expensive, labor-intensive, and time-
consuming. Although high-throughput technology has been developed for HPV 
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detection (34), the cost remains an issue. In this study, detection method was base on 
DNA; however, as proposed above, gene expression analysis could provide more 
detailed information that may have direct clinical application. For oral cancer screening 
to have meaningful impact on public health, it must become widely accessible and used. 
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CONSENT TO BE PART OF A RESEARCH STUDY
INFORMATION ABOUT THIS FORM
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1.2  Company or agency sponsoring the study: University of Michigan 
1.3  Names, degrees, and affiliations of the researchers conducting the study: 
Mikiko Senga, Department of Epidemiology, School of Public Health
James Riddell IV, M.D., Department of Internal Medicine, Medical School
Thomas E. Carey, Ph.D., Department of Otolaryngology; Medical School
Gregory T. Wolf, M.D., F.A.C.S., Department of Otolaryngology; Medical School
Heather Walline, Department of Otolaryngology; Medical School 
2.  PURPOSE OF THIS STUDY
2.1  Study purpose: 
The purpose of this study is to examine saliva samples from both HIV positive and negative 
individuals and look for DNA associated with human papillomavirus (HPV).  Additionally, 
questionnaires will be requested of study participants.
3.  INFORMATION ABOUT STUDY PARTICIPANTS (SUBJECTS)
Taking part in this study is completely voluntary.  You do not have to participate if you don't 
want to.  You may also leave the study at any time.  If you leave the study before it is finished, 
there will be no penalty to you, and you will not lose any benefits to which you are otherwise 
entitled.  
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3.1  Who can take part in this study?
HIV-positive and HIV-negative subjects will be asked to take part in this study.  HIV patients 
seen at the University of Michigan and their partners may be asked to participate in this study, 
regardless of HIV status. HIV-negative individuals seeking HIV testing and counseling at 
HIV/AIDS Resource Center (HARC) and HIV-negative individuals from the community may also 
participate in the study. Each subject must be at least 18 years of age and willing to return for 
required follow-up visits, outlined below.
3.2  How many people (subjects) are expected to take part in this study?
It is expected that 100 HIV-positive subjects will participate in this study at the University of 
Michigan.  Up to 100 partners of HIV-positive individuals will be included in this study. 100 HIV-
negative subjects are expected to participate.
4.  INFORMATION ABOUT STUDY PARTICIPATION 
4.1  What will happen to me in this study?  
At your initial visit for the study, the study staff will provide you with a questionnaire that you will 
be asked to complete either by yourself or with the help of staff.  You will be asked to complete 
this survey in the privacy of a research room with a staff member.  Or you may be asked to take 
the survey home and mail it back once you complete it with pre-paid postage to the study 
coordinator.   This survey will be linked to you only through a study number and will not bear 
your name.
At each visit, you will be asked to spit your saliva into a collection cup, or swish an oral rinse in 
your mouth and spit it into a cup.  This oral sample will be banked for future testing, should you 
provide your consent.  At each visit after your initial visit, you will be asked to complete a shorter 
questionnaire, asking if there have been any changes in the answers you gave in the 
questionnaire at your initial visit.   Again, this questionnaire will be done in the privacy of an 
exam room, either by yourself or with the help of staff. 
The researchers in this study would like to bank your oral sample for future testing.  If you 
withdraw your consent for this study, every effort will be made to destroy any remaining sample.  
However, the researchers are requesting to keep the oral rinse sample(s) you have already 
provided.  If you are in agreement with banking your samples for future use by the researchers, 
please indicate here:
Yes, I am in agreement with the banking of my oral samples for future testing:
Initials:______   Date:_____
No, I do not agree that the researchers can bank my oral samples for future testing:
Initials:______  Date:______
4.2  How much of my time will be needed to take part in this study?  
The initial visit will take longer, as you will be asked to complete a more detailed questionnaire.  
The total estimated time for this visit is 1 hour.  Follow-up visits may be scheduled along with 
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your routine care visits and will either add an additional 30 minutes to your routine visit in a 
separate research room, or will take 30 minutes on its own in a research exam room.  
4.3 When will my participation in the study be over? 
Your participation in this study will be over once you have completed all follow-up visits, should 
you agree to return, for approximately 2 years.  Each visit will be 3-4 months apart, timed with 
your routine care visits. You may participate in as little as one visit or as many as 6 visits (i.e. up 
to 3 times per year for 2 years).
5.  INFORMATION ABOUT RISKS AND BENEFITS 
5.1  What risks will I face by taking part in the study?  What will the researchers do to 
protect me against these risks?
The known or expected risks are:
 Saliva collection: If you are asked to provide saliva using the oral rinse method, the oral 
rinse may sting your mouth and produce an unfavorable taste.
 Questionnaire(s):  There is a risk that the questionnaire may contain questions that 
make you feel uncomfortable or uneasy.  If at any time you feel uncomfortable, you may 
notify the staff member administering the questionnaire and you will be permitted to skip 
questions or portions of the survey that bring your discomfort.  
5.2  What happens if I get hurt, become sick, or have other problems as a result of this 
research?
The researchers have taken steps to minimize the risks of this study.  Even so, you may still 
have problems or side effects, even when the researchers are careful to avoid them. Please tell 
the researchers listed in Section 10 about any injuries, side effects, or other problems that you 
have during this study.  
5.3  If I take part in this study, can I also participate in other studies?
 Being in more than one research study at the same time, or even at different times, may 
increase the risks to you.  It may also affect the results of the studies.  You should not take part 
in more than one study without approval from the researchers involved in each study.  
5.4  How could I benefit if I take part in this study?  How could others benefit?  
You may not receive any personal benefits from being in this study.   
Future individuals who are HIV positive and diagnosed with head and neck cancer may benefit if 
a better screening method is developed after this research is completed.
5.5  Will the researchers tell me if they learn of new information that could change my 
willingness to stay in this study?
Yes, the researchers will tell you if they learn of important new information that may change your 
willingness to stay in this study. If new information is provided to you after you have joined the 
study, it is possible that you may be asked to sign a new consent form that includes the new 
information.
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6.  OTHER OPTIONS 
6.1  If I decide not to take part in this study, what other options do I have?
This study is not providing any care. You can receive the same treatment without being in this 
study. 
7.  ENDING THE STUDY
7.1  If I want to stop participating in the study, what should I do?
You are free to leave the study at any time.  If you leave the study before it is finished, there will 
be no penalty to you. You will not lose any benefits to which you may otherwise be entitled.  If 
you choose to tell the researchers why you are leaving the study, your reasons for leaving may 
be kept as part of the study record. If you decide to leave the study before it is finished, please 
tell one of the persons listed in Section 10 “Contact Information” (below).
7.2  Could there be any harm to me if I decide to leave the study before it is finished? 
If you want to withdraw from the study at any time, you are free to do so, even if you do not give 
a reason. If you do withdraw, your usual medical care will not be affected in any way. If 
necessary for your medical care, your study doctor may advise you to have some follow-up 
tests. 
If you withdraw from the study, no new information (data) about you will be added to the 
database. The researchers would still like to be able to examine the oral samples you provided if 
you decide to leave the study before it is finished.
7.3  Could the researchers take me out of the study even if I want to continue to 
participate?
Yes. There are many reasons why the researchers may need to end your participation in the 
study.  Some examples are:
 The researcher believes that it is not in your best interest to stay in the study.
 You become ineligible to participate.
 Your condition changes and you need treatment that is not allowed while you are taking 
part in the study.
 You do not follow instructions from the researchers.
 The study is suspended or canceled.
8.  FINANCIAL INFORMATION
8.1  Who will pay for the costs of the study? Will I or my health plan be billed for any 
costs of the study?  
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There are no costs to participants associated with being in this study.
By signing this form, you do not give up your right to seek payment if you are harmed as a result 
of being in this study.  
8.2  Will I be paid or given anything for taking part in this study?
Yes, you will be paid $10 per study visit.
8.3  Who could profit or financially benefit from the study results?
None of the personnel involved in this study could profit or benefit financially from the study 
results.
9.  CONFIDENTIALITY OF SUBJECT RECORDS AND AUTHORIZATION TO RELEASE 
YOUR PROTECTED HEALTH INFORMATION 
The information below describes how your privacy and the confidentiality of your research 
records will be protected in this study.
9.1  How will the researchers protect my privacy?
Your research information will be stored in a locked cabinet.  All specimens will be coded before 
they are analyzed, and the research personnel who analyze the specimens will not be able to 
link them with any of your identifying information or medical history.  All data regarding your oral 
rinse sample will be stored in a password-protected database with barcoding of each sample to 
further enhance the privacy of your sample.
9.2  What information about me could be seen by the researchers or by other people?  
Why?  Who might see it?
Signing this form gives the researchers your permission to obtain, use, and share information 
about you for this study, and is required in order for you to take part in the study.  Information 
about you may be obtained from any hospital, doctor, and other health care provider involved in 
your care, including:
 Hospital/doctor's office records, including test results (X-rays, blood tests, urine tests, 
etc.)
 Alcohol/substance abuse treatment records
 Your AIDS/HIV status
 All records relating to your illness, the treatment you have received, and your 
response to the treatment
 Billing information
There are many reasons why information about you may be used or seen by the researchers or 
others during or after this study.  Examples include:
 The researchers may need the information to make sure you can take part in the 
study.  
 The researchers may need the information to check your test results or look for side 
effects.  
 University, Food and Drug Administration (FDA), and/or other government officials 
may need the information to make sure that the study is done in a safe and proper 
manner.   
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 Study sponsors or funders, or safety monitors or committees, may need the 
information to: 
o Make sure the study is done safely and properly
o Learn more about side effects 
o Analyze the results of the study 
 Insurance companies or other organizations may need the information in order to pay 
your medical bills or other costs of your participation in the study.
 The researchers may need to use the information to create a databank of information 
about your condition or its treatment.
 Information about your study participation may be included in your regular UMHS 
medical record.
 If you receive any payments for taking part in this study, the University of Michigan 
accounting department may need your name, address, social security number, 
payment amount, and related information for tax reporting purposes. 
 Federal or State law may require the study team to give information to government 
agencies. For example, to prevent harm to you or others, or for public health reasons.
The results of this study could be published in an article, but would not include any information 
that would let others know who you are. 
9.3  What happens to information about me after the study is over or if I cancel my 
permission?
As a rule, the researchers will not continue to use or disclose information about you, but will 
keep it secure until it is destroyed.  Sometimes, it may be necessary for information about you to 
continue to be used or disclosed, even after you have canceled your permission or the study is 
over.  Examples of reasons for this include:
 To avoid losing study results that have already included your information 
 To provide limited information for research, education, or other activities  (This 
information would not include your name, social security number, or anything else that 
could let others know who you are.) 
 To help University and government officials make sure that the study was conducted 
properly
As long as your information is kept within the University of Michigan Health System, it is 
protected by the Health System’s privacy policies.  For more information about these policies, 
ask for a copy of the University of Michigan Notice of Privacy Practices.  This information is also 
available on the web at http://www.med.umich.edu/hipaa/npp.htm. Note that once your 
information has been shared with others as described under Question 9.2, it may no longer be 
protected by the privacy regulations of the federal Health Insurance Portability and 
Accountability Act of 1996 (HIPAA).  
9.4  When does my permission expire?  
Your permission expires at the end of the study, unless you cancel it sooner. You may cancel 
your permission at any time by writing to the researchers listed in Section 10 "Contact 
Information" (below).  
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10.  CONTACT INFORMATION
10.1  Who can I contact about this study?
Please contact the researchers listed below to:
 Obtain more information about the study
 Ask a question about the study procedures or treatments
 Talk about study-related costs to you or your health plan 
 Report an illness, injury, or other problem (you may also need to tell your regular doctors)
 Leave the study before it is finished
 Express a concern about the study
Principal Investigator: Mikiko Senga
Mailing Address: 1500 E. Medical Center Drive, 3210 Taubman CenterAnn Arbor, MI 
48109-5378
Telephone: 734-647-9830
Study Coordinator: Mary Reyes
Mailing Address: 1500 E. Medical Center Drive, 3120 Taubman CenterAnn Arbor, MI 
48109-5378
Telephone: 734-647-9830
You may also express a concern about a study by contacting the Institutional Review Board 
listed below, or by calling the University of Michigan Compliance Help Line at 1-888-296-2481.
University of Michigan Medical School Institutional Review Board (IRBMED)
2800 Plymouth Road
Building 200, Room 2086




If you are concerned about a possible violation of your privacy, contact the University of 
Michigan Health System Privacy Officer at 1-888-296-2481.
When you call or write about a concern, please provide as much information as possible, 
including the name of the researcher, the IRBMED number (at the top of this form), and details 
about the problem.  This will help University officials to look into your concern.  When reporting a 
concern, you do not have to give your name unless you want to.
11.  RECORD OF INFORMATION PROVIDED
11.1  What documents will be given to me?
Your signature in the next section means that you have received copies of all of the following 
documents:
 This "Consent to be Part of a Research Study" document.  (Note: In addition to the copy 
you receive, copies of this document will be stored in a separate confidential research file 
and may be entered into your regular University of Michigan medical record.)
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I understand the information printed on this form.  I have discussed this study, its risks and potential benefits, and 
my other choices with ____________________.  My questions so far have been answered.  I understand that if I 
have more questions or concerns about the study or my participation as a research subject, I may contact one of the 
people listed in Section 10 (above).  I understand that I will receive a copy of this form at the time I sign it and later 
upon request.  I understand that if my ability to consent for myself changes, either I or my legal representative may 
be asked to re-consent prior to my continued participation in this study.
Signature of Subject: Date: 
Name (Print legal name):                     
Patient ID: Date of Birth: 
Principal Investigator (or Designee):
I have given this research subject (or his/her legally authorized representative, if applicable) information about this 
study that I believe is accurate and complete.  The subject has indicated that he or she understands the nature of 
the study and the risks and benefits of participating.
Name: Title: 
Signature: Date of Signature: 
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CONSENT TO BE PART OF A RESEARCH STUDY
INFORMATION ABOUT THIS FORM
You may be eligible to take part in a research study.  This form gives you important information 
about the study.  It describes the purpose of the study, and the risks and possible benefits of 
participating in the study.  
Please take time to review this information carefully.  After you have finished, you should talk to 
the researchers about the study and ask them any questions you have.  You may also wish to 
talk to others (for example, your friends, family, or other doctors) about your participation in this 
study.  If you decide to take part in the study, you will be asked to sign this form.  Before you 
sign this form, be sure you understand what the study is about, including the risks and possible 
benefits to you.
1.  GENERAL INFORMATION ABOUT THIS STUDY AND THE RESEARCHERS
1.1  Study title: The Etiology of Papillomavirus Infections (EPI) Study
1.2  Company or agency sponsoring the study: University of Michigan 
1.3  Names, degrees, and affiliations of the researchers conducting the study: 
Mikiko Senga, Department of Epidemiology, School of Public Health
James Riddell IV, M.D., Department of Internal Medicine, Medical School
Thomas E. Carey, Ph.D., Department of Otolaryngology; Medical School
Gregory T. Wolf, M.D., F.A.C.S., Department of Otolaryngology; Medical School
Heather Walline, Department of Otolaryngology; Medical School 
2.  PURPOSE OF THIS STUDY
2.1  Study purpose: 
The purpose of this study is to examine saliva samples from both HIV positive and negative 
individuals and look for DNA associated with human papillomavirus (HPV).  Additionally, 
questionnaires will be requested of study participants.
3.  INFORMATION ABOUT STUDY PARTICIPANTS (SUBJECTS)
Taking part in this study is completely voluntary.  You do not have to participate if you don't 
want to.  You may also leave the study at any time.  If you leave the study before it is finished, 
there will be no penalty to you, and you will not lose any benefits to which you are otherwise 
entitled.  
eResearch Users—Do not type in Header Fields.
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3.1  Who can take part in this study?
HIV-positive and HIV-negative subjects will be asked to take part in this study.  HIV patients 
seen at the University of Michigan and their partners  may be asked to participate in this study, 
regardless of HIV status. HIV-negative individuals seeking HIV testing and counseling at 
HIV/AIDS Resource Center and HIV-negative individuals from the community may also 
participate in the study. Each subject must be at least 18 years of age and willing to return for 
required follow-up visits, outlined below.
3.2  How many people (subjects) are expected to take part in this study?
It is expected that 100 HIV-positive subjects will participate in this study at the University of 
Michigan.  Up to 100 partners of HIV-positive individuals will be included in this study. 100 HIV-
negative subjects are expected to participate.
4.  INFORMATION ABOUT STUDY PARTICIPATION 
4.1  What will happen to me in this study?  
The study staff will provide you with a questionnaire that you will be asked to complete either by 
yourself or with the help of staff.  You will be asked to complete this survey in the privacy of a 
research room with a staff member.  Or you may be asked to take the survey home and mail it 
back once you complete it with pre-paid postage to the study coordinator.   This survey will be 
linked to you only through a study number and will not bear your name.
You will be asked to spit your saliva into a collection cup, or swish an oral rinse in your mouth 
and spit it into a cup.  This oralsample will be banked for future testing, should you provide your 
consent. At each visit after your initial visit, you will be asked to complete a shorter 
questionnaire, asking if there have been any changes in the answers you gave in the 
questionnaire at your initial visit.   Again, this questionnaire will be done in the privacy of an 
exam room, either by yourself or with the help of staff. 
The researchers in this study would like to bank your oral sample for future testing.  If you 
withdraw your consent for this study, every effort will be made to destroy any remaining sample.  
However, the researchers are requesting to keep the oral rinse sample(s) you have already 
provided.  If you are in agreement with banking your samples for future use by the researchers, 
please indicate here:
Yes, I am in agreement with the banking of my oral samples for future testing:
Initials:______   Date:_____
No, I do not agree that the researchers can bank my oral samples for future testing:
Initials:______  Date:______
4.2  How much of my time will be needed to take part in this study?  
The initial visit will take longer, as you will be asked to complete a more detailed questionnaire.  
The total estimated time for this visit is 1 hour.  Each follow-up visit, which is scheduled every 3-
4 months, will take about 30 minutes.
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4.3 When will my participation in the study be over? 
Your participation in this study will be over once you have completed all follow-up visits, should 
you agree to return for approximately 2 years.  Each visit will be 3-4 months apart. You may 
participate in as little as one visit or as many as 6 visits (i.e. up to 3 times per year for 2 years).
5.  INFORMATION ABOUT RISKS AND BENEFITS 
5.1  What risks will I face by taking part in the study?  What will the researchers do to 
protect me against these risks?
The known or expected risks are:
 Saliva collection: If you are asked to provide saliva using the oral rinse method, the oral 
rinse may sting your mouth and produce an unfavorable taste.
 Questionnaire(s):  There is a risk that the questionnaire may contain questions that 
make you feel uncomfortable or uneasy.  If at any time you feel uncomfortable, you may 
notify the staff member administering the questionnaire and you will be permitted to skip 
questions or portions of the survey that bring your discomfort.  
5.2  What happens if I get hurt, become sick, or have other problems as a result of this 
research?
The researchers have taken steps to minimize the risks of this study.  Even so, you may still 
have problems or side effects, even when the researchers are careful to avoid them. Please tell 
the researchers listed in Section 10 about any injuries, side effects, or other problems that you 
have during this study.  
5.3  If I take part in this study, can I also participate in other studies?
Being in more than one research study at the same time, or even at different times, may 
increase the risks to you.  It may also affect the results of the studies.  You should not take part 
in more than one study without approval from the researchers involved in each study.  
5.4  How could I benefit if I take part in this study?  How could others benefit?  
You may not receive any personal benefits from being in this study.   
Future individuals who are HIV positive and diagnosed with head and neck cancer may benefit if 
a better screening method is developed after this research is completed.
5.5  Will the researchers tell me if they learn of new information that could change my 
willingness to stay in this study?
Yes, the researchers will tell you if they learn of important new information that may change your 
willingness to stay in this study. If new information is provided to you after you have joined the 
study, it is possible that you may be asked to sign a new consent form that includes the new 
information.
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6.  OTHER OPTIONS 
6.1  If I decide not to take part in this study, what other options do I have?
This study is not providing any care. You can receive the same treatment without being in this 
study. 
7.  ENDING THE STUDY
7.1  If I want to stop participating in the study, what should I do?
You are free to leave the study at any time.  If you leave the study before it is finished, there will 
be no penalty to you. You will not lose any benefits to which you may otherwise be entitled.  If 
you choose to tell the researchers why you are leaving the study, your reasons for leaving may 
be kept as part of the study record. If you decide to leave the study before it is finished, please 
tell one of the persons listed in Section 10 “Contact Information” (below).
7.2  Could there be any harm to me if I decide to leave the study before it is finished? 
If you want to withdraw from the study at any time, you are free to do so, even if you do not give 
a reason. If you do withdraw, your usual medical care will not be affected in any way. If 
necessary for your medical care, your study doctor may advise you to have some follow-up 
tests. 
If you withdraw from the study, no new information (data) about you will be added to the 
database. The researchers would still like to be able to examine the oral samples you provided if 
you decide to leave the study before it is finished.
7.3  Could the researchers take me out of the study even if I want to continue to 
participate?
Yes. There are many reasons why the researchers may need to end your participation in the 
study.  Some examples are:
 The researcher believes that it is not in your best interest to stay in the study.
 You become ineligible to participate.
 Your condition changes and you need treatment that is not allowed while you are taking 
part in the study.
 You do not follow instructions from the researchers.
 The study is suspended or canceled.
8.  FINANCIAL INFORMATION
8.1  Who will pay for the costs of the study? Will I or my health plan be billed for any 
costs of the study?  
There are no costs to participants associated with being in this study.
By signing this form, you do not give up your right to seek payment if you are harmed as a result 
of being in this study.  
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8.2  Will I be paid or given anything for taking part in this study?
Yes, you will be paid $10 for your participation.
8.3  Who could profit or financially benefit from the study results?
None of the personnel involved in this study could profit or benefit financially from the study 
results.
9.  CONFIDENTIALITY OF SUBJECT RECORDS AND AUTHORIZATION TO RELEASE 
YOUR PROTECTED HEALTH INFORMATION 
The information below describes how your privacy and the confidentiality of your research 
records will be protected in this study.
9.1  How will the researchers protect my privacy?
Your research information will be stored in a locked cabinet.  All specimens will be coded before 
they are analyzed, and the research personnel who analyze the specimens will not be able to 
link them with any of your identifying information or medical history.  All data regarding your oral 
rinse sample will be stored in a password-protected database with barcoding of each sample to 
further enhance the privacy of your sample.
9.2  What information about me could be seen by the researchers or by other people?  
Why?  Who might see it?
Signing this form gives the researchers your permission to obtain, use, and share information 
about you for this study, and is required in order for you to take part in the study.  Information 
about you may be obtained from any hospital, doctor, and other health care provider involved in 
your care, including:
 Hospital/doctor's office records, including test results (X-rays, blood tests, urine tests, 
etc.)
 Alcohol/substance abuse treatment records
 Your AIDS/HIV status
 All records relating to your illness, the treatment you have received, and your 
response to the treatment
 Billing information
There are many reasons why information about you may be used or seen by the researchers or 
others during or after this study.  Examples include:
 The researchers may need the information to make sure you can take part in the 
study.  
 The researchers may need the information to check your test results or look for side 
effects.  
 University, Food and Drug Administration (FDA), and/or other government officials 
may need the information to make sure that the study is done in a safe and proper 
manner.   
 Study sponsors or funders, or safety monitors or committees, may need the 
information to: 
o Make sure the study is done safely and properly
o Learn more about side effects 
o Analyze the results of the study 
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 Insurance companies or other organizations may need the information in order to pay 
your medical bills or other costs of your participation in the study.
 The researchers may need to use the information to create a databank of information 
about your condition or its treatment.
 Information about your study participation may be included in your regular UMHS 
medical record.
 If you receive any payments for taking part in this study, the University of Michigan 
accounting department may need your name, address, social security number, 
payment amount, and related information for tax reporting purposes. 
 Federal or State law may require the study team to give information to government 
agencies. For example, to prevent harm to you or others, or for public health reasons.
The results of this study could be published in an article, but would not include any information 
that would let others know who you are. 
9.3  What happens to information about me after the study is over or if I cancel my 
permission?
As a rule, the researchers will not continue to use or disclose information about you, but will 
keep it secure until it is destroyed.  Sometimes, it may be necessary for information about you to 
continue to be used or disclosed, even after you have canceled your permission or the study is 
over.  Examples of reasons for this include:
 To avoid losing study results that have already included your information 
 To provide limited information for research, education, or other activities  (This 
information would not include your name, social security number, or anything else that 
could let others know who you are.) 
 To help University and government officials make sure that the study was conducted 
properly
As long as your information is kept within the University of Michigan Health System, it is 
protected by the Health System’s privacy policies.  For more information about these policies, 
ask for a copy of the University of Michigan Notice of Privacy Practices.  This information is also 
available on the web at http://www.med.umich.edu/hipaa/npp.htm. Note that once your 
information has been shared with others as described under Question 9.2, it may no longer be 
protected by the privacy regulations of the federal Health Insurance Portability and 
Accountability Act of 1996 (HIPAA).  
9.4  When does my permission expire?  
Your permission expires at the end of the study, unless you cancel it sooner. You may cancel 
your permission at any time by writing to the researchers listed in Section 10 "Contact 
Information" (below).  
Study ID: HUM00047989   IRB: IRBMED   Date Approved: 3/23/2012   Expiration Date: 2/15/2013
Page 7 of 8
Consent Subtitle: HIV/HPV oral rinse consent 
(partner)
Consent Version: 27Sep2011
10.  CONTACT INFORMATION
10.1  Who can I contact about this study?
Please contact the researchers listed below to:
 Obtain more information about the study
 Ask a question about the study procedures or treatments
 Talk about study-related costs to you or your health plan 
 Report an illness, injury, or other problem (you may also need to tell your regular doctors)
 Leave the study before it is finished
 Express a concern about the study
Principal Investigator: Mikiko Senga
Mailing Address: 1500 E. Medical Center Drive, 3210 Taubman Center
Ann Arbor, MI 48109-5378
Telephone: 734-647-9830
Study Coordinator: Mary Reyes
Mailing Address: 1500 E. Medical Center Drive, 3120 Taubman Center
Ann Arbor, MI 48109-5378
Telephone: 734-647-9830
You may also express a concern about a study by contacting the Institutional Review Board 
listed below, or by calling the University of Michigan Compliance Help Line at 1-888-296-2481.
University of Michigan Medical School Institutional Review Board (IRBMED)
2800 Plymouth Road
Building 200, Room 2086




If you are concerned about a possible violation of your privacy, contact the University of 
Michigan Health System Privacy Officer at 1-888-296-2481.
When you call or write about a concern, please provide as much information as possible, 
including the name of the researcher, the IRBMED number (at the top of this form), and details 
about the problem.  This will help University officials to look into your concern.  When reporting a 
concern, you do not have to give your name unless you want to.
11.  RECORD OF INFORMATION PROVIDED
11.1  What documents will be given to me?
Your signature in the next section means that you have received copies of all of the following 
documents:
 This "Consent to be Part of a Research Study" document.  (Note: In addition to the copy 
you receive, copies of this document will be stored in a separate confidential research file 
and may be entered into your regular University of Michigan medical record.)
Study ID: HUM00047989   IRB: IRBMED   Date Approved: 3/23/2012   Expiration Date: 2/15/2013
Page 8 of 8





I understand the information printed on this form.  I have discussed this study, its risks and potential benefits, and 
my other choices with ____________________.  My questions so far have been answered.  I understand that if I 
have more questions or concerns about the study or my participation as a research subject, I may contact one of the 
people listed in Section 10 (above).  I understand that I will receive a copy of this form at the time I sign it and later 
upon request.  I understand that if my ability to consent for myself changes, either I or my legal representative may 
be asked to re-consent prior to my continued participation in this study.
Signature of Subject: Date: 
Name (Print legal name):                     
Patient ID: Date of Birth: 
Principal Investigator (or Designee):
I have given this research subject (or his/her legally authorized representative, if applicable) information about this 
study that I believe is accurate and complete.  The subject has indicated that he or she understands the nature of 
the study and the risks and benefits of participating.
Name: Title: 
Signature: Date of Signature: 
Appendix 4.4  Epidemiology of Papillomavirus Infections Study questionnaire for male participants 
 
University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     




Thank you for your willingness to participate in the EPI 
Study. This study is to understand the role of human 
papillomavirus (HPV), a virus which causes cervical 
cancer, in people with and without HIV.  
 
Please complete the survey by checking the appropriate 
answer and filling in the blanks as requested. You may 
feel that some questions do not apply to you, and that is 
okay.  
 
All of your answers are strictly confidential, and your 
responses will not affect your clinical care you receive 





A. What is your gender? 
 
 __ Male 
__ Female (STOP. Please ask for the correct 
version of the questionnaire) 
  
BI. Race (check one only) 
 
 __ White, not Hispanic origin 
 __ Hispanic 
 __ Black, not Hispanic origin 
 __ Native Hawaiian or other Pacific Islander 
 __ Asian 
 __ Native American/Alaskan Nation 
 __ Other, specify __________________________ 








BII. Additional Race/Ethnicity (If you consider yourself 
multiracial, check all additional categories that apply in this 
question). Do not include what you reported in BI. 
 
 __ White, not Hispanic origin 
 __ Hispanic 
 __ Black, not Hispanic origin 
 __ Native Hawaiian or other Pacific Islander 
 __ Asian 
 __ Native American/Alaskan Nation 
 __ Other, specify __________________________ 
 __ Unknown/I prefer not to answer 
 
C. Highest school grade completed (check one) 
 
 __ 8th or less 
 __ 9-11th grade 
 __ High school graduate/GED 
 __ Vocational/technical school 
 __ Associate degree/some college 
 __ Bachelor’s degree 
 __ Advanced degree 
 __ Other, specify __________________________ 
 __ I prefer not to answer 
 
D. Marital status 
 
 __ Married  __ Divorced/Separated 
 __ Widowed  __ Living as married 
 __ Single  __ I prefer not to answer 
 
E. Religion during childhood 
 
 __ Protestant 
 __ Catholic 
 __ Jewish 
 __ Mormon/Latter Day Saints 
 __ Muslim/Islam 
 __ None 
 __ Other, specify __________________________ 




University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
F. Where were you born? 
 
 __ USA, specify the 2 letter state code _________ 
 __ Other country, specify ___________________ 
 
G. Where did you live longest? 
 
 __ USA, specify the 2 letter state code _________ 
 __ Other country, specify ___________________ 
 
2. Cigarette history 
 
A. Have you smoked at least 100 cigarettes (5 packs) 
during your lifetime? 
 __ No (Skip to #3) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently smoke (answer B-E) 
B. Age you began smoking cigarettes                   _______ 
C. Number of years you smoked cigarettes          _______ 
D. Average # of cigarettes smoked per day          _______ 
E. If quit, age you stopped smoking completely    _______ 
 
3. Cigar history 
 
A. Have you ever smoked cigars during your lifetime? 
 __ No (Skip to #4) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently (answer B-E) 
B. Age you began smoking cigars                         _______ 
C. Number of years you smoked cigars                _______ 
D. Average number of cigars smoked per day      _______ 
E. If quit, age stopped smoking cigars completely_______ 
 
4. Chewing tobacco history 
 
A. Have you ever chewed tobacco during your 
lifetime? 
 __ No (Skip to #5) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently chew (answer B-E) 
B. Age began chewing tobacco                             _______ 
C. Number of years having chewed tobacco         _______ 
D. Average times chewed tobacco per day           _______ 
E. If quit, age stopped chewing completely           _______ 
5. Pipe smoking history 
 
A. Have you ever smoked pipes during your lifetime? 
 __ No (Skip to #6) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently smoke (answer B-E) 
B. Age you began smoking pipes                          _______ 
C. Number of years you smoked pipes                 _______ 
D. Average # of pipes you smoked per day           _______ 
E. If quit, age you stopped smoking it completely _______ 
 
6. Snuff history 
 
A. Have you ever snorted or smoked snuff during 
your lifetime? 
 __ No (Skip to #7) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently use snuff (answer B-E) 
B. Age you began using snuff                               _______ 
C. Number of years you used snuff                       _______ 
D. Average times you used snuff per day              _______ 
E. If quit, age you stopped using it completely      _______ 
 
7. Marijuana history 
 
A. Have you ever smoked marijuana during your 
lifetime? 
 __ No (Skip to #8) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently smoke (answer B-E) 
B. Age you began smoking marijuana                  _______ 
C. Number of years you smoked marijuana          _______ 
D. Average times you smoked marijuana per day _______ 
E. If quit, age you stopped smoking it completely _______ 
 
8. Other substance use 
 
A. Do you use any drugs other than marijuana? 
__ No (Skip to #9)   
 __ Yes 
 





University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
9. Sexual practices 
 
A. What is your sexual preference? 
__ Sex with a man 
__ Sex with a woman 
__ Sex with a man or woman 
 
B. At what age did you become sexually active?   
 _______ 
 
10. Vaginal intercourse 
 
A. Have you ever had vaginal intercourse? 
 __ No (Skip to #11) 
 __ Yes 
__ Don’t know 
 
B. Number of women with whom you had vaginal 
intercourse   
 _______ 
 
C. Did you use condoms during vaginal intercourse? 
 __ Never  __ Most of the time 
 __ Rarely  __ All of the time 
 
D. If you answered never, rarely, or most of the time to 
10C, during what age range did you most frequently 
have unprotected sex? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
E. When was the last time you had vaginal 
intercourse?  
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
F. Have you ever had vaginal sex with someone who 
had warts on her vagina? 
 __ No 
 __ Yes 
 
11. Oral sex 
 
A. Have you ever performed oral sex?  
 __ No (Skip to #12)  
 __ Yes 
 
B. At what age did you first perform oral sex?     _____ 
 
C. Number of partners of each gender on whom oral 
sex was performed 
 Male      _______ 
 Female  _______ 
 
D. Did you use condoms during oral sex? 
 __ Never  __ Most of the time 
 __ Rarely  __ All of the time 
 
E. If you answered never, rarely, or most of the time to 
11D, during what age range did you most frequently 
have unprotected oral sex? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
F. When was the last time you had oral intercourse? 
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
G. Have you ever had oral sex with someone who had 
warts on his/her genitals? 
 __ No 
 __ Yes 
__ Don’t know 
 
12. Anal sex 
 
A. Have you ever engaged in anal intercourse? 
 __ No (Skip to #13) 
 __ Yes 
 




University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
C. Number of partners of each gender with whom you 
engaged in anal intercourse 
 Male     _______ 
 Female _______ 
 
D. Did you use condoms during anal intercourse? 
 __ Never  __ Most of the time 
 __ Rarely  __ All of the time 
 
E. If you answered never, rarely, or most of the time to 
12D, during what age range did you most frequently 
have unprotected anal sex? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
F. When was the last time you had anal intercourse?  
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
G. Have you ever had anal sex with someone who had 
warts on his/her anus? 
 __ No   
 __ Yes 
 
13. French kissing 
 
A. Have you ever engaged in deep kissing (aka 
“French kissing” or kissing with tongue)? 
 __ No (Skip to #14) 
 __ Yes 
 
B. At what age did you begin deep kissing?           
_______ 
 
C. Number of partners of each gender with whom you 
engaged in deep kissing 
 Male     _______ 
 Female _______   
 
 
D. During what age range did you most frequently 
engage in deep kissing? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
E. When was the last time you French kissed 
someone? 
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
F. Have you ever kissed or French kissed someone 
who had a wart on his/her mouth?  
 __ No   
 __ Yes 
 
14. Other sexual practices 
 
A. Do you ever use your saliva as lubricant during 
sex? 
 __ No   
 __ Yes 
 
B. Do you ever use your partner’s saliva as lubricant 
during sex? 
 __ No   
__ Yes 
 
C. Do you masturbate? 
__ No   
__ Yes 
 
D. If yes, how often? 
__ Once a day 
__ Within the past week 
__ Within the past month 








University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
E. Do you wash your hands after you masturbate? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
15. Sexual Health 
 
A. Have you ever had an anal pap smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
B. Have you ever had an abnormal anal pap smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
C. If your partner is female, what kind(s) of birth 
control do you and your partner use? 
 __ Cervical cap 
 __ Female condom 
 __ Male condom 
 __ Dental dam 
 __ Diaphragm 
 __ Spermicides 
 __ Pills 
 
D. If your partner is female, has she ever had an 
abnormal cervical pap smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
E. Have you ever had syphilis?  
 __ No 
 __ Yes 
 __ Don’t know 
 
F. Have you ever had chlamydia?  
 __ No 
 __ Yes 
 __ Don’t know 
 
G. Have you ever had genital herpes? 
 __ No 
 __ Yes 
 __ Don’t know 
 
H. Have you ever had oral herpes? 
 __ No 
 __ Yes 
 __ Don’t know 
 
I. Do you exchange sex for money? 
 __ No 
 __ Yes 
 __ Don’t know 
 
J.  Do you exchange sex for drugs? 
 __ No 
 __ Yes 
 __ Don’t know 
 
16. General health history 
 
A. Have you had your tonsils out? 
 __ No 
 __ Yes 
 __ Don’t know 
 
B. Have you ever had warts on your hands or feet? 
 __ No 
 __ Yes 
 __ Don’t know 
 
C. Have you ever had warts in your genital area? 
 __ No 
 __ Yes 










University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
D. Have you ever had any of the following types of 
cancer? 
__ Nose 
__ Mouth, throat, tongue, or voice box 
__ Tonsil 








E. How many times a week do you brush your teeth? 
 ____ times a week 
 
F. How many times a day do you brush your teeth? 
 ____ times a day 
 
G. How many times a week do you use mouthwash? 
____ times a week 
 
H. How many times a day do you use mouthwash? 
______ times a day 
 
I. What kind of mouthwash do you use? 
__ Alcohol-based 
__ Non alcohol-based 
__ I do not use any kind of mouthwash 
__ Don’t know 
 
J. Do you wash your hands after you had any contact 
with someone? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
K. Do you wash your hands after you go to the 
bathroom? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
L. Do you share eating utensils with another person?  
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
M. Do you share a drink from the same bottle/cup 
with someone? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
N. Have you ever received an HPV vaccine? 
 __ No 
 __ Yes 
 __ Don’t know 
 
O.  If yes, when did you receive this vaccine? 
Date: ______/_______/_______ 
         Month     Day       Year 
 
P. Have you ever had or been told that you had 
infectious mononucleosis (or “mono”)? 
__ No 
__ Yes 
__ Don’t know 
 
Q. If yes, when did you have mono? 
Date: ______/_______/_______ 
         Month     Day       Year 
  
R. Are you circumcised?  
 __ No 
 __ Yes 
 __ Don’t know 
 
S. If you have a male sexual partner, is he 
circumcised? 
 __ No 
 __ Yes 





University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
17. Drinking history 
Note: One drink is equivalent to 1 oz. of liquor, 5 oz. of   
wine, or 12 oz. of beer 
 
A. Have you ever consumed alcohol? 
 __ No (Skip to #18) 
 __ Yes, but quit 
 __ Yes, currently 
 
B. At what age did you begin drinking alcohol?     
 _______ 
 
C. Number of years you have consumed alcohol  
 _______ 
 
D. Frequency of consumption of beverages containing 
alcohol while you were under the age of 18 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
E. Number of drinks containing alcohol on a typical 
day when drinking while you were under the age of 
18 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
F. Frequency of consumption of beverages containing 
alcohol while you were between age 18-22 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 





G. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 18-
22 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
H. Frequency of consumption of beverages containing 
alcohol while you were between age 23-29 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
I. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 23-
29 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
J. Frequency of consumption of beverages containing 
alcohol while you were between age 30-39 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
K. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 30-
39 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 








University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
L. Frequency of consumption of beverages containing 
alcohol while you were between age 40-49 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
M. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 40-
49 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
N. If you quit, age you stopped drinking completely 
 ______ 
 
18. Dietary factors: 
A. How much water do you drink per day? 
 __ One 8 oz glass 
 __ Two 8oz glasses 
 __ Three 8oz glasses 
 __ Four 8oz glasses 
 __ Five 8oz glasses 
 __ Six 8oz glasses 
 __ Seven 8oz glasses 
 __ Eight 8oz glasses 
 __ More than eight 8oz glasses 
 
B. How many drinks that contain caffeine do you drink 
per day? 
 __ None 
 __ One 8 oz glass 
 __ Two 8oz glasses 
 __ Three 8oz glasses 
 __ Four 8oz glasses 
 __ Five 8oz glasses 
 __ Six 8oz glasses 
 __ Seven 8oz glasses 
 __ Eight 8oz glasses 
 __ More than eight 8oz glasses 
 
C. Do you chew nicotine gum? 
 __ Yes 
 __ No 
 __ Don’t know 
 
19. Second-hand smoking exposure 
A. Have you ever been exposed to second-hand 
smoking? 
 __ No (answer E, F, G, H) 
 __ Yes 
 
B. Where did this exposure take place and for about 
how long? 
 __ Work ____ hours/day for ____ years 
 __ Home ____ hours/day for ____ years 
 __ Other ____ hours/day for ____ years 
 
C. At what age did your second-hand smoking 
exposure begin?  _______ 
 
D. If exposure ceased, at what age? _______ 
 
E. Did your mother use any tobacco while she was 
pregnant with you? 
 __ Yes  
 __ No  
 __ Don’t know 
 
F. Did your mother use any marijuana while she was 
pregnant with you? 
 __ Yes 
 __ No 
 __ Don’t know 
 
G. Did your father use any tobacco while your mother 
was pregnant with you? 
 __ Yes  
 __ No  







University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Male) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
H. Did your father use any marijuana while your 
mother was pregnant with you? 
 __ Yes 
 __ No 
 __ Don’t know 
 
I. Did your parents or other family members smoke in 
your home when you were growing up? 
 __ Yes 
 __ No 
 __ Don’t know 
 
J. Did your parents or anyone else use marijuana in 
your home when you were growing up 
 __ Yes 
 __ No 
 __ Don’t know 
 
20. Exposure to chemicals 
 
A. Do you work in any of the following job categories? 
 __ Mining 
 __ Oil industry, including gas stations 
 __ Welding 
 __ Work involving smoke 
 __ Soft wood work 
 __ Hard wood work 
 
B. Are you exposed to any of the following chemicals 
or substances on a regular basis? 
 __ Diesel exhaust 
 __ Asbestos 
 __ Dust 
 __ Welding 
 __ Smoke at work 
 __ Wood work 
 
21. HIV Patients Only: 
 
A. How old were you when you first tested 
positive for HIV? 
____ years old 
 
 
B. Do you take your medications every day? 
 __ No 
 __ Yes 
 __ Don’t know 
 
C. Has your CD4 count ever been below 200? 
 __ No 
 __ Yes 
 __ Don’t know 
171 
 
University of Michigan Head & Neck Oncology Program 
Social Behaviors and Family History Form        
Date completed ___-___-_______ (mm-dd-yyyy)                     
Form ID _______________________                                                               Resp. No. ______________________          
 
Instructions: Complete the information by checking the appropriate answer and filling in the blanks as requested. 
22. Family history 
A. How many of the following family members (living and dead) do you have? Include only those who are blood-
related. 
 ____ Brothers  ____ Sisters  ____ Sons  ____ Daughters 
 
B. Are you adopted?  
 ____ No   ____ Yes (In 11C, complete the question only for your children) 
 
C. Check the box under blood relatives for each family member who developed cancer and give an estimate of the 
age that the first cancer was diagnosed.  For each relative with cancer, check off all types of cancer that apply. 





Type of Cancer 




Other (check and specify) 
__ Father  ____ ____ ____ ____ ____ ____ __ specify ____________ 
__ Mother  ____ ____ ____ xxxxxx ____ ____ __ specify ____________ 
__ Brother #1 
__ Brother #2 
__ Brother #3 

























__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ Sister #1 
__ Sister #2 
__ Sister #3 






















__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ Child #1 
__ Child #2 
__ Child #3 

























__ specify ____________ 
__ specify ____________ 
__ specify ____________ 








Appendix 4.5  Epidemiology of Papillomavirus Infections Study questionnaire for female participants 
 
University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Female) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________ 
Instructions:  
 
Thank you for your willingness to participate in the EPI 
Study. This study is to understand the role of human 
papillomavirus (HPV), a virus which causes cervical 
cancer, in people with and without HIV.  
 
Please complete the survey by checking the appropriate 
answer and filling in the blanks as requested. You may 
feel that some questions do not apply to you, and that is 
okay.  
 
All of your answers are strictly confidential, and your 
responses will not affect your clinical care you receive 





A. What is your gender? 
 
__ Male (STOP. Please ask for the correct version 
of the questionnaire) 
 __ Female 
  
BI. Race (check one only) 
 
 __ White, not Hispanic origin 
 __ Hispanic 
 __ Black, not Hispanic origin 
 __ Native Hawaiian or other Pacific Islander 
 __ Asian 
 __ Native American/Alaskan Nation 
 __ Other, specify __________________________ 










BII. Additional Race/Ethnicity (If you consider yourself 
multiracial, check all additional categories that apply in this 
question). Do not include what you reported in BI. 
 
 __ White, not Hispanic origin 
 __ Hispanic 
 __ Black, not Hispanic origin 
 __ Native Hawaiian or other Pacific Islander 
 __ Asian 
 __ Native American/Alaskan Nation 
 __ Other, specify __________________________ 
 __ Unknown/I prefer not to answer 
 
C. Highest school grade completed (check one) 
 
 __ 8th or less 
 __ 9-11th grade 
 __ High school graduate/GED 
 __ Vocational/technical school 
 __ Associate degree/some college 
 __ Bachelor’s degree 
 __ Advanced degree 
 __ Other, specify __________________________ 
 __ I prefer not to answer 
 
D. Marital status 
 
 __ Married  __ Divorced/Separated 
 __ Widowed  __ Living as married 
 __ Single  __ I prefer not to answer 
 
E. Religion during childhood 
 
 __ Protestant 
 __ Catholic 
 __ Jewish 
 __ Mormon/Latter Day Saints 
 __ Muslim/Islam 
 __ None 
 __ Other, specify __________________________ 




University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Female) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
F. Where were you born? 
 
 __ USA, specify the 2 letter state code _________ 
 __ Other country, specify ___________________ 
 
G. Where did you live longest? 
 
 __ USA, specify the 2 letter state code _________ 
 __ Other country, specify ___________________ 
 
2. Cigarette history 
 
A. Have you smoked at least 100 cigarettes (5 packs) 
during your lifetime? 
 __ No (Skip to #3) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently smoke (answer B-E) 
B. Age you began smoking cigarettes                   _______ 
C. Number of years you smoked cigarettes          _______ 
D. Average # of cigarettes smoked per day          _______ 
E. If quit, age you stopped smoking completely    _______ 
 
3. Cigar history 
 
A. Have you ever smoked cigars during your lifetime? 
 __ No (Skip to #4) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently (answer B-E) 
B. Age you began smoking cigars                         _______ 
C. Number of years you smoked cigars                _______ 
D. Average number of cigars smoked per day      _______ 
E. If quit, age stopped smoking cigars completely_______ 
 
4. Chewing tobacco history 
 
A. Have you ever chewed tobacco during your 
lifetime? 
 __ No (Skip to #5) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently chew (answer B-E) 
B. Age began chewing tobacco                             _______ 
C. Number of years having chewed tobacco         _______ 
D. Average times chewed tobacco per day           _______ 
E. If quit, age stopped chewing completely           _______ 
5. Pipe smoking history 
 
A. Have you ever smoked pipes during your lifetime? 
 __ No (Skip to #6) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently smoke (answer B-E) 
B. Age you began smoking pipes                          _______ 
C. Number of years you smoked pipes                 _______ 
D. Average # of pipes you smoked per day           _______ 
E. If quit, age you stopped smoking it completely _______ 
 
6. Snuff history 
 
A. Have you ever snorted or smoked snuff during 
your lifetime? 
 __ No (Skip to #7) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently use snuff (answer B-E) 
B. Age you began using snuff                               _______ 
C. Number of years you used snuff                       _______ 
D. Average times you used snuff per day              _______ 
E. If quit, age you stopped using it completely      _______ 
 
7. Marijuana history 
 
A. Have you ever smoked marijuana during your 
lifetime? 
 __ No (Skip to #8) 
 __ Yes, but quit (answer B-E) 
 __ Yes, currently smoke (answer B-E) 
B. Age you began smoking marijuana                  _______ 
C. Number of years you smoked marijuana          _______ 
D. Average times you smoked marijuana per day _______ 
E. If quit, age you stopped smoking it completely _______ 
 
8. Other substance use 
 
A. Do you use any drugs other than marijuana? 
__ No (Skip to #9)   
 __ Yes 
 





University of Michigan Etiology of Papillomavirus Infections (EPI) Study (Female) 
 
Date completed ___-___-_______ (mm-dd-yyyy)                     
Study ID: ______________________           
 
9. Sexual practices 
 
A. What is your sexual preference? 
A. __ Sex with a man 
B. __ Sex with a woman 
C. __ Sex with a man or woman 
 
B. At what age did you become sexually active?   
 _______ 
 
10. Vaginal intercourse 
 
A. Have you ever had vaginal intercourse? 
 __ No (Skip to #11) 
 __ Yes 
__ Don’t know 
 
B. Number of partners of each gender with whom you 
had vaginal intercourse  
 Male  _______  
 Female  _______ 
 
C. Did you use condoms during vaginal intercourse? 
 __ Never  __ Most of the time 
 __ Rarely  __ All of the time 
 
D. If you answered never, rarely, or most of the time to 
10C, during what age range did you most frequently 
have unprotected sex? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
E. When was the last time you had vaginal 
intercourse?  
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 




F. Have you ever had vaginal sex with someone who 
had warts on his penis (if your partner was male) or 
her vagina (if your partner was female)? 
 __ No 
 __ Yes 
 
11. Oral sex 
 
A. Have you ever performed oral sex?  
 __ No (Skip to #12)  
 __ Yes 
 
B. At what age did you first perform oral sex?     _____ 
 
C. Number of partners of each gender on whom oral 
sex was performed 
 Male      _______ 
 Female  _______ 
 
D. Did you use condoms during oral sex? 
 __ Never  __ Most of the time 
 __ Rarely  __ All of the time 
 
E. If you answered never, rarely, or most of the time to 
11D, during what age range did you most frequently 
have unprotected oral sex? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
F. When was the last time you had oral intercourse? 
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
G. Have you ever had oral sex with someone who had 
warts on his/her genitals? 
 __ No 
 __ Yes 
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12. Anal sex 
 
A. Have you ever engaged in anal intercourse? 
 __ No (Skip to #13) 
 __ Yes 
 
B. At what age did you first engage in anal 
intercourse? _______ 
 
C. Number of partners of each gender with whom you 
engaged in anal intercourse 
 Male     _______ 
 Female _______ 
 
D. Did you use condoms during anal intercourse? 
 __ Never  __ Most of the time 
 __ Rarely  __ All of the time 
 
E. If you answered never, rarely, or most of the time to 
12D, during what age range did you most frequently 
have unprotected anal sex? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
F. When was the last time you had anal intercourse?  
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
G. Have you ever had anal sex with someone who had 
warts on his/her anus? 
 __ No   
 __ Yes 
 
13. French kissing 
 
A. Have you ever engaged in deep kissing (aka 
“French kissing” or kissing with tongue)? 
 __ No (Skip to #14) 
 __ Yes 
 
 
B. At what age did you begin deep kissing?           
_______ 
 
C. Number of partners of each gender with whom you 
engaged in deep kissing 
 Male     _______ 
 Female _______   
 
 
D. During what age range did you most frequently 
engage in deep kissing? 
 __ Under age 18 __ Age 18-22 
 __ Age 23-29  __ Age 30-39 
 __ Age 40-49  __ Over age 50 
 
E. When was the last time you French kissed 
someone? 
 __ Within the past day 
 __ Within the past week 
 __ Within the past month 
 __ More than one month ago 
 
F. Have you ever kissed or French kissed someone 
who had a wart on his/her mouth?  
 __ No   
 __ Yes 
 
14. Other sexual practices 
 
A. Do you ever use your saliva as lubricant during 
sex? 
 __ No   
 __ Yes 
 
B. Do you ever use your partner’s saliva as lubricant 
during sex? 
 __ No   
__ Yes 
 
C. Do you masturbate? 
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D. If yes, how often? 
__ Once a day 
__ Within the past week 
__ Within the past month 
__ More than one month ago 
 
E. Do you wash your hands after you masturbate? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
15. Sexual Health 
 
A. Have you ever had an anal pap smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
B. Have you ever had an abnormal anal pap smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
C. Have you ever used birth control? 
 __ No 
 __ Yes 
__ Don’t know 
 
D. Are you currently on birth control? 
 __ No 
 __ Yes (answer E) 
 __ Don’t know 
 
E. What kind(s) of birth control do you use? 
 __ Cervical cap 
 __ Female condom 
 __ Male condom 
 __ Dental dam 
 __ Diaphragm 
 __ Spermicides 
 __ Pills 
 
 
F. Have you ever had a cervical pap smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
G. How often do you have a cervical pap smear? 
 __ More than once a year 
 __ Once a year 
 __ Once every two years 
 __ Once every five years 
 __ Once every  
 
H. Have you ever had an abnormal cervical pap 
smear? 
 __ No 
 __ Yes 
 __ Don’t know 
 
I. Have you ever had syphilis?  
 __ No 
 __ Yes 
 __ Don’t know 
 
J. Have you ever had chlamydia?  
 __ No 
 __ Yes 
 __ Don’t know 
 
K. Have you ever had genital herpes? 
 __ No 
 __ Yes 
 __ Don’t know 
 
L. Have you ever had oral herpes? 
 __ No 
 __ Yes 
 __ Don’t know 
 
M. Do you exchange sex for money? 
 __ No 
 __ Yes 
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N.  Do you exchange sex for drugs? 
 __ No 
 __ Yes 
 __ Don’t know 
 
16. General health history 
 
A. Have you had your tonsils out? 
 __ No 
 __ Yes 
 __ Don’t know 
 
B. Have you ever had warts on your hands or feet? 
 __ No 
 __ Yes 
 __ Don’t know 
 
C. Have you ever had warts in your genital area? 
 __ No 
 __ Yes 
 __ Don’t know 
 
D. Have you ever had any of the following types of 
cancer? 
__ Nose 
__ Mouth, throat, tongue, or voice box 
__ Tonsil 








E. How many times a week do you brush your teeth? 
 ____ times a week 
 
F. How many times a day do you brush your teeth? 
 ____ times a day 
 
G. How many times a week do you use mouthwash? 
____ times a week 
 
H. How many times a day do you use mouthwash? 
______ times a day 
 
I. What kind of mouthwash do you use? 
__ Alcohol-based 
__ Non alcohol-based 
__ I do not use any kind of mouthwash 
__ Don’t know 
 
J. Do you wash your hands after you had any contact 
with someone? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
K. Do you wash your hands after you go to the 
bathroom? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
L. Do you share eating utensils with another person?  
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
M. Do you share a drink from the same bottle/cup 
with someone? 
 __ No 
 __ Yes, always 
 __ Yes, sometimes 
 __ Yes, rarely 
 
N. Have you ever received an HPV vaccine? 
 __ No 
 __ Yes 
 __ Don’t know 
 
O.  If yes, when did you receive this vaccine? 
Date: ______/_______/_______ 
         Month     Day       Year 
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P. Have you ever had or been told that you had 
infectious mononucleosis (or “mono”)? 
__ No 
__ Yes 
__ Don’t know 
 
Q. If yes, when did you have mono? 
Date: ______/_______/_______ 
         Month     Day       Year 
 
R. Have you ever been pregnant? 
__ No 
__ Yes 
__ Don’t know 
 
S. How many children have you given birth to? 
__ 0  __ 4 
__ 1  __ 5 
__ 2  __ more than 5 
__ 3  
  
T. If you have a male sexual partner, is he 
circumcised? 
 __ No 
 __ Yes 
 __ Don’t know 
 
17. Drinking history 
Note: One drink is equivalent to 1 oz. of liquor, 5 oz. of   
wine, or 12 oz. of beer 
 
A. Have you ever consumed alcohol? 
 __ No (Skip to #18) 
 __ Yes, but quit 
 __ Yes, currently 
 
B. At what age did you begin drinking alcohol?     
 _______ 
 
C. Number of years you have consumed alcohol  
 _______ 
 
D. Frequency of consumption of beverages containing 
alcohol while you were under the age of 18 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
E. Number of drinks containing alcohol on a typical 
day when drinking while you were under the age of 
18 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
F. Frequency of consumption of beverages containing 
alcohol while you were between age 18-22 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
G. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 18-
22 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
H. Frequency of consumption of beverages containing 
alcohol while you were between age 23-29 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
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I. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 23-
29 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
J. Frequency of consumption of beverages containing 
alcohol while you were between age 30-39 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
K. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 30-
39 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 
L. Frequency of consumption of beverages containing 
alcohol while you were between age 40-49 (please 
check only one) 
 __ Never 
 __ Less than monthly 
 __ 2-4 times per month 
 __ 2-4 times per week 
 __ 4 or more times per week 
 
M. Number of drinks containing alcohol on a typical 
day when drinking while you were between age 40-
49 (please check only one) 
 __ 1 or 2  __ 3 or 4 
 __ 5 or 6  __ 7-9 
 __ 10 or more 
 





18. Dietary factors: 
A. How much water do you drink per day? 
 __ One 8 oz glass 
 __ Two 8oz glasses 
 __ Three 8oz glasses 
 __ Four 8oz glasses 
 __ Five 8oz glasses 
 __ Six 8oz glasses 
 __ Seven 8oz glasses 
 __ Eight 8oz glasses 
 __ More than eight 8oz glasses 
 
B. How many drinks that contain caffeine do you drink 
per day? 
 __ None 
 __ One 8 oz glass 
 __ Two 8oz glasses 
 __ Three 8oz glasses 
 __ Four 8oz glasses 
 __ Five 8oz glasses 
 __ Six 8oz glasses 
 __ Seven 8oz glasses 
 __ Eight 8oz glasses 
 __ More than eight 8oz glasses 
 
C. Do you chew nicotine gum? 
 __ Yes 
 __ No 
 __ Don’t know 
 
19. Second-hand smoking exposure 
A. Have you ever been exposed to second-hand 
smoking? 
 __ No (answer E, F, G, H) 
 __ Yes 
 
B. Where did this exposure take place and for about 
how long? 
 __ Work ____ hours/day for ____ years 
 __ Home ____ hours/day for ____ years 
 __ Other ____ hours/day for ____ years 
 
C. At what age did your second-hand smoking 
exposure begin?  _______ 
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D. If exposure ceased, at what age? _______ 
 
E. Did your mother use any tobacco while she was 
pregnant with you? 
 __ Yes  
 __ No  
 __ Don’t know 
 
F. Did your mother use any marijuana while she was 
pregnant with you? 
 __ Yes 
 __ No 
 __ Don’t know 
 
G. Did your father use any tobacco while your mother 
was pregnant with you? 
 __ Yes  
 __ No  
 __ Don’t know 
 
H. Did your father use any marijuana while your 
mother was pregnant with you? 
 __ Yes 
 __ No 
 __ Don’t know 
 
I. Did your parents or other family members smoke in 
your home when you were growing up? 
 __ Yes 
 __ No 
 __ Don’t know 
 
J. Did your parents or anyone else use marijuana in 
your home when you were growing up 
 __ Yes 
 __ No 








20. Exposure to chemicals 
 
A. Do you work in any of the following job categories? 
 __ Mining 
 __ Oil industry, including gas stations 
 __ Welding 
 __ Work involving smoke 
 __ Soft wood work 
 __ Hard wood work 
 
B. Are you exposed to any of the following chemicals 
or substances on a regular basis? 
 __ Diesel exhaust 
 __ Asbestos 
 __ Dust 
 __ Welding 
 __ Smoke at work 
 __ Wood work 
 
21. HIV Patients Only: 
 
A. How old were you when you first tested 
positive for HIV? 
____ years old 
 
B. Do you take your medications every day? 
 __ No 
 __ Yes 
 __ Don’t know 
 
C. Has your CD4 count ever been below 200? 
 __ No 
 __ Yes 
 __ Don’t know 
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Instructions: Complete the information by checking the appropriate answer and filling in the blanks as requested. 
22. Family history 
A. How many of the following family members (living and dead) do you have? Include only those who are blood-
related. 
 ____ Brothers  ____ Sisters  ____ Sons  ____ Daughters 
 
B. Are you adopted?  
 ____ No   ____ Yes (In 11C, complete the question only for your children) 
 
C. Check the box under blood relatives for each family member who developed cancer and give an estimate of the 
age that the first cancer was diagnosed.  For each relative with cancer, check off all types of cancer that apply. 





Type of Cancer 




Other (check and specify) 
__ Father  ____ ____ ____ ____ ____ ____ __ specify ____________ 
__ Mother  ____ ____ ____ xxxxxx ____ ____ __ specify ____________ 
__ Brother #1 
__ Brother #2 
__ Brother #3 

























__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ Sister #1 
__ Sister #2 
__ Sister #3 






















__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ Child #1 
__ Child #2 
__ Child #3 

























__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
__ specify ____________ 
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